Investigation of pre-therapy scintigraphic parameters related to radioiodine therapy outcome in cats by Volckaert, Veerle
  
Investigation of pre-therapy scintigraphic parameters 
related to radioiodine therapy outcome in cats 
 
Veerle Volckaert 
 
 
Dissertation submitted in fulfilment of the requirements 
for the degree of Doctor of Philosophy (PhD) 
18th of November 2016 
 
 
Promoters: 
Dr. Kathelijne Peremans 
Prof. Dr. Jimmy Saunders 
Dr. Eva Vandermeulen 
 
 
 
Department of Veterinary Medical Imaging and Small Animal Orthopaedics 
Faculty of Veterinary Medicine 
Ghent University  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“I was taught that the way of progress is neither swift nor easy” 
(Marie S. Curie) 
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 GENERAL INTRODUCTION 
Hyperthyroidism in cats:  
Thyroid glands, diagnosis of hyperthyroidism, scintigraphy and 
radioiodine treatment 
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1. Thyroid gland anatomy 
The thyroid gland is an endocrine gland that consists of two small, elongated structures, 
located caudal to the larynx and lateral to the trachea on each side (Figures 1 and 2). 
Ventrally, they are covered by the sternothyroid muscle and laterally by the sternocephalic 
and sternohyoid muscles. The recurrent laryngeal nerve passes over their dorsal aspect. The 
size of a single lobe in cats is approximately 2 cm in length and 0.3 cm in width. The size of 
the gland can vary depending on factors such as the dietary iodine content. In case of iodine 
deficiency for example, the thyroid gland will increase in size.1,2 Accessory, also known as 
ectopic thyroid tissue, can occur in any location from the larynx along the trachea, at the 
level of the thoracic inlet or along the thoracic part of the descending aorta, until the level 
of the diaphragm. An epithelial outgrowth from the pharyngeal floor gives rise to the 
thyroidal primordium, which is closely associated to the aortic sac during development. The 
thyroidal primordium will divide itself in two parts during development, expand laterally, 
and form the two separate thyroid lobes. At the same time, a migration from the region of 
origin at the tongue base towards its normal cervical position will take place. Little islets of 
thyroid cells can separate from the thyroidal primordium and become incorporated in 
developing structures of the thorax and brachial arch region due to this close relationship 
with the developing aortic sac. These islets will then form foci of ectopic thyroid tissue.1-6 In 
hyperthyroid cats a prevalence of 3.9% for ectopic thyroid tissue has been reported.6 
Each thyroid lobe is vascularized by a cranial thyroid artery, branching from the common 
carotid artery at the level of the larynx. Venous drainage occurs by cranial and caudal 
thyroid veins, draining into the internal jugular veins or into the larger veins at the level of 
the thoracic inlet. Lymphatic drainage is provided by the deep cranial cervical lymph nodes. 
Nervous innervation consists of both sympathetic origin, via the cranial cervical ganglia, and 
parasympathetic origin, via laryngeal branches of the vagus nerve. Their most important 
function is vasomotor control. The thyroid glands are each associated with usually four 
parathyroid glands, two external to the thyroid gland cranially and two embedded within 
the thyroid capsule or thyroid parenchyma caudally. In cats, the cranial parathyroid gland 
can descend and locate itself near the caudal pole.1,2 
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Figure 1. Anatomical image of a feline thyroid gland (star: thyroid gland; IJV: internal jugular vein; CCA: 
common carotid artery; T: trachea) (From: Sebastiani and Fishbeck, 2005).
7
 
 
 
 
Figure 2. Drawing of the anatomy of the thyroid gland in a cat (From: Scott-Moncrieff, 2015).
8
  
 
2. Thyroid gland physiology: synthesis and secretion of thyroid hormones 
The process starts at the level of the intestinal tract where iodine (I2) is trapped and 
converted to iodide (I-) that is transported by the bloodstream. At the level of the thyroid 
gland, the iodide ion will be extracted from the bloodstream by the sodium iodide (Na+I-) 
symporters (NIS) of the thyroid follicular cells. These follicular cells are typically arranged in 
a circular manner, lining the thyroid follicles that are surrounding the centrally located 
substance known as the colloid. The iodide ion is then oxidized to iodine by the peroxidase 
enzyme and tyrosine molecules will be incorporated in thyroglobulin, a glycoprotein 
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produced by the thyroid follicular cells. The tyrosyl residues will then be attached to iodine 
to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). These can be coupled with the 
help of the peroxidase enzyme to form biologically active iodothyronines: 
tetraiodothyronine or thyroxine (T4) and triiodothyronine (T3). These molecules are stored 
outside of the peripheral follicular cells, within the colloid, which forms the center of a 
thyroid follicle and where a large reserve can be stored. When these molecules return to the 
follicular cell lumen and fuse with lysosomes, T4 and T3 are cleaved from the thyroglobulin 
and can be secreted into the bloodstream. In the peripheral tissues, mainly the liver and the 
kidneys, a large amount of T4 is deiodinated to T3, the more potent hormone (Figure 3).
3,9 
Thyrotropin-releasing hormone (TRH), produced by the hypothalamus, and thyroid-
stimulating hormone (TSH), produced by the adenohypophysis and released into the 
bloodstream in response to TRH, are the two controlling factors of thyroid hormone 
secretion. They interact in a negative feedback system controlling serum hormone 
concentrations (hypothalamus – hypophysis – thyroid – axis). When the thyroid hormone 
concentration in the bloodstream decreases, the hypothalamus is triggered to release TRH 
into the portal system of the adenohypophysis. TSH will then be secreted and stimulates the 
thyroid gland to increase the expression of the NIS and increase the production and release 
of hormones. The reverse is also true, when the circulating thyroid hormone concentration 
increases, synthesis and release will be decreased.3,10 
Thyroid hormones are responsible for the basal metabolic regulation. They work at all levels 
of the metabolism and are known to work generally catabolic. They cause an increased 
intestinal absorption of glucose and increased glycolysis and gluconeogenesis; an increase in 
the protein synthesis and lipid metabolism. At the same time they will activate lipoprotein 
lipase and create an increased sensitivity of the adipose tissue to lipolysis, regulated by 
other hormones. They also increase the conversion of cholesterol into bile acids and other 
substances. All these processes increase the oxygen consumption and heat production of 
tissues and as a consequence the body temperature will increase. Other effects that can be 
observed are an increase in heart frequency, contraction force, cardiac output and finally 
blood flow; and an increase in neural transmission and cerebration. Thyroid hormones are 
also responsible for the development of the nervous system in young animals and normal 
growth and development in cooperation with growth hormone.3,9 
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Figure 3. Schematic representation of the thyroid hormone synthesis (DIT: diiodotyrosine; Lys: lysosome; MIT: 
monoiodotyrosine; NIS: sodium iodide symporter; PE/    : thyroid peroxidase enzyme; TGB: thyroglobulin). 
 
3. Feline hyperthyroidism 
Hyperthyroidism refers to the overproduction of thyroid hormones from abnormally 
functioning thyroid tissue and is the most common endocrine disorder in middle- to older 
aged feline patients. It was first described in the late seventies and early nineteen-
eighties.11-14 The prevalence of hyperthyroidism in cats has much increased since it was first 
reported. Increased awareness of the disease, environmental factors and better veterinary 
care most likely play an important role in this apparent increased incidence. The overall 
prevalence varies geographically from 2.4% to 11.4%, with more specifically a prevalence of 
8.7 to 11.4% in older cats. Only about 5% of hyperthyroid cats are younger than 10 years at 
the time of diagnosis.8,15-17 
 
3.1 Etiology 
The underlying factors causing hyperthyroidism in cats are unknown. Multiple factors have 
been suggested to increase the risk of development of this disease, e.g. the consumption of 
mainly canned food, an indoor lifestyle, using cat litter, sleeping on the floor gathering dust 
enriched with chemicals that may be ingested during grooming, treatment with flea 
powders, exposure to herbicides and fertilizers, and other goitrogenic substances, e.g. 
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present in soy. Other factors that might influence the disease development are the selenium 
and iodine content of the food.3,8,15,16,18-21 Some of these substances are thought to mimic T4 
and therefore stimulate cell division in the thyroid gland, increasing the risk of developing 
hyperthyroidism, although no conclusive evidence is available to support these theories.   
In humans there are two main conditions associated with hyperthyroidism. Graves’ disease 
is an autoimmune disorder where antibodies mimicking TSH, bind to the TSH receptors. The 
role of antibodies in feline hyperthyroidism has been questioned but to this day no evidence 
for a similar pathogenesis has been found.15,20,22 Gene mutations may however play a role in 
the pathogenesis.20 Feline hyperthyroidism has been found to resemble toxic nodular goiter 
in humans, also known as Plummer’s disease, a progressive disease, due to the intrinsic 
growth of autonomously functioning thyroid nodules. The initiating cause to this growth 
however is unknown.18,20 
Hyperthyroidism in cats is most commonly secondary to functional (multi)nodular 
adenomatous hyperplasia (70 - 75%) or follicular cell adenomas (20 - 25%). A combination of 
both is also possible. More rarely, in about 1-3% of the cases, a thyroid carcinoma is 
present. Adenomas are mostly small, solid nodules that compress the remaining normal 
thyroid parenchyma.  When these tumors become very large, necrosis, mineralization and 
cyst formation can occur.3,15,20,23,24 These cystic adenomas can compress surrounding 
structures and may or may not be functional.23,25   
Thyroid carcinomas are often large tumors, with areas of necrosis, hemorrhage and possible 
mineralization. They can be locally invasive, and can metastasize to the lungs and lymph 
nodes (retropharyngeal and caudal cervical lymph nodes). It has been suggested that the 
prevalence of malignancy increases with the duration of the disease.3,24,26,27 The most 
common underlying disease, adenomatous hyperplasia, is often bilateral, in about 70% of 
cases, and unilateral in about 30% of cases. Any of these underlying pathologies can also 
develop within ectopic thyroid tissue. A definitive diagnosis of the underlying disease can 
only be made by histopathology.3,15,24 
 
3.2 Diagnosis of hyperthyroidism 
The diagnostic work-up of hyperthyroidism is often based on a strong clinical suspicion. 
However, the disease may sometimes be accidentally recognized on annual health 
screenings. Most cases are diagnosed based on history, physical examination and an 
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increased serum TT4 concentration. Medical imaging may be performed, with scintigraphy 
as the most important imaging modality. Thyroid scintigraphy allows a functional evaluation 
of the thyroid gland, can be used in confirming the diagnosis of hyperthyroidism when blood 
test results are equivocal, and may be helpful in planning further treatment, either using 
radioiodine or for surgery.28-31 
 
a. Clinical features 
Clinical hyperthyroidism is the result of an increased production of thyroid hormones and 
the effect of these hormones throughout the body. As previously discussed, thyroid 
hormones have a broad range of action and consequently clinical signs are variable and 
multisystemic. Cats show a limited biliary excretion of T4 compared to dogs. Therefore, 
clinical signs will be evident even with small increases in thyroid hormone concentrations.3 
Hyperthyroidism is a disease typically seen in middle-aged to older cats. A large age range 
has been reported, from 2 to 23 years, with an average age of 12 – 13 years. A case of 
juvenile hyperthyroidism has been reported in an 8-month-old cat that had typical clinical 
signs accompanied by a palpable thyroid nodule and an increased serum T4 and T3. The 
etiology for this early occurrence of hyperthyroidism could however not be explained. There 
is no sex predilection for the disease; however, regarding breeds, some authors have 
reported an influence, with purebred cats and more specifically Himalayan and Siamese 
cats, to have a decreased risk of developing hyperthyroidism.6,9,15,32 A recent study has 
described that the prevalence of different aspects of hyperthyroidism increases with 
duration of the disease. An increased serum total T4 and T/S ratio, larger thyroid mass 
volume, an increased number of patients with multifocal disease and intrathoracic masses, 
as well as an increased risk for suspected malignancy were observed in the patients that had 
been diagnosed for the longest time.27 The most important clinical sign of hyperthyroidism is 
weight loss while preserving a good to increased appetite. Other symptoms that have been 
described are hyperactivity, an increased body temperature, aggressiveness, stress 
intolerance, altered behavior, muscle atrophy, hair coat changes, polyuria/polydipsia, 
systemic hypertension, polyphagia, vomiting, an increased frequency of defecation with an 
increased volume of stool, diarrhea, tachycardia, systolic murmurs, cardiac arrhythmias, a 
mild form of hypertrophic cardiomyopathy with longstanding disease, tachypnea, panting, 
dyspnea, palpable cervical nodule(s) and papillary dilation (Figure 4).3,8,9,12,15,20,33 
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An atypical form of hyperthyroidism, also known as apathetic or masked hyperthyroidism, 
has been observed and is associated with signs of depression and anorexia, often still 
accompanied by weight loss. It is important to keep in mind that not all hyperthyroid 
patients demonstrate the typical clinical presentation and signs may be subtle, especially in 
early stages.15,30,33 An additional part of the physical examination in cats, and especially 
when hyperthyroidism is suspected, is palpation of the thyroid gland. This is a simple and 
reliable diagnostic aid and a significant difference between normal and hyperthyroid cat 
palpation scores have been found in different studies.8,34-36 It has to be borne in mind that 
thyroid nodules may also be an incidental finding, e.g. rare nonfunctional thyroid tumors or 
thyroid cysts, so finding a nodule on cervical palpation will not always translate itself in 
hyperthyroidism. Moreover, a cervical nodule can also be of non-thyroidal origin, e.g. 
salivary gland disease, lymphadenopathy, a cervical abscess or granuloma.3,8,30,31 
 
 
Figure 4. Picture of a 14-year-old, female, hyperthyroid cat. Typical clinical features that are visible in this 
patient are a poor body condition, muscle atrophy and a poorly maintained hair coat.   
 
b. Blood tests 
Diagnosing hyperthyroidism usually starts in practice with a measurement of circulating 
total T4 (TT4). An increased TT4 is indicative for hyperthyroidism. T3 is less commonly 
measured but is also clearly increased in most hyperthyroid patients. Both are good markers 
for the disease; however T3 is not recommended as a screening test, since it lies within the 
normal reference range in about 25 to 30% of hyperthyroid cats. Both TT4 and T3 may be 
falsely low in animals with (concomitant) non-thyroidal illness.3,9,15,30,31,37,38  
Hyperthyroidism is a progressive disease that may sometimes be diagnosed in an early 
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stage, when the clinical signs are subtle and when serum TT4 measurements may, in a small 
number of cases, still be within normal limits. The opposite can also occur, when a patient 
not showing any clinical signs demonstrates a mildly elevated serum TT4 on a check-up 
blood test.3,15,30,31,37,38 To confirm true hyperthyroidism in these patients, several options 
are available. First of all, a recheck TT4 measurement can be performed 2 to 3 weeks later. A 
dynamic test such as the T3 suppression test could be performed, however this test is rarely 
used today.16,30,31,37 The serum free T4 (fT4) concentration may be of additional help in cases 
where the TT4 has not yet clearly increased or when the patient’s clinical state is doubtful, 
as it is more sensitive than a TT4 measurement. Since the fT4 increases whenever the TT4 has 
increased, it is however of little use in the more straightforward cases of hyperthyroidism. 
The fT4 concentration has a poor specificity though. The concentration of fT4 increases in 
animals with non-thyroidal illness and may even be increased in normal animals, potentially 
creating false positive diagnoses when this is the only measurement performed.6,9,15,30,31,37,38 
The method to determine the fT4 concentration is also important, with equilibrium dialysis 
being considered the gold standard. This is an expensive technique, and is not widely 
available. Other commercial techniques, like the modified equilibrium dialysis (MED) or 
analog radioimmunoassay (RIA), have shown an acceptable performance.8,30,31  
TSH is commonly measured in human medicine for diagnosing hyperthyroidism. 
Unfortunately, to this day, no TSH assay is available for feline patients however. The canine 
TSH assay may be used for cats but is not sensitive enough to differentiate all hyperthyroid 
cats from normal cats. As expected, TSH measurements are low or unmeasurable using the 
canine TSH assay in hyperthyroid cats.38 However, low or undetectable measurements are 
also seen in euthyroid patients, or patients with non-thyroidal illness. Excluding 
hyperthyroidism may therefore be a more useful aspect of this test and a TSH measurement 
should not be used as a sole diagnostic parameter.15,20,30,31,37,38 In contrast to normal cats, 
TSH stimulation will not create a significant increase in T4 or T3 concentrations in 
hyperthyroid cats, as the cells responsible for the excess hormone concentration function 
autonomously, and the surrounding thyroid tissue is suppressed and atrophied. For patients 
in an early stage, the TSH stimulation test is however not sensitive and moreover, the high 
cost of recombinant human TSH that can be used for the TSH stimulation test in cats, has 
made this test of little importance in practice.3,15,37,39 Another test that may be used is the 
TRH stimulation test. However, this test has again a limited specificity and the 
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administration of TRH is commonly accompanied by side effects, such as vomiting, 
salivation, tachypnea and defecation.16,37  
Apart from changes in serum hormone concentrations, other abnormalities may be present 
on blood test results. The most important abnormality that is commonly present is the 
increased liver enzyme activity, represented by parameters such as alanine 
aminotransferase (ALT), alkaline phosphatase (AP), and aspartate aminotransferase (AST). 
Liver function tests on the contrary are within normal limits.3,9,12,15,37,40-42 
 
4. Thyroid gland imaging 
A review of the literature on imaging of the thyroid gland in both normal and hyperthyroid 
cats is given. In contrast to scintigraphy, ultrasonography, radiography, CT or MRI are of 
little value for the diagnosis of hyperthyroidism. Although on rare occasions, when patients 
undergo imaging for non-thyroid related disease, an abnormal thyroid gland may be 
detected as an incidental finding, leading to further examinations and possibly an early 
stage diagnosis of hyperthyroidism. 
 
4.1 Ultrasonography 
Normal thyroid lobes are ellipsoid or fusiform in shape with a more rounded cranial and a 
pointed caudal pole on longitudinal plane, and they are ovoid - triangular to polygonal in 
shape on the transverse plane. The lobes have a homogeneous appearance and are mildly 
hyperechoic compared to the surrounding musculature. They are outlined by a thin 
hyperechoic capsule.43-46 Occasionally, thyroid lobes show hypo- or hyperechoic foci or 
diffuse mottling of the parenchyma.45 The size and volume of a normal feline thyroid gland 
have been reported on ultrasonography. A single thyroid lobe measures approximately 2 cm 
in length, 0.2 cm in width and 0.3 cm in height. The mean total thyroid volume is 169 mm3, 
with a mean thyroid lobe volume of 85 mm3. A significantly increased volume has been 
detected for thyroid glands of hyperthyroid cats and a fair correlation has been observed 
between the total thyroid volume and the serum T4 concentration of hyperthyroid cats.
43,46 
The parathyroid glands may be visualized on ultrasonography, adjacent to or embedded 
within the thyroid parenchyma. They are oval to round in shape, up to 3.3 mm in diameter, 
with a hypoechoic to almost anechoic appearance, and may be difficult to differentiate from 
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vessels, small cystic lesions or thyroid lobules. Their location and number may vary.44-47 
The use of ultrasonography in thyroid pathology has been described for the diagnosis of 
canine primary hypothyroidism and the differentiation from non-thyroidal illness, as well as 
for the diagnosis and work-up of thyroid cysts and neoplasia in both dogs and cats.23,44,46,48 
The ultrasonographic appearance of adenomas or adenomatous hyperplasia, causing 
hyperthyroidism in cats, may show different features (Figure 5). The thyroid lobe can be 
diffusely affected or show a discrete nodule deforming the normal outline. The lobe is 
usually increased in size, more rounded in shape, shows increased vascularization, and 
becomes hypoechoic and heterogeneous. Anechoic areas may be observed, representing 
necrosis or cystic lesions. In cats with a unilateral hyperthyroid adenoma or adenomatous 
hyperplasia, the other lobe is difficult to find or cannot be found at all.15,43-46,49 Foci of 
mineralization have also been described in a cat with suspected benign disease.49 Thyroid 
carcinomas are presented as heterogeneous, hypoechoic masses with a variable 
delineation. Mineralization within these masses as well as invasion of adjacent structures 
have been described, and local lymph nodes should be checked for metastatic infiltration.44-
46 Ectopic thyroid tissue can occur anywhere from the larynx until the level of the diaphragm 
and it is therefore important to always scan at least the entire cervical region.1-6 In a study 
comparing the diagnostic ability of ultrasonography and scintigraphy for hyperthyroidism in 
cats, a fair agreement of 85.7% was found in differentiating normal from abnormal thyroid 
lobes on ultrasonography. Despite being an excellent imaging tool and permitting 
visualization of abnormal thyroid glands, it has been concluded however that 
ultrasonography cannot replace scintigraphy as a diagnostic tool for hyperthyroidism, in 
particular for evaluating potential metastatic and ectopic lesions.43 
Ultrasonography has also been described in the follow-up of hyperthyroid cats after 
receiving radioiodine therapy, to assess the visible changes that took place. At six months 
after therapy, thyroid lobe volume had markedly decreased by approximately 75%, and 
there was a significant reduction of the rounded shape and the heterogeneity and 
vascularization of the parenchyma.49  
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Figure 5. Transverse ultrasonographic image. A diffusely affected, mildly heterogeneous, enlarged right thyroid 
lobe in a cat with hyperthyroidism. The calipers indicate the height (1: 7.9 mm) and width (2: 9.6 mm) of the 
thyroid lobe (T: trachea; arrow: common carotid artery). 
 
4.2 Radiography 
Normal thyroid glands are not visible on radiography. In case of severe thyroid gland 
enlargement this may become visible as a soft tissue mass effect in the cervical region, or in 
the mediastinal region in case of ectopic thyroid tissue pathology (Figure 6).23,50,51 However, 
radiography cannot differentiate these lesions from other soft tissue masses. When a 
thyroid carcinoma is suspected or confirmed, radiography can be used as a screening tool 
for pulmonary metastases (Figure 7). In about 50% of cats with hyperthyroidism, 
cardiomegaly can be observed on thoracic radiography, with or without secondary signs of 
heart failure. This is most commonly due to a certain degree of hypertrophic 
cardiomyopathy, or dilated cardiomyopathy in rare cases.12,15 
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Figure 6. Lateral radiograph of the cervical area of a 15-year-old cat with hyperthyroidism and a severely 
enlarged thyroid gland (star). The enlarged thyroid gland is visible as an ovoid shaped, well-defined, soft tissue 
opacity, ventral to the 3
rd
 and 4
th
 cervical vertebrae. The lesion is creating a ventral displacement of the 
trachea and is well visualized thanks to the presence of a moderate amount of gas in the esophagus 
surrounding it. Wet hair artifacts are seen superimposed onto the ventral cervical region.  
 
       
Figure 7. A) Left to right lateral projection of the thorax of a 14-year-old cat with hyperthyroidism. A large, ill-
defined, rounded, soft tissue opacity (star) is seen in the cranial mediastinum at the level of the 1
st
 – 3
rd
 
intercostal space, creating a dorsal displacement of the trachea. B) A small, pulmonary, soft tissue opacity is 
seen right to the midline on the ventrodorsal projection (VD), superimposed onto the caudal vena cava 
(arrow), and at the level of the 7
th
 intercostal space on the lateral projection. On further examination these 
lesions were found to represent a mediastinal thyroid carcinoma and pulmonary metastasis. 
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4.3 Computed Tomography 
Due to the high iodine content of the thyroid glands, these structures have a characteristic 
hyperattenuating appearance compared to the surrounding tissues on computed 
tomography (CT). The Hounsfield Units (HU) of a normal feline thyroid gland ranges around 
123.2 HU on precontrast images, around 168.5 HU immediately after intravenous contrast 
administration and around 132.1 HU with delayed contrast imaging (t = 8.6 ± 3.0 minutes). 
The thyroid glands are recognized as ovoid, homogeneous structures dorsolateral to the 
trachea, between the second and fourth cervical vertebrae (Figure 8).52-54  
CT of the thyroid glands in hyperthyroid cats shows that the oval shape of the lobe is usually 
maintained, with a smooth delineation, while being moderately increased in size. In case of 
bilateral disease the most active lobe on scintigraphy is usually the largest one detected on 
CT. The affected lobes most commonly become isoattenuating to their surrounding soft 
tissues and can show a heterogeneous appearance. Less commonly, mineralization within 
the parenchyma is observed. The loss of the normal strong attenuation has been suggested 
to be caused by an increased amount of follicular cells and interstitial tissue associated with 
a decrease in the normally high iodine concentration.55 This loss of normal thyroid gland 
hyperattenuation has also been reported in a rare case of hypothyroidism due to follicular 
hyperplasia in a 5-year-old cat.56 CT images of a hyperthyroid cat with a cystic thyroid lesion 
are illustrated in Figure 9.  
 
 
Figure 8. Precontrast transverse image (A), at the level of C3, and postcontrast dorsal (B) and sagittal plane (C) 
CT images of the thyroid gland of a normal cat (arrows). An endotracheal tube is present in the lumen of the 
trachea (star). Note the higher attenuation of the thyroid gland compared to the surrounding musculature.  
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Figure 9. Pre- (A) and postcontrast (B), transverse CT images of a 15-year-old cat with hyperthyroidism. This is 
the same cat as in Figure 4. Note the decreased attenuation of the thyroid gland parenchyma and that the 
center of the lesion is not contrast enhancing (star), suggesting a cystic thyroid lesion. This cystic nature was 
confirmed on ultrasonography (arrow: enlarged thyroid gland; T: trachea). 
 
4.4 Magnetic Resonance Imaging 
The normal size and appearance of thyroid glands on MRI has been described in dogs but 
not yet in cats.57 One case of a cystic adenoma in a cat on MRI has been reported in the 
literature. The lesion was hyperintense on T2-, proton density (PD)-, and T2-fat suppressed 
weighted images, with a fluid line and decreased signal intensity in the dependent part of 
the mass. The wall had a signal intensity similar to the surrounding soft tissues. The other 
thyroid lobe in this cat had similar signal intensities to the large mass and was found to be a 
hyperplastic thyroid gland as well on the following scintigram.25  
 
4.5 Scintigraphy 
Scintigraphy stands out as an imaging modality by providing not only anatomical but also 
functional information of the thyroid gland. One of the most routine applications of 
scintigraphy is the evaluation of thyroid function, i.e. to assess the degree of thyroid gland 
radionuclide uptake, to confirm hyperthyroidism in equivocal cases or for use in patients 
with non-thyroidal illness.  
The radionuclide mostly used in thyroid scintigraphy is 99mtechnetium (99mTc) or its chemical 
form pertechnetate (99mTcO4
-). 99mTc is obtained from a 99molybdenum (99Mo) generator 
and has a physical half-life of 6 hours. It decays by emitting electromagnetic γ-radiation of 
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140 keV, which will be detected by the NaI crystal within the gamma camera.58,59 
Another radionuclide that can be used in thyroid gland imaging is 123iodine (123I), which also 
decays by the emission of electromagnetic γ-rays (159 keV). In contrary to pertechnetate, 
123I will be organified in the thyroid gland and incorporated in the normal iodine metabolic 
pathway. It has a longer physical half-life of approximately 13 hours. The ideal imaging time 
for 123I is strongly delayed at 8 hours after injection, compared to pertechnetate that allows 
scanning from 20 minutes after injection onwards. Another major drawback of 123I is the 
high cost in comparison to pertechnetate.28,29,58,59 Although theoretically possible, another 
radioisotope of iodine, 131I, is generally not used for imaging given its longer half-life, high 
cost and inferior image quality which results from the high energy γ-photons (364 keV). 
Furthermore, 131I also emits β- particles that, given their destructive nature, are usable for 
therapeutic purposes but do not contribute to diagnostic scans.37,58 This radionuclide will be 
further addressed in the chapter about radioiodine therapy. Diagnostic scintigraphy in this 
manuscript will always refer to the use of pertechnetate. 
 
a. Protocol 
Thyroid scintigraphy is based on the ability of the thyroid follicular cells’ iodide pumps to 
trap iodide as well as pertechnetate. The pertechnetate ion has a similar size and charge as 
iodide and will be trapped by the thyroid gland, but will not be used in thyroglobulin 
organification and hormone production, nor will it be stored in the colloid fluid like iodide is. 
It will be excreted back into the bloodstream and removed from the body, mainly via the 
kidneys.28,29,58 It is important to remember that the iodide pumps are also present at the 
level of the salivary glands, the gastric mucosa, the choroid plexus, the ciliary body of the 
eye, the placenta and lactating mammary glands.3,29 More specifically, uptake at the level of 
the head is seen in the nasal cavity, the region of the nasopharynx and soft palate, and at 
the level of the zygomatic, molar, parotid and mandibular salivary glands. The major hot 
focus seen on a typical feline pertechnetate scan represents the combination of the 
zygomatic and molar salivary glands. Radionuclide uptake in the area of the mediastinum 
may represent the esophagus containing saliva, or blood pool activity in one of the large 
vessels. Therefore, uptake in these areas should not be mistaken for an abnormality.29  
The radionuclide is injected intravenously prior to the scan to allow the substance to be 
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trapped by the thyroid gland and cleared from the soft tissues. Cats will receive an activity 
of 18.5 to 148 MBq of pertechnetate, with an average of 74 MBq. Scans can be acquired 
from 20 minutes after injection onwards, with a peak uptake in feline thyroid glands seen at 
45 – 60 minutes.29,58,60 
The cat will be positioned in ventral recumbency above the gamma camera (Figure 10). The 
scan is performed using a low energy - high resolution (LEHR) collimator. Thyroid scans are 
count based, with a minimum of 100.000 counts advised. This means that the duration of 
the scan is set by a preset number of counts and therefore the time of the scan varies from 
patient to patient.28,29,58 The higher the uptake of pertechnetate in the thyroid gland (i.e. 
the higher the thyroid gland activity), the sooner the preset amount of counts is reached, 
thus resulting in a shorter scan time. On average, a diagnostic feline thyroid scan takes 1 to 
1.5 minutes. The use of different sedatives or anesthetic protocols has been described: 
ketamine, a combination of ketamine and diazepam, propofol, and the use of inhalant 
anesthetics. Cats may also be scanned awake.6,61-66 The preferred drug or ideal protocol may 
vary however from patient to patient. 
A pinhole collimator can also be used in cats, even for quantitative measurements. It gives a 
more detailed image of the thyroid gland and can often distinguish two affected thyroid 
lobes when only one is seen on the 2-dimensional planar scan, potentially missing a 
diagnosis of bilateral hyperthyroidism. An important disadvantage of the use of a pinhole 
collimator is the increased scan time due to a lower sensitivity, decreasing the tolerance to 
motion and requiring anesthesia.28,62  
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Figure 10. Picture of a hyperthyroid cat positioned for a thyroid scan. The cat is placed on the scan bed in 
ventral recumbency. The head of the gamma camera underneath the table will record the activity at the level 
of the thyroid gland. The head of the gamma camera on top is not active in this case. 
 
b. Thyroid scintigram 
Thyroid scintigraphy is the number one imaging modality in the diagnosis of 
hyperthyroidism in cats. It is sporadically used in cases of suspected post-treatment 
hypothyroidism or rarely, in case of congenital hypothyroidism. A normal thyroid scintigram 
in cats shows the two thyroid lobes as elongated, oval structures in the cervical region, 
smoothly delineated, symmetrical in size and position and with a homogeneous distribution 
of the radionuclide (Figure 11). A certain level of thyroid lobe asymmetry can be present in 
euthyroid cats.67 Ectopic thyroid tissue is less commonly seen. It has been reported to be 
present in about 3.9% of hyperthyroid cats and is typically found on the midline and 
intrathoracic, usually in the cranial mediastinum.6,29,58,60,61,68 In case of hyperthyroidism, 
several uptake patterns can be observed. The remaining normal thyroidal tissue will be 
suppressed to a degree, depending on the serum T4 concentration and subsequent TSH 
suppression. In truly unilateral disease, the normal thyroid lobe should be entirely 
suppressed and not visible on the scintigram. In hyperthyroid cats that are not under any 
form of treatment for hyperthyroidism, a normal looking thyroid lobe, aside a hyperactive 
lobe with marked increased radionuclide uptake is considered to be abnormal and indicates 
that this lobe is also functioning autonomously. Multifocal nodular hyperplasia or 
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adenomatous hyperplasia may show different features on the scintigram: an increased 
radionuclide uptake, homogeneous radionuclide uptake, smooth margins, and this bilateral 
in about 70% of the cases. With the help of a pinhole collimator, an enlarged, more detailed 
image of the thyroid gland can be obtained and the (multi)focal appearance may be better 
observed. In case of cystic adenomas, the area of the cyst may be seen as a photopenic 
region, i.e. no accumulation of pertechnetate. When hyperactive nodules form a linear 
alignment rather than affecting the entire thyroid lobe, a “string of pearls” pattern can be 
seen. Carcinomas are described as large areas of multifocal increased uptake, with a 
heterogeneous uptake pattern, irregular margins, and radionuclide uptake extending 
beyond the normal contours of the thyroid lobes (Figure 12). A linear, multifocal pattern 
may indicate metastatic extension along the fascial planes, or uptake in ectopic thyroid 
tissue. The thorax can be included in the scanned area to search for pulmonary 
metastases.6,25,29,58,60 
In a recent study including 2096 hyperthyroid cats, the scintigraphic patterns of uptake were 
categorized and their percentage of occurrence was recorded as follows: 31.7% had 
unilateral disease, 50.6% had bilateral-asymmetric disease (two thyroid lobes of unequal 
size), 12.3% had bilateral-symmetric disease and 3.9% had multifocal disease, defined as 3 
or more areas of increased uptake. Finally, 1.6% of the cats had a pattern not fitting into one 
of these categories. The most common location for foci of increased uptake was the cervical 
area (98.1%), followed by the thoracic inlet (13.5%) and the thoracic cavity (5.5%). A pattern 
consistent with thyroid carcinoma was seen in 1.7% of the hyperthyroid patients.6 It is 
important to note that carcinomas may show benign scintigraphic characteristics and vice 
versa. A reliable differentiation between benign and malignant thyroid tissue can therefore 
not be made based on the scintigram.29,68,69  
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Figure 11. Thyroid scan of a normal cat. The same image is presented in A and B. Image B shows the different 
regions of interest (ROI) typically drawn on a thyroid scan: thyroid lobe (1), salivary gland (2), background ROI 
in the axillary region (3), background ROIs in the cervical area (4). (L: left). 
 
 
Figure 12. Thyroid scans of two cats with hyperthyroidism. The cat in A shows the typical image of a 
unilaterally affected hyperthyroid cat. The scan shows no features suggestive of malignancy. The cat in B 
shows an excessive uptake of radionuclide over an area that is far more extensive than the normal contours of 
the thyroid lobes. The uptake pattern is multifocal and heterogeneous. This patient also showed severe clinical 
signs of hyperthyroidism and thoracic X-rays demonstrated the presence of multiple pulmonary nodules, 
compatible with metastatic disease (L: left).   
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c. Quantitative thyroid scintigraphy 
The uptake of radionuclide in the thyroid gland is proportional to its metabolic activity, 
therefore quantification of this uptake has been found to be a good assessor of thyroid 
activity. However, when evaluating quantitative parameters, it has to be borne in mind that 
several substances can interfere with the uptake by the thyroid sodium iodide symporters 
(NIS) and consequently with the uptake of pertechnetate or radioiodine. Examples are 
competitive anion inhibitors (perchlorate, thiocyanate), sedatives and anesthetic 
medication, certain plants, thyroid hormone supplementation, the amount of dietary iodine, 
the administration of medicine, such as sulfonamide, phenylbutazone and antithyroid drugs 
(methimazole, carbimazole) or iodinated contrast media, e.g. iohexol.3,9,29,37,70-73   
The radionuclide uptake can be easily and reliably assessed visually, but to assess the uptake 
in a more objective quantitative manner, semi-quantitative ratios have been introduced. 
Commonly used is the thyroid to salivary gland ratio (T/S), a reproducible and reliable 
parameter.74 Regions of interest (ROIs) will be drawn around the thyroid lobes and the 
ipsilateral salivary glands (Figure 11). The ratio of the mean counts of these ROIs is then 
calculated. The normal T/S ratio in cats varies in the literature, with a range from 0.48 up to 
1.9.6,28,29,58,61,63,64,70,72,74,75 The T/S ratio increases up to 20 minutes after injection of 
pertechnetate.63 It has further been demonstrated that the T/S ratio will not significantly 
change within a time range of 20 minutes to 2 hours after the injection of pertechnetate; 
this is therefore a reliable time range to perform the thyroid scans.29,70,71 The T/S ratio of the 
most active thyroid lobe or an average ratio of both lobes has been reported to be a simple 
method and good representation of the metabolic thyroidal status, correlating with the 
serum T4 concentration both in normal and hyperthyroid cats at 20 minutes after tracer 
injection.6,63,71,76 Cats with only mildly elevated T4 concentrations may show T/S ratios 
overlapping with the normal range and with the large range of normal values reported, a 
cut-off T/S ratio value of 2 has been suggested as being both sensitive and specific for feline 
hyperthyroidism.71,74 In a more recent study including 2096 cats, a lower cut-off value of 1.5 
was proposed.6 
Another ratio that has been introduced is the thyroid to background ratio (T/B). This ratio is 
independent of potential salivary gland disease and variation in uptake. The T/B ratio is 
calculated in a similar way to the T/S ratio, using the average counts of two ROIs, one 
around the thyroid lobe and the second one at the level of the shoulder or axillary region, 
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with a size similar to the thyroid ROI or using a fixed-size ROI (Figure 11). The normal T/B 
ratio has a wider range, from 1.6 to 6.4.6,29,60,61 A correlation with the serum T4 has also 
been observed for the T/B ratio and a cut-off value of 6.1 has been proposed to be highly 
sensitive for the diagnosis of hyperthyroidism. However, the sensitivity of the T/S ratio has 
been found to be still slightly higher.6 Persistent post-therapy hyperthyroidism has been 
correlated to the T/B ratio, and cut-off ratios of ≥ 5.8 (> 148 MBq) and ≥ 11 (259 MBq) have 
been suggested by the authors to increase the dose of radioiodine.77 
Whether the thyroid gland image, the T/S ratio and T/B ratio change with age is not certain. 
In one study these features were found to be similar between two age groups; however, the 
age range of the young adult group was not mentioned in the study, the ages of the group 
of older cats ranged from 9 to 11 years. Another limitation of that study was the low 
number of patients included (n=10).61  
A single study reported the potential role of the thyroid:thyroid (T:T) ratio in the diagnosis 
of hyperthyroidism. The T:T ratio refers to a lobe to lobe ratio, where the value of the most 
active thyroid lobe is divided by the value of the less active lobe. The T:T ratio in normal, 
euthyroid cats has been found to range from 1 to 2.1 (median 1.2), whereas in hyperthyroid 
cats, the T:T ratio ranges from 1.1 up to 12.6 (median 2.5). A cut-off value of 1.5 has been 
suggested to be a good differentiator between normal and hyperthyroid cats, but the 
interpretation has to be made with care, since the T:T ratio has shown that some 
asymmetry, although less commonly, may occur in normal cats as well.67  
Finally, a quantitative parameter, the percentage of the injected radionuclide that is 
accumulated by the thyroid gland, can also be calculated. When radioactive iodine is used 
for this quantification, this is called a RadioActive Iodine Uptake study (RAIU). This study can 
be performed using 123I or 131I. The uptake of 131I in normal cats has been shown to be 
variable in time, with 33% of the injected activity in the thyroid gland at 1 hour after 
injection, 21% between 4 and 24 hours after injection and 18% remaining at 48 hours after 
injection.75 In the past, these tracer studies were used for dose determination for 
therapeutic purposes.78 The percentage of radionuclide uptake by the thyroid gland can also 
be calculated using the safer technetium pertechnetate, as % technetium uptake or % 
thyroid uptake (%TcU). The normal %TcU ranges in the literature from 0.25 to 
3.9%.29,62,63,72,79 In hyperthyroid cats a correlation between the serum T4 and T3 and the 
%TcU at 20 minutes after injection of pertechnetate has been reported.62,71  The mean %TcU 
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at 20 minutes after injection has been determined in hyperthyroid cats to be 7%, with a 
large range of 0.7 up to 61%.62,63,71 In contrast to the T/S ratio, the %TcU still increases in 
normal and hyperthyroid cats up to 4 hours after injection, and a significant difference has 
been reported in hyperthyroid cats between a quantification at 20 minutes and at 60 
minutes after injection.70,71 This has been contradicted in an earlier study, in which the 
maximum uptake was seen at 1 hour after injection, therefore considered the ideal imaging 
time, followed by a decrease in %TcU, in both normal and hyperthyroid cats.79 However, 
different measurement techniques were used in the evaluation of the percentage 
technetium uptake in these studies, which could explain the different findings. The use of 
these (semi-)quantitative parameters lies in a more complete evaluation of the disease 
status of the patient and in patient-based dosimetric calculations for radioiodine treatment, 
as opposed to a fixed dose strategy. 
Diagnostic pertechnetate scans have also been used to estimate thyroid gland volume in 
hyperthyroid cats, and different formulas have been proposed to approach the true volume. 
The total thyroid volume estimated on scintigraphy in hyperthyroid cats ranges from a 
minimum of 1089 mm3 to a maximum of 28400 mm3, whereas thyroid lobe volume has 
been described to range from 113 to 29157 mm3.65,66,80 
None of the hereinabove described methods is ideal to diagnose and evaluate 
hyperthyroidism. The serum T4 concentration, as well as the T/S or T/B ratio on scintigraphy 
may fall within the normal reference range in cats with hyperthyroidism. However, the 
sensitivity of both semi-quantitative ratios has been reported to be superior to the 
measurement of the serum T4 concentration, allowing an earlier detection of the disease.
6,20 
It is therefore important to combine tests when there is a strong clinical suspicion of occult 
or mild hyperthyroidism. 
 
5. Radioiodine (131I) therapy in hyperthyroid cats 
Four treatment options are available for cats with hyperthyroidism: the use of radioactive 
iodine, medicinal treatment (methimazole, carbimazole), dietary adjustments and surgery 
(thyroidectomy), each one having its own advantages and disadvantages. Medicinal 
treatment means daily pilling and potential adverse side effects on other organs systems. 
Dietary adjustments, in the form of low iodine diets, have also been proposed for the 
management of hyperthyroidism. A specifically commercially developed food for this 
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purpose is Hill’s® Y/D Prescription Diet. To this day, no long-term follow-up studies are 
available assessing these diets however. A very strict diet is required, as other foods and 
treats might contain a lot of iodine, and similar to antithyroid medication the underlying 
pathology will not be cured. This may result in an increased risk for malignant 
transformation secondary to continuing and therefore prolonged disease duration.8,27,73,81 
Surgery is an invasive procedure, holds an anesthetic risk in patients like these that often 
suffer from concurrent cardiac or renal disease, and recurrence of disease occurs when not 
all thyroid tissue has been removed, especially when unresectable ectopic tissue is present. 
Another potential complication is the inadvertent removal of parathyroid tissue, with 
hypoparathyroidism as a consequence. Radioiodine treatment has evidently also some 
drawbacks, such as the need for appropriate equipment, infrastructure and licenses, and a 
relatively long hospitalization period that varies between institutions depending on national 
radioprotection regulations, ranging from 5 days to several weeks after treatment. On the 
other hand, in cats of which their health status allows so, radioiodine therapy is a safe, easy 
and permanent solution in most cases and does not require a long anesthesia.15,20,82,83 
Radioiodine therapy has also been reported to be associated with a significantly longer 
survival time compared to the use of medicinal treatment only.84 Cats treated with 
radioiodine show an increased median survival time of 2 years compared to cats treated 
with methimazole. Cats that were treated with a combination of methimazole followed by 
radioiodine showed an extra median survival time of 3.3 years compared to those treated 
with methimazole only.84 Today, if the patient’s condition allows so, radioiodine is the 
therapy of choice in the majority of cases.  
 
5.1 Radioiodine therapy 
The radionuclide used for therapy is 131I. It differs from 123I by emitting not only γ-rays (364 
keV), but also the therapeutic β- particles. It has a physical half life of 8.06 days and is 
excreted mainly by the kidneys, saliva and feces. Radioactive iodine is treated by the body in 
the same way as non-radioactive iodine, and will be trapped by the follicular cells of the 
thyroid gland and organified. Thyroid gland uptake of iodine may be influenced by the same 
factors that influence technetium uptake, i.e. antithyroid drugs, alimentary iodine, contrast 
media and iodine based surgical solutions.58,85,86 When the 131I decays, it will emit its high 
energy, mostly in the form of β- particles, for 90% in a radius of ± 1 mm with a maximum 
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travel distance of 2 mm and an average path length of 400 µm. This will create destruction 
of tissues in the immediate vicinity, sparing surrounding structures like the external 
parathyroid glands. Due to the low TSH concentration in hyperthyroidism, the functionality 
of normal thyroid tissue will be suppressed and this tissue will therefore not concentrate the 
radioactive iodine. The remaining 10% of the local radiation is γ-radiation, which can be 
used for imaging purposes.18,20,58,85,87 As expected a significantly increased uptake and 
higher turnover of radioiodine is seen in hyperthyroid cats versus euthyroid cats. The peak 
uptake in normal cats is at 48 hours after injection (20.6%), whereas in hyperthyroid cats the 
maximum uptake is faster and occurs around 24 hours (56%). In hyperthyroid cats, the 
uptake can range up to 87.7%.88 Another study described a different uptake pattern after 
oral administration of radioiodine in euthyroid cats, with a mean uptake of 33% at 1 hour 
after injection, followed by a decline to 18% at 48 hours.75 
In hyperthyroid cats on antithyroid medication, pertechnetate uptake has been seen in 
thyroid tissue that was suppressed on scintigraphy prior to drug administration. Radiation of 
this normal thyroid tissue could lead to an increased incidence of post-therapy 
hypothyroidism.71 It is therefore generally advised to discontinue antithyroid medication 
prior to radioiodine therapy. The time of discontinuation however varies from institution to 
institution, and depends on whether the patient’s clinical condition allows a prolonged time 
off medication. A time range of 4 to 14 days has been reported in the literature.6,80,89-92 
Although the recommendation to stop antithyroid medication is generally accepted, little 
research has been done on the effect of antithyroid medication on radioiodine therapy. The 
studies that have been performed are difficult to compare and show contradicting results. 
Today, the ideal time to stop the medication before radioiodine administration is still not 
known. Antithyroid medication does not work directly on the NIS but inhibits the synthesis 
of thyroid hormones.93 In normal, euthyroid cats, an increased uptake of pertechnetate and 
radioiodine was seen during methimazole treatment and a so called “rebound effect” was 
also reported. This means that an increased uptake of radioiodine was observed after 
stopping antithyroid medication. The uptake was most significantly increased 4 to 9 days 
after the withdrawal.70 However, the cats in this study showed a subnormal serum T4 
concentration before discontinuation. Also in hyperthyroid cats recent discontinuation of 
antithyroid drugs has shown to influence radioiodine uptake.78 At our institution, a 
withdrawal period of 14 days is recommended. If the patient’s condition does not allow this, 
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then a withdrawal period of 3 days is generally advised in an attempt to avoid a possible 
maximal increased uptake due to a rebound effect. 
Regarding radioiodine dose estimation, different protocols can be found in the literature. 
Scoring systems have been proposed, based on the severity of clinical signs, pre-therapy 
serum T4, size and number of thyroid nodules, and the patient’s body weight. The 
radioiodine dose can also be estimated based on the total thyroid volume or thyroid gland 
weight, on the T/B ratio or on RAIU tracer studies. Finally, another possible method is a 
fixed empirical dose system.58,76-78,80,85,87,89-92,94,95 The empirical dose that is advised is 148 to 
185 MBq for adenomas or adenomatous hyperplasia, administered by intravenous or 
subcutaneous injection. Both routes of administration have been found effective, without 
side effects and with a similar final outcome.85,87,90,91,95 
The ideal method of dose estimation has not yet been determined, although most methods 
seem to be effective for a positive treatment outcome. Oral administration of radioiodine 
has also been reported, using slightly higher doses in the form of capsules. The major 
disadvantage of oral administration is the high risk of spilling, increasing the exposure of 
personnel and potentially contaminating the premises, as cats may not always be 
cooperative. Additionally, the hospitalization period for these patients is longer due to the 
higher activities of radioiodine that are being used (200 – 300 MBq).96 Activities used for the 
treatment of thyroid carcinomas are 3 to 10 times higher than for benign disease, typically 
reported around 1110 to 1480 MBq and administered intravenously.68,69,85 
In case the patient remains hyperthyroid the treatment can be repeated. Radioiodine is well 
tolerated, even in higher doses. The only important complication reported in cats is the 
induction of iatrogenic hypothyroidism. One study also reported a transient voice change in 
one cat, while another study reported a transient period of swallowing difficulties, 
presumably induced by radiation thyroiditis.91,94 After radioiodine therapy, control scans can 
be performed to confirm sufficient uptake. When a thyroid carcinoma is suspected or 
confirmed, follow-up scans are advised at 4 to 6 weeks after radioiodine therapy and then at 
a 3 to 6 months interval to ensure tumor regression or detect potential tumor recurrence.85 
The effect of radioiodine on the serum T4 concentration occurs rapidly. The most rapid 
decrease is seen the first 3 to 6 days after treatment.97 Fifty-five percent of patients were 
shown to have a normal serum T4 concentration 4 days after treatment, 74% was reached 
after 8 days and 83% had normal a serum T4 concentration by 1 month post-therapy.
97 
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Follow-up of the serum T4 concentration may at first show a marked decreased value, below 
the normal reference range, without any clinical consequence. This transient post-therapy 
hypothyroidism is presumed to represent the time when normal thyroid tissue, previously 
suppressed, starts to regenerate and slowly starts functioning normally again. With a small 
delay, the T4 concentration then restores itself to normal values in most cases. Regular 
monitoring is therefore useful, and more importantly, a final control blood test should not 
be performed too early after treatment. Waiting 6 months is often advised; however the 
ideal time for a recheck after treatment is unknown and may vary from patient to 
patient.87,90,91,95 Given the negative effect of a decreased thyroid function on renal function, 
it may be indicated to start thyroid supplementation before 6 months after therapy.98-103 In 
these cases it is also important to exclude possible non-thyroidal illness and make a good 
but often difficult diagnosis of true hypothyroidism.15,37,104,105 
When dealing with radioactive substances it is clear that certain safety measures must be 
taken into account. Diagnostic pertechnetate scans and radioiodine therapy are only 
performed in specifically equipped centers working with trained personnel. Cats that have 
been treated with radioiodine are held in isolation for a time that varies between 
institutions and countries. In our facility the hospitalization time is typically 5 days. When 
these cats are discharged from the hospital, they are considered a source of radioactive 
radiation and the owner will receive instructions to minimize radiation exposure for a 
certain period of time after the discharge. Safety precautions include limited contact with 
the cat, no contact between the cat and children or pregnant women and the safe collection 
and storage of the cat litter and feces.82,83,85 
 
5.2 Radioiodine therapy outcome 
Radioiodine therapy is generally considered a very effective treatment with a success rate 
ranging in literature from 70 to 95%.58,77,80,87,89-92,95-97 The definition of a successful therapy 
is however not always clearly defined and could refer to the resolution of clinical signs, as 
well as a serum T4 concentration within the normal reference range, or the combination of 
both. Some studies therefore include cats that are (sub)clinically hypothyroid in their 
successful group. The median time of follow-up also ranges widely from 1 to 18 
months.77,80,89-92,95,97 Several factors influencing and/or predicting radioiodine therapy 
outcome have been suggested but overall, little research has been done on this subject in 
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cats and results are often contradicting. In one study, iohexol, an iodinated contrast medium 
commonly used in radiography and CT, was surprisingly not found to have any significant 
impact on the outcome when given 24 hours prior to treatment, despite clearly decreased 
thyroid absorption of the radioiodine. However, the dose of iodine (iohexol) administered in 
this study for glomerular filtration rate (GFR) measurements in hyperthyroid cats, was lower 
than the dose normally used for contrast studies. Moreover, only a relatively small group of 
cats was included precluding definite conclusions.86  The pre-therapy serum T4 concentration 
has been observed to correlate to post-therapy T4 measurements, but not to a degree 
where it could predict therapy outcome.76,77 In earlier studies however, higher pre-therapy 
serum T4 concentrations have been suggested to increase the risk of persistent 
hyperthyroidism.80,91 The age at the time of diagnosis has been included in one study but 
the authors did not see an effect on therapy outcome.106 Two semi-quantitative ratios, the 
T/S ratio and the T/B ratio, have also been investigated. An increased T/S ratio has not been 
found to increase the risk of persistent hyperthyroidism.76,77 In contrast, one study has 
reported on the relationship between therapy outcome and the T/B ratio, and significantly 
higher T/B ratios were noted in cats that showed persistent hyperthyroidism after 
radioiodine therapy. The authors suggested that the T/B ratio could predict therapy failure 
or alarm clinicians to increase the administered dose of radioiodine.77  
As aforementioned, the administration of antithyroid medication may alter the uptake of 
radioiodine by the thyroid gland but the ideal time to discontinue drugs before radioiodine 
therapy has not yet been determined.70,71,78 The use of antithyroid medication prior to 
radioiodine therapy and the timing at which antithyroid medication is discontinued have 
been reported not to influence radioiodine therapy outcome.76,80,91,106 However, the timing 
of discontinuation prior to radioiodine treatment varies widely among these studies, and 
therefore these results are difficult to compare.  
Regarding the number of affected thyroid lobes or the uptake pattern on scintigraphy no 
significant relationship with a persistent hyperthyroid outcome has been found for the 
presence of ectopic tissue, or bilateral versus unilateral disease.80 On the contrary, Nykamp 
et al. (2005) observed a significant effect of bilateral disease towards a hypothyroid 
outcome, with an almost doubled increased risk of post-therapy hypothyroidism in patients 
with bilateral disease.92 Thyroid gland volume, estimated on diagnostic pertechnetate scans, 
has also been suggested as a factor influencing radioiodine therapy outcome. Larger total 
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thyroid volumes have been reported to increase the risk of persistent hyperthyroidism after 
treatment; however no cut-off values have been determined.66,80,91 Finally, neither the dose 
of radioiodine administered, the peak level of radiation to the patient, nor the rate at which 
radiation measured at the level of the thyroid surface decreased, were found to affect 
radioiodine therapy outcome.106 However, the route of radioiodine administration may play 
a role. As mentioned before, intravenous and subcutaneous administration of radioiodine 
show similar success rates.87,90 On the contrary, Forrest et al. (1996) suggested that oral 
administration of radioiodine is less successful than the intravenous route.80 
Although in human medicine more studies are available, there is also no complete 
consensus on which factors reliably affect or predict radioiodine therapy outcome. Possible 
factors that have been put forward are the severity of the disease, gender, thyroid gland 
echogenicity and volume, the presence of autoantibodies, the %TcU prior to therapy, 
radioiodine dose and uptake, radioiodine turnover rate, prior antithyroid medication and its 
withdrawal time and finally the etiology, which varies more in humans than in cats, may also 
play a role.107-121  
 
6. Conclusion 
Although hyperthyroidism is a well-recognized disease in cats and radioactive iodine is 
generally the therapy of choice with a good outcome in most cases, the inconveniences for 
the patient and its owner, associated with therapy failure, are real. Research on scintigraphy 
and radioiodine therapy in cats is relatively limited compared to human medicine and given 
the number of years scintigraphy is already being used in veterinary medicine. In particular, 
research on identifying causes for therapy failure is scarce in feline medicine. Identifying 
those factors that could predict or influence radioiodine therapy outcome may help in 
optimizing protocols to determine the dose of administered radioactive iodine and 
consequently further improving therapy outcome.  
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Radioiodine therapy is commonly used since many years to treat hyperthyroidism in cats 
and shows a good outcome in most patients. The diagnosis and assessment of disease 
severity is mainly based on measuring the serum TT4 concentration, sometimes combined 
with parameters that are evaluated on pre-therapy pertechnetate scans. While some clinics 
use a fixed dose of radioiodine, factors such as thyroid volume and the degree of thyroid 
activity on pre-therapy scans can also be used in the radioiodine dose determination. 
Although radioiodine therapy has a good outcome in most patients, the underlying reasons 
for treatment failure are still unknown. Multiple factors that may increase the risk for 
therapy failure have been proposed in human and, to a lesser extent, in feline medicine. 
Factors related to the severity and extension of the disease, such as the serum TT4 
concentration, thyroid volume, the T/B ratio, unilateral versus bilateral disease, and the 
route of radioiodine administration have been taken into consideration with regard to 
therapy outcome. 
The aims of this thesis were to investigate several thyroid related (semi-)quantitative 
parameters, with emphasis on those obtained from the pre-therapy pertechnetate scan, 
which may be involved in the outcome of radioiodine therapy. Identifying factors that may 
influence or predict radioiodine therapy outcome could help further optimize treatment 
protocols and consequently improve therapy outcome.  
1. In some cases the disease is mild and both imaging and serum thyroid hormone 
concentrations may be inconclusive. Moreover, little is known about the intra-
individual fluctuations of thyroid hormones and the different scintigraphic 
parameters calculated on the pertechnetate scan. These fluctuations might become 
important when evaluating borderline cases. The aim of this first study was to 
evaluate physiological fluctuations over time of commonly used thyroid hormones 
and scintigraphic parameters in healthy cats.  
 
2. The diagnosis of hyperthyroidism is often based on a combination of clinical signs, 
serum thyroid hormone concentrations and the pertechnetate uptake registered in 
the thyroid gland. Regarding the thyroid pertechnetate scan, several parameters to 
assess disease severity can be calculated and these parameters are being used in the 
determination of radioiodine dosages. However, information on the reliability of 
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these parameters performed by different observers and at different occasions is 
scarce. The aim of this study was to investigate inter- and intraobserver variability of 
scintigraphy based parameters commonly used in the diagnosis and evaluation of 
hyperthyroidism.  
 
3. As disease severity has been reported as one of the factors that might influence the 
outcome of radioiodine therapy, the aim of this study was to evaluate the predictive 
value of several (semi-)quantitative thyroid scintigraphic parameters, that are 
representative of thyroid gland activity, on radioiodine therapy outcome in 
hyperthyroid cats. 
 
4. Apart from disease severity, also thyroid gland volume has been described as a 
factor to evaluate disease severity, to aid in radioiodine dose determination and 
which has been suggested as a factor contributing to the effect of radioiodine 
therapy outcome. In contrast to human medicine, no efforts have been made to 
refine formulas for volume calculations on pertechnetate scans specifically for cats. 
In this study a number of formulas were tested to assess their value for feline use. 
 
5. In the final study we evaluated whether total thyroid volume, using a formula 
designed specifically for cats, could influence radioiodine therapy outcome. 
 
 
  CHAPTER 1 
 
61 
 
 
 
 
 
 
 
 
CHAPTER 1 
Week-to-week variation of total thyroxine, thyroid stimulating 
hormone and scintigraphic thyroid (semi-)quantitative parameters 
in 14 healthy experimental cats. 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Volckaert V, Vandermeulen E, Stock E, Duchateau L, Hesta M, Daminet S, Saunders JH, Dockx R, 
Peremans K. Week-to-week variation of total thyroxine, thyroid stimulating hormone and 
scintigraphic thyroid (semi-)quantitative parameters in 14 healthy experimental cats. Submitted to 
Journal of Feline Medicine and Surgery 
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Summary 
The diagnosis of hyperthyroidism relies mostly on the measurement of thyroid hormones. 
Confirmation of the diagnosis in less straightforward cases can be done with the help of 
thyroid scintigraphy. The aim of this study was to investigate whether a week-to-week 
variation of thyroid hormone levels and scintigraphic parameters exists in healthy cats of a 
magnitude that is clinically relevant, as this could lead to misinterpretation of results. 
Fourteen adult, healthy, experimental cats were included in the study. At 3 time points, with 
7-day intervals, the cats underwent a thyroid pertechnetate scan and blood samples were 
collected to measure total T4 and TSH. The scintigraphic parameters that were calculated 
were the T/S ratio, the T/B ratio, the percentage technetium uptake in the thyroid glands 
(%TcUT) and additionally the percentage technetium uptake in the salivary glands (%TcUSG). 
All scintigraphic parameters, with the exception of the %TcUT and the T/Bneck ratio, were 
within the normal reference ranges reported in literature. A single total T4 value and seven 
TSH values were found outside the reported reference ranges over the 3-week period. No 
clinically relevant week-to-week variation was observed for any of the parameters included 
in this study. 
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1. Introduction 
Despite the common occurrence of hyperthyroidism in cats the diagnosis is not always 
straightforward. Currently, the diagnosis is usually based on blood work and scintigraphy 
may be used as an aid in confirming the diagnosis when blood tests are inconclusive.1,2 Total 
thyroxine (TT4) and thyroid stimulating hormone (TSH) are two serum parameters used in 
the evaluation of thyroid function in cats. However, the results of the blood work may be 
inconclusive as not all patients with hyperthyroidism show abnormal values.1,2 Serum levels, 
especially of hormones, such as ACTH, cortisol, α-MSH and thyroxine, can vary in time.3-7 
Daily fluctuations in thyroid hormone concentrations have been described in both healthy 
and hyperthyroid cats; in normal dogs thyroxine concentrations have been shown to 
fluctuate episodically but without a predictable pattern within a 25-hour period.3,4,8,9  
While commonly used in dogs, little is known about TSH in cats and a feline specific TSH 
assay is not available today. It is therefore advised not to use TSH in practice as a single 
diagnostic parameter for hyperthyroidism but either to help confirm or exclude 
hyperthyroidism when TT4 is equivocal, or as an aid in confirming true iatrogenic 
hypothyroidism after radioiodine treatment as opposed to sick euthyroid syndrome.10-12 
Wakeling et al. (2011) reported that in normal cats, TSH values were fluctuating in and out 
of their assay’s detectable range. This was later confirmed by Peterson et al. (2015) where 
30% of the older, euthyroid cats were found to have immeasurably low TSH values, despite 
being euthyroid, emphasizing that TSH should not be used as a single diagnostic parameter.  
Thyroid scintigraphy, when available, can be used as a second step for further patient work-
up.1,2 Different (semi-)quantitative scintigraphic parameters, such as the thyroid to salivary 
gland ratio (T/S), thyroid to background ratio (T/B) and percentage technetium uptake 
(%TcU), have been described to assess thyroid function. Normal values for these parameters 
have been reported extensively, however nothing has been reported on their individual 
variation in time.13-23  
The goal of this study was to assess the week-to-week variation of TT4, TSH and scintigraphic 
(semi-)quantitative parameters routinely used to evaluate thyroid disease, in adult healthy 
cats, as significant fluctuations could potentially lead to misinterpretation of results. 
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2. Materials and Methods 
With approval of the local ethical committee (EC 2014/148), 14 European shorthair cats, 3 
male neutered and 11 female neutered, were included in this study. Their median age was 7 
years and 4 months (range 3 years 11 months – 14 years 1 month) and 8/14 cats were > 7 
years old. Their median weight was 3.3 kg (range 2.05 – 3.8 kg). All cats received a thorough 
physical exam including a cervical palpation for the detection of enlarged thyroid glands, 
and a complete blood work and urine analysis on two occasions with a two-month interval 
just before the study, to confirm a normal health status. All cats were on commercial foods 
prior to and during the study. Nine cats were on a light diet (Adult Light Chicken Dry, Hill’s®), 
four cats received optimal care (Optimal Care Chicken Dry, Hill’s®) and one cat was on a 
hypo-allergenic diet (Hypo-allergenic feline Dry, Royal Canin®).  
The cats underwent thyroid scintigraphy and blood sampling at 3 points in time with a 7-day 
interval. At every time point a catheter was placed in one of the cephalic veins. Blood was 
sampled from the jugular vein or acquired via the venous catheter if possible. The cats were 
then injected with an activity of 74 MBq of sodium pertechnetate (99mTcO4
-). Thyroid scans 
were acquired precisely 30 minutes after injection. To perform these scans the cats were 
anaesthetized with propofol (4–8 mg/kg to effect, IV, Propovet; Ecuphar, 10 mg/ml). A 
single static count based image (200 kcounts) was acquired with the cats positioned in 
ventral recumbency, on a gamma camera equipped with a low energy high resolution 
(LEHR) collimator (GCA 7200 A; Toshiba). Matrix size was 256 × 256 and the pixel size was 
0.1 cm. A syringe containing a small known amount of sodium pertechnetate was scanned 
simultaneously with each cat for the calculation of the percentage injected activity uptake in 
the thyroid and salivary glands ('standard'). Scan processing was performed by a single 
observer (VV), using multimodality software (Hermes V5.0; Nuclear Diagnostics AB). 
A total of 14 regions of interest (ROIs) per scan were placed on the image to calculate the 
following parameters: 1) T/S ratio (left and right), 2) T/B ratio (left and right, using 3 
different background ROIs), 3) percentage technetium uptake in the thyroid glands (%TcUT) 
(left and right, using 3 different background ROIs), 4) percentage technetium uptake in the 
salivary glands (%TcUSG) (left and right) (Figure 1). Of these 14 ROIs, 5 were drawn manually: 
one over the standard, one over each thyroid lobe and one over each salivary gland. Three 
different background ROIs were investigated for background correction: fixed-size circular 
ROIs were placed in each axillary region (T/Bcircle/TcUT circle); 2 fixed-size rectangular ROIs 
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were placed in the cervical area, cranial and caudal to the thyroid glands (T/Bneck/TcUT neck), 
and thirdly a copy image of each thyroid lobe ROI was placed in the axillary region (T/Bcopy 
ROI/TcUT copy ROI). A copy image of the standard ROI, required for the calculation of the %TcU, 
was placed as a background ROI (room activity) as far away as possible from the standard or 
the cat. The T/S ratio and T/B ratio were calculated using the mean counts per pixel for each 
ROI. For the T/B ratio this was calculated with each of the three previously described patient 
background ROIs. The %TcUT was calculated using the same three background ROIs. Copy 
image ROIs of both salivary glands were used for background correction in the calculation of 
the %TcUSG. For each of the scintigraphic parameters the mean of both thyroid lobes and 
salivary glands was calculated. 
Total thyroxine concentration measurements were performed using a canine TT4, solid-
phase, chemiluminescent competitive immunoassay (IMMULITE 2000, Siemens Healthcare 
Diagnostics®). The normal reference range for the TT4 was 14.19 – 45.15 nmol/l. TSH was 
measured with a canine TSH, solid-phase, enzyme-labeled, chemiluminescent 
immunometric assay (IMMULITE 2000, Siemens Healthcare Diagnostics®). A normal 
reference range for TSH in cats is not available as a canine assay is used and the 
quantification is limited to a lower reference of 0.03 ng/mL. An upper reference value has 
not been determined in the laboratory that was used in this study. 
The within and between cat variance was estimated by a restricted maximum likelihood 
approach. The variance components were used to derive 95% reference ranges for within 
cat and between cat assessments. The within cat 95% reference range contains 95% of the 
repeated values of one cat. The between cat 95% reference range contains 95% of the 
values of different cats. The reference ranges are constructed around the overall mean of 
the parameters.  
 
  CHAPTER 1 
 
67 
 
 
Figure 1. Illustration of the different regions of interest (ROIs). To improve image processing and delineation of 
thyroid and salivary glands from soft tissue background activity, the standard was initially masked, and then 
placed back onto the image in box A to illustrate. 1) standard ROI, 2) background ROI for the standard, 3) left 
thyroid lobe ROI, 4) copy of the left thyroid lobe ROI as a background ROI in the axillary region, 5) fixed-size 
circular ROI in the axillary region superimposed onto 4), 6  + 7) fixed-size rectangular ROIs in the cervical 
region, 8) right thyroid lobe ROI, 9) copy of the right thyroid lobe ROI as a background ROI in the axillary 
region, 10) fixed-size circular ROI in the axillary region superimposed onto 9), 11) left salivary gland ROI, 12) 
copy of the left salivary gland ROI as a background ROI in the caudal aspect of the head, 13) right salivary gland 
ROI, 14) copy of the right salivary gland ROI as a background ROI in the caudal aspect of the head.  
 
3. Results 
The weight of the cats remained stable over the course of the study period and no 
remarkable events were reported by the care takers in the time prior to, during or in the 
weeks following the study. 
 
TT4 and TSH 
None of the cats included had a TT4 that was in the upper reference range at any point in 
time (30 – 45.15 nmol/L). A single measurement below the normal reference range (10.32 
nmol/L) was seen in week 3 for one of the cats. This measurement was accompanied by a 
normal TSH of 0.03 ng/mL and all scintigraphic parameters were within normal limits. A TSH 
of < 0.03 ng/mL was observed in four cats. One of the cats showed a TSH < 0.03 ng/mL for 3 
consecutive weeks, along with a low normal TT4 (24.51 nmol/L in the first week, 21.93 
nmol/L and 20.64 nmol/L in the second and third week respectively). All scintigraphic 
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parameters of this cat were also within normal limits. The other three cats each showed 
only a single TSH measurement of < 0.03 ng/mL over the three week period. For one of 
these cats, this measurement was associated with a low T/Bneck ratio (1.4) and %TcUT neck 
(0.14%). All other parameters and TT4 were within normal limits. The other two cats showed 
none of the other parameters to be outside of the normal reference range.  
In week 2 there was one cat with a TSH measurement of 0.16 ng/mL, exceeding the only 
reported upper reference range in literature.11 The TT4 and all scintigraphic parameters, 
apart from the %TcUT neck which was below the reported reference range (0.18%), were 
within normal limits.  
 
T/S ratio 
The mean T/S ratio for all cats was within reported references ranges at all times (0.48 - 
1.9).13,16,18,19,21,22 
  
T/B ratio 
The mean T/B ratio was very similar for both ROIs placed in the axillary region and the 
values were within normal reference ranges reported in literature at all times (1.6 – 
6.4).13,20,23 The mean T/Bneck ratios were lower than those measured in the axillary region 
and showed values < 1.6 in 3 cats. Two of these cats only showed this single value below 
reference range. The third cat showed a value of 1.4 for 3 consecutive weeks. This was 
associated with a three week consecutive %TcUT neck <0.21% and a single TSH measurement 
< 0.03ng/mL in week 3. 
 
%TcUT  
Regarding the mean %TcUT, minimum values of < 0.21% were seen in the first week for the 
%TcUT neck for 4 cats. Only one of these cats showed a second parameter outside the normal 
reference range (T/Bneck < 1.6). In week 2 this was true for 5 cats, and in week 3 for 7 cats. In 
week 2 this was associated with all other parameters within normal reference range for one 
cat, a T/Bneck ratio below the reported normal reference range for two cats, a TSH above 
normal reference range for one cat and the TcUT copy ROI and TcUT circle below reference range 
for the last cat. In week 3 the low values were associated with all other parameters within 
normal limits for five cats, the TcUT copy ROI and TcUT circle below reference range for one cat 
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and finally a T/Bneck ratio < 1.6 and TSH < 0.03ng/mL for the last cat. In week 2 and 3 one cat 
also showed a TcUT copy ROI and TcUT circle with values below the in literature reported 
reference range (0.21 – 3.9%).15,17,18,20,22 This was in both weeks associated with a %TcUT neck 
<0.21% but all other parameters within normal limits.  
 
%TcUSG 
Concerning the normal reference range for the %TcUSG, no information is currently available 
in cats. In other work from our department on 100 hyperthyroid cats without known or 
suspected salivary gland disease the mean uptake was determined as 0.31% with a 
minimum value of 0.01% and a maximum value of 2.8%.24 All cats in this study 
demonstrated values within this range.     
 
Week-to-week variation 
An overview of the within and between cat variation for the different parameters in this 
study is given in Table 1 and Figure 2, in the form of 95% reference ranges. The within and 
between cat 95% reference ranges are found to be narrow. For those parameters for which 
the within cat 95% reference range is wider, the between cat 95% reference range is still 
substantially wider than the within cat 95% reference range. This signifies that the variation 
of repeated measures on the same cat is substantially smaller than the natural variation of 
such a parameter in the healthy cat population. 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 1 
 
70 
 
Variable Mean Residual 
Variance 
Cat variance Within cat 95% RR Between cat 95% RR 
TT4 22.114 9.70725 12.7144 [16.00;28.22] [12.83;31.40] 
TSH 0.0450 0.00043 0.0007 [0.004;0.086] [0;0.112] 
TcUSG R 0.2207 0.00386 0.0012 [0.1;0.34] [0.08;0.36] 
TcUSG mean 0.2169 0.00266 0.0008 [0.11;0.32] [0.1;0.33] 
TcUSG L 0.213 0.00254 0.0009 [0.11;0.31] [0.1;0.33] 
TcUT neck mean 0.3099 0.00183 0.073 [0.22;0.4] [-0.24;0.86] 
TcUT circle mean 0.4302 0.0041 0.0894 [0.3;0.56] [-0.18;1.04] 
TcUT copy ROI mean 0.4321 0.00419 0.089 [0.3;0.56] [-0.18;1.04] 
TcUT circle R 0.4072 0.00547 0.0615 [0.26;0.56] [-0.11;0.92] 
TcUT copy ROI R 0.4084 0.00535 0.0619 [0.26;0.55] [-0.11;0.93] 
TcUT neck R 0.2861 0.00265 0.0498 [0.18;0.39] [-0.17;0.74] 
TcUT circle L 0.4532 0.00698 0.1266 [0.29;0.62] [-0.28;1.18] 
TcUT copy ROI L 0.4557 0.00653 0.1249 [0.29;0.62] [-0.27;1.18] 
TcUT neck L 0.3338 0.00357 0.1033 [0.21;0.45] [-0.32;0.99] 
T/S mean 1.0247 0.00882 0.0688 [0.84;1.21] [0.47;1.58] 
T/S R 0.9936 0.03011 0.0633 [0.65;1.34] [0.38;1.6] 
T/S L 1.0558 0.01129 0.0801 [0.84;1.27] [0.45;1.66] 
T/Bneck mean 1.9901 0.0292 0.1965 [1.65;2.33] [1.04;2.94] 
T/Bcircle mean 3.2798 0.17491 0.5527 [2.44;4.12] [1.57;4.99] 
T/Bcopy ROI mean 3.3239 0.08532 0.5946 [2.74;3.91] [1.67;4.97] 
T/Bcircle R 3.1777 0.1565 0.462 [2.39;3.97] [1.6;4.75] 
T/Bcopy ROI R 3.1898 0.14718 0.4865 [2.42;3.96] [1.6;4.78] 
T/Bneck R 1.8893 0.02131 0.1502 [1.6;2.18] [1.06;2.72] 
T/Bcircle L 3.3819 0.33818 0.7069 [2.22;4.54] [1.34;5.43] 
T/Bcopy ROI L 3.458 0.09094 0.7553 [2.85;4.06] [1.62;5.3] 
T/BneckL 2.0909 0.09137 0.2574 [1.49;2.7] [0.91;3.27] 
Table 1. Mean, residual and cat variance components, and the within and between cat 95% reference ranges 
for each of the investigated thyroid and salivary gland parameters. For each parameter the mean value and the 
value for the right (R) and left (L) lobe are given.  
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Figure 2. The within and between cat 95% reference ranges for the different scintigraphic parameters. The 
within cat 95% reference range (upper line) contains 95% of the repeated values on the same cat, whereas the 
between cat 95% reference range (bottom line) contains 95% of the values obtained from different cats. The 
circle represents the average value. For each parameter the mean value and the value for the right (R) and left 
(L) lobe are given.  
 
4. Discussion 
Fluctuations in the TT4 concentration have been described in normal and hyperthyroid cats. 
However, the reason for these fluctuations is unknown and no pattern has been found.4,8,9 It 
has been demonstrated that the serum TT4 in hyperthyroid cats can vary enough to fall 
within normal reference range from time to time. This excludes a single high TT4 
measurement as definitively diagnostic, especially when hyperthyroidism is not necessarily 
suspected, e.g. during a routine health check in older animals. A repeated blood exam, not 
within the same day, is then advised given that fluctuations may result in misinterpretation 
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of results.8 A TT4 within normal limits in hyperthyroid cats has been confirmed in more 
recent studies, also in cats where concurrent non-thyroidal disease had been certainly 
excluded.25 A theory that has been put forward to explain normal TT4 values is the existence 
of “subclinical hyperthyroidism”, where nodular thyroid disease is evident on histology but 
cats show little or no clinical signs of the disease. The normal TT4 can be associated with low 
TSH measurements in these cats.1,26 Skinner (1998) also suggested an age-related decrease 
of TT4 in healthy cats, although the measured values all remained within the described 
normal limits.27 This has been argued by other authors but whether new reference ranges 
for older cats might facilitate the diagnosis of occult or subclinical hyperthyroidism, should 
be topic of future research.1,11,28,29 Regarding healthy cats, one study reported the presence 
of episodic variations of the TT4 over 3-hour periods but these were not found to be 
significant.4 In this study there has not been a single TT4 value registered in the upper 
reference range. This adds evidence to the fact that none of the cats was suffering from a 
subclinical or early form of hyperthyroidism. A single TT4 measurement below the normal 
reference range was detected in one cat. This cat was later treated for gingivitis and a small 
skin nodule was removed but never showed any clinical signs of hypothyroidism. The skin 
nodule was diagnosed on histological examination as a basaloid ductular adenoma, a benign 
cutaneous adnexal tumor. The low TT4 measurement in this cat may therefore represent an 
episode of non-thyroidal illness or may just represent an incidental fluctuation of normal 
thyroid hormone levels. A TSH value below the measurable range was observed in 4 cats 
and a single TSH measurement exceeding the reference range was detected for one cat, 
using the normal range of values that has been proposed in cats older than 8 years using 
canine assays (0.03-0.15 ng/mL).11 Two of these cats in our study, each with a TSH value 
below the measurable range, were younger than 8 years, but unfortunately no other normal 
reference values have been reported to today. Whereas TT4 is a parameter commonly used 
in practice, there is much less known about feline TSH. Although less sensitive in cats, it is 
currently accepted to use a canine assay for the measurement of feline TSH and its value 
has been reported on as an aid in confirming or excluding the diagnosis of hyperthyroidism, 
of post-therapeutic iatrogenic hypothyroidism as well as being a possible indicator for the 
development of future clinical hyperthyroidism.6,10-12 Most importantly, TSH may be below 
the measureable range in euthyroid cats and it has also been shown to vary within the same 
healthy individual, in and out of the assay’s detectable range, emphasizing that these 
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fluctuations may be normal and/or demonstrating the lack of sensitivity of the canine TSH 
assay.6,12 
The T/S ratio and T/B ratio, with background ROIs placed in the axillary region, were found 
to vary within described normal reference ranges.13,16,18,19-23 Recently proposed cut-off 
values for the diagnosis of hyperthyroidism are 1.5 for the T/S ratio and 6.1 for the T/B ratio, 
with the background ROI placed in the axillary region.23 A T/S ratio of up to 1.75 was seen in 
our group of healthy cats with normal thyroid hormone concentrations, which is higher than 
most authors have reported, but conforming with the study of Page et al. (2006) who 
proposed a T/S ratio cut-off value of 2. 13,20,21,23 
Up to now no information exists on the normal reference range for the T/B ratio in cats 
using two rectangular ROIs in the cervical region. In other work from our department it was 
demonstrated that the inter- and intraobserver variability of this method was substantially 
less though than for the other two described methods.24 The T/Bneck ratio showed minimum 
values below the reported minimum value of 1.6 for backgrounds ROIs placed in the axillary 
region.23 Given the different method by which the T/Bneck ratio is calculated this may 
however be within normal limits. It is possible that the greater relative volume of muscle 
and large blood vessels in the cervical area in comparison to the axillary region, where 
mostly fat and connective tissue are present, may play a role herein. The difference in 
vascularization and perfusion may affect this measured background activity. Although only a 
small group of cats were included in this study (n=14) the results may be of guidance for 
future use of this T/B ratio calculation method.  
The %TcU values in our study deviated from those reported in literature. The reason for this 
discrepancy may be the different placement of the background ROIs, which were placed 
lateral to the thyroid glands or near the thoracic inlet in these previous studies.17,18,22 It may 
also represent a normal variation and suggest that lower values should be included in the 
normal reference range. Cut-off values for the diagnosis of hyperthyroidism have not been 
reported and a large range of overlap is seen between normal and hyperthyroid 
cats.14,15,18,20,22,30 Concerning the variation of the T/S ratio, T/B ratio and %TcU in time, 
nothing has been reported to this day to our knowledge.  
Salivary gland disorders are rare in cats.31,32 None of the cats in this study had clinical signs 
or any other indication suggesting salivary gland disease, however a limitation of the study 
is that no fine needle aspiration or biopsies were performed. There are no reports available 
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on the normal %TcU of feline salivary glands or its variation, and presumed normal %TcU 
values of salivary glands in hyperthyroid cats were found to range from 0.01 to 2.8%.24 All 
cats included in this study were healthy, adult animals without evidence of salivary gland 
disease and their uptake values fitted within this described reference range. Whether the 
%TcUSG could be of any diagnostic use for salivary gland disease or aid in thyroid 
quantification is uncertain but the normal baseline values reported could be of value for 
further research.  
Limitations of this study include first of all the limited number of cats (n=14). Furthermore, 
the cats in this study were fed balanced, yet commercial diets, of which the exact iodine 
content and bioavailability is unknown. This will however represent the general feline 
population that forms the veterinary clientele. The nutritional iodine content may affect the 
thyroid hormone concentration and uptake of pertechnetate on scintigraphy, but to which 
extent it might have affected the results of this study is unclear.33 Finally, a validation of the 
thyroid hormone assays was not performed prior to this study as it has been done in the 
study of Peterson et al. (2015).12 However, the assays’ coefficients of variation were 
acquired from the manufacturer of the assays used in this study, and the differences 
between the coefficients of variation between the two studies are small (Appendix). The 
contribution of these assay variations to the results of this study is difficult to estimate but 
similar coefficients of variation were found, primarily for the TT4 assays, between the study 
of Peterson et al. (2015) and the numbers provided by the manufacturer of the assays used 
in this study.12 Information regarding the determination of the TT4 and TSH reference 
intervals was requested from the laboratory but could not be acquired. Therefore, detailed 
information on the population of animals that was used to determine the reference 
intervals is unknown.  Although the degree of variation was clearly larger for certain 
parameters included in this study, none of them showed a clinically relevant week-to-week 
variation. This suggests that there is little chance of a false positive diagnosis of 
hyperthyroidism in cats during a routine health screening or when patients show clinical 
signs that could include hyperthyroidism as a differential diagnosis.  Our results also 
demonstrated that the mean T/Bneck ratio and the mean %TcUT, calculated with all three 
three background ROIs, showed values lower than those previously reported, suggesting 
these may need to be included in new, wider reference ranges. Given the aforementioned 
limitations, the results of this study should be replicated in future studies. 
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Appendix  
Intra- and inter-assay coefficients of variation (CV) are given for the current study, as 
acquired from the assays’ manufacturer, and the study of Peterson et al. (2015), for 
comparable concentrations or concentration ranges. Depending on the information that 
was available, absolute, range or mean values are given. 
 
Total T4 assay 
 Current study Peterson et al., 2015 
Intra-assay CV   
1.5-9 µg/dl range: 3.7 – 4.7% (mean 4.1%)  
1.5-10 µg/dl  6.5% 
Inter-assay CV   
1.5-9 µg/dl range: 6.7 – 10.9% (mean 8.6%)  
1.5-10 µg/dl  6.6% 
Current study: using a canine, solid-phase, chemiluminescent, competitive immunoassay. 
Peterson et al., 2015: using a homogenous, enzyme immunoassay. 
 
TSH assay 
 Current study Peterson et al., 2015 
Intra-assay CV   
0.2 ng/ml 5%  
0.035 – 0.3 ng/ml  range: 4.8-15.6% (mean 9.2%) 
0.03 ng/ml  >20% 
Inter-assay CV   
0.2 ng/ml 10%  
0.035 – 0.45 ng/ml  range: 10.5 – 20.4% (mean 14.2%) 
Current study, Peterson et al., 2015: using a canine, chemiluminescent, enzyme immunoassay. 
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CHAPTER 2 
Inter- and intraobserver variability of (semi-)quantitative 
parameters commonly used in feline thyroid scintigraphy 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Volckaert V, Vandermeulen E, Duchateau L,  Saunders JH, Peremans K. Inter- and intraobserver 
variability of (semi-) quantitative parameters commonly used in feline thyroid scintigraphy (2016). 
Research in Veterinary Science, 105: 87 – 91. 
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Summary 
The aim of this study was to assess inter- and intraobserver variability of commonly used 
semi-quantitative and quantitative parameters in feline thyroid scintigraphy: thyroid to 
salivary gland ratio (T/S), thyroid to background ratio (T/B) and the percentage technetium 
pertechnetate uptake for the thyroid glands (%TcUT). These parameters are being used to 
diagnose thyroid disease and to assess its severity, but may be influenced by operator 
related factors when processing the images. Additionally, inter- and intraobserver variability 
of the percentage technetium pertechnetate uptake for the salivary glands was determined 
(%TcUSG). The study included pertechnetate scans of 100 hyperthyroid cats. Variability within 
and between three observers was determined using a random effects model and variance 
components were estimated by the restricted maximum likelihood procedure.  The %TcU for 
the thyroid and salivary glands, as well as the T/S ratio, showed little to no difference in 
inter- and intraobserver variability, whereas this was clearly present for the T/B ratio. 
Overall, the T/S ratio and %TcUSG showed a good repeatability and reproducibility with low 
inter- and intraobserver variabilities. Inter- and intraobserver variability was higher for the 
%TcUT, however variations were still considered to be acceptable. On the contrary, inter- 
and intraobserver variability was clearly larger for the T/B ratio. These findings suggest the 
preferential use of the T/S ratio or %TcU, especially in facilities with a less experienced staff.   
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1. Introduction 
Thyroid scintigraphy is the most common imaging modality used in the diagnosis or 
confirmation of hyperthyroidism in cats because of its ability to assess thyroid function and 
the anatomical distribution of hyperfunctional thyroid tissue, including possible ectopic 
tissue. Further, it can be used to evaluate the severity of the hyperfunctional state. Although 
visual inspection already allows interpretation of the anatomical distribution and a 
subjective evaluation of the amount of radionuclide uptake, a more objective evaluation can 
be performed by using parameters such as the thyroid to salivary gland ratio (T/S), the 
thyroid to background ratio (T/B) or the percentage uptake of injected radionuclide, either 
using radioactive iodine (RAIU, using 131I or 123I) or technetium pertechnetate (%TcU). The 
normal T/S ratio in literature varies substantially with a range of 0.48 to 1.9.1-6 The range is 
even larger for the T/B ratio, going from 1.6 up to 6.4.1,7-9  The %TcU of the thyroid glands 
has been reported ranging from 0.21 up to 3.9% in normal cats, and from 0.7 to 61% in 
hyperthyroid cats.3,6,7,10-13 Scintigraphy is an imaging modality with an inherent low 
resolution compared to other imaging techniques, and gamma camera sensitivity and 
resolution may differ between institutions. Additionally, manually drawing regions of 
interest (ROI) and possible patient dependent factors may result in variations between 
measurements of different clinicians and facilities. Despite the fact that these parameters 
have been reported extensively in literature for the evaluation of thyroid function and 
therapeutic radioiodine (131I) dose estimation, no studies are available assessing their 
variability between observers. The purpose of this study was therefore to assess inter- and 
intraobserver variability of these commonly used (semi-)quantitative parameters.  
 
2. Materials and methods 
Technetium pertechnetate (99mTcO4
-) thyroid scintigrams of 100 hyperthyroid cats, 
presented at our nuclear medicine department for radioiodine treatment between 2010 and 
2013, were selected. The cats were diagnosed with hyperthyroidism based on clinical signs 
and the serum total thyroxine (TT4) concentration. The median age of the population was 12 
years (range 6 – 18 years), 46/100 were male, 54/100 were female. Seventy cats were 
selected with two hyperfunctional foci on the thyroid scan and 30 cats were selected with a 
single hyperfunctional focus. These numbers were chosen to approximate the described 
prevalence of bilateral and unilateral thyroid disease in cats.14 
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A median activity of 92.87 MBq (range 48.1 – 148 MBq) was injected into the cephalic vein 
via an intravenous catheter.7 Thyroid scans were acquired 30 minutes after injection of 
pertechnetate. For the scans the cats were anesthetized with propofol (4–8 mg/kg to effect, 
IV, Propovet; Ecuphar, 10 mg/ml) and scanned in ventral recumbency with the gamma 
camera, equipped with a low energy high resolution (LEHR) collimator, located underneath 
the table (GCA 7200 A, Toshiba). Zoomed 25.6 × 25.6 cm field-of-view (FOV) planar images 
were acquired on counts (200 kcounts) in a 256 × 256 matrix, with a 0.1 cm pixel size. A 
syringe containing a known, small amount of pertechnetate was placed on the scan bed next 
to the cat and was scanned simultaneously as a standard to calculate the percentage 
pertechnetate uptake. 
Following parameters were obtained: percentage technetium uptake (%TcU) of thyroid 
glands and salivary glands (%TcUT and %TcUSG), thyroid to salivary gland ratio (T/S) and 
thyroid to background ratio (T/B). To calculate these parameters regions of interest (ROI) 
were drawn, partially manually, using multimodality software (Hermes V5.0; Nuclear 
Diagnostics AB). The background activity had to be corrected for, in order to calculate the 
percentage technetium uptake. To correct the standard activity a copy of the ROI drawn 
over the standard was used and placed in the FOV as far away from the patient and the 
standard as possible. Similarly, ROIs to correct for background activity originating from 
within the patient were placed. For the salivary glands, ROIs were drawn over the glands, 
and then copies of these ROIs were placed within the contours of the head. For the thyroid 
gland(s), ROIs were drawn manually over the gland(s) and background correction was done 
using three different methods; 1: two rectangular, fixed-size ROIs were placed cranial and 
caudal to the thyroid lobe(s) and the obtained values from these ROIs were averaged 
(background "neck"); 2: a fixed-size circular ROI was placed in the ipsilateral axillary region of 
the patient (background "circle"); 3: a copy of the thyroid lobe ROI was placed in the 
ipsilateral axillary region (background "copy ROI"). The T/B ratio was calculated as the ratio 
of the mean counts per pixels of the thyroid lobe ROI and the mean counts per pixels of the 
three different body background ROIs, which were also used for %TcU calculations. The T/S 
ratio was calculated as the ratio of the mean counts per pixels of the thyroid lobe ROI to the 
mean counts per pixels of the ipsilateral salivary gland ROI.  
In contrast to the calculation of %TcU, background correction is not performed for the T/S 
ratio and the T/B ratio. The standard activity was often masked from the image in a second 
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step, as the relatively high activity in this region made it otherwise difficult to visualize the 
image of the patient, even after adjusting window settings ("count stealing" phenomenon). 
Placement of the different regions of interest on the scintigram is demonstrated in Figure 1. 
Three different observers with variable experience in scintigraphy (VV, an ECVDI resident; 
EV, a nuclear medicine clinician and KP, Dipl. ECVDI), performed all measurements twice. 
Time in between the two sessions was 3 weeks.  
A random effects model was fitted with thyroid gland, observer nested in the thyroid gland, 
and measurements nested in the observer as random effects. The restricted maximum 
likelihood procedure was used to estimate the variance components. These variance 
components were then used to derive the 95% ranges for the differences between two 
measurements of the same observer and of two different observers on the same thyroid 
gland. 
 
 
Figure 1. Illustration of the different regions of interest used for the calculation of the investigated parameters, 
in a cat with unilateral hyperthyroidism. Before (A) and after (B) masking the standard, mildly improving image 
quality in this case. 1) standard ROI, 2) standard background ROI, 3) left thyroid lobe ROI, 4) left thyroid lobe 
copied ROI as a background ROI in the axillary region, 5) fixed-size circular ROI in the axillary region, 
superimposed onto (4), 6 + 7) fixed-size rectangular ROIs in the cervical region, 8) left salivary gland ROI, 9) left 
salivary gland copied ROI as a background ROI in the caudal aspect of the head, 10) right salivary gland ROI, 11) 
right salivary copied ROI as a background ROI in the caudal aspect of the head. Note that in this patient the 
axillary region and the head are still well visible in A, and masking of the standard would not have been 
absolutely necessary in this case.   
 
 
  CHAPTER 2 
 
87 
 
3. Results 
The variance components due to repeated measurements (σ²), observers (σo²) and thyroid 
glands (σt²) are given in Table 1. Remark that the variance components denote the extra 
variation due to the particular source. For instance, σo² refers to the extra variation when 
two measurements are performed by two different observers; a value of 0 for σo² signifies 
that the variation between two measurements is the same regardless whether the 
measurement comes from the same or a different observer. The variance components can 
be used to depict the 95% reference ranges that contain 95% of the differences between 
two measurements from the same or from a different observer (Figure 2).  The 95% 
reference ranges for between observer differences were small for the TcUSG and T/S ratio, 
indicating a good interobserver variability. Moreover, the variation due to different 
observers had little effect on the variation of these parameters. Concerning the thyroid 
percentage technetium uptake (TcUT), all three methods of measuring showed a similar, and 
acceptable, interobserver variability. Again, the variation due to different observers had little 
effect. The variation for the T/B ratios is remarkably larger. Especially the T/Bcircle and T/Bcopy 
ROI, show a substantially larger inter- and intraobserver variability than the other parameters. 
In case of all the T/B ratios, the effect of the observer cannot be neglected, with a marked 
increased variation between the measurements performed by two different observers 
rather than when performed by the same observer. Median and range values for the 
different (semi-)quantative parameters calculated in this study, on both left and right thyroid 
lobes and salivary glands, are summarized in Table 2.  
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 Source of  variation 
 Measurement (σ²) Observer (σo²) Thyroid gland (σt²) 
TcUSG 0.006 0.002 0.103 
TcUT circle 2.945 0.138 64.908 
TcUT copy ROI 2.975 0.153 64.869 
TcUT neck 1.926 0.184 60.552 
T/Bcircle 14.942 50.489 56.989 
T/Bcopy ROI 12.798 47.694 61.711 
T/Bneck 1.277 6.064 8.866 
T/S  0.232 0.141 5.648 
Table 1. The variance components due to the three different sources of variation, measurement, observer and 
thyroid gland for the different (semi-)quantitative scintigraphic parameters. 
 
 
 
 
 
 Median Range 
TcUSG 0.22 0.01 – 2.8 
TcUT circle 4 0.2 – 67.8 
TcUT copy ROI 4 0.2 – 67.9 
TcUT neck 3.8 0.1 – 65.1 
T/Bcircle 13 0.7 – 111 
T/Bcopy ROI 13.1 0.6 – 111 
T/Bneck 5.8 0.4 – 25.1 
T/S  3.8 0.3 – 14.2 
Table 2. Median and range values for the different (semi-)quantitive parameters. 
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Figure 2. 95% reference ranges for the differences between two measurements of the same observer (full line) 
and of two different observers (dotted line) of the same thyroid gland and for the different (semi-)quantitative 
parameters.  
 
4. Discussion 
In this study inter- and intraobserver variability of commonly used (semi-)quantitative 
parameters for feline thyroid scintigraphy was investigated. Recent literature emphasizes 
that the diagnosis of hyperthyroidism in cats is not always straightforward and suggests a 
combination of diagnostic methods, such as a thorough clinical examination, the use of 
different blood parameters and scintigraphy, to be of high value.15,16 Scintigraphy is often 
used and highly appreciated in the diagnosis of feline hyperthyroidism and (semi-)quantitive 
parameters can be used to assess disease severity, to determine radioiodine dose or to 
predict therapy outcome.3,9,10,17-20 However, all measurements are prone to errors caused by 
technical factors, patient and observer related components. To minimize any unnecessary 
systematic or random errors being introduced it is important to keep equipment well 
maintained and to standardize acquisition protocols. Apart from these technical factors 
there is also a certain patient and observer variability, which may be more difficult to bypass. 
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Lower measurement variability would suggest a more precise method of measuring and 
therefore a more reliable diagnostic test. With a relatively wide normal range for some of 
the described parameters it was interesting to investigate to which extent operator 
dependency could be of relevant influence. 
The results of this study demonstrated that the T/S ratio and the percentage technetium 
uptake for both the thyroid glands and the salivary glands show little operator dependency, 
as the inter- and intraobserver variance component differences were practically negligible. 
This is an important advantage that allows people with different levels of experience to 
reliably perform these measurements. The T/S ratio measurement in this study was 
performed in a similar manner as described before.1,4,8 In cats the salivary gland best 
visualized after pertechnetate injection is the zygomatic/molar salivary gland and is 
therefore by standard used for ROI placement.7 One study reported on observer agreement 
for the thyroid and salivary gland ROI placement by calculation of the limits of agreement 
and the agreement was found to be acceptable for both.5 To obtain the T/B ratio and the 
percentage technetium uptake, background correction was based on 3 different ROIs. A 
fixed-size circular ROI and a copy of the thyroid lobe ROI were placed in the axillary region, 
methods already described in cats.1,19 The third method, based on two rectangular fixed-size 
ROIs placed in the cervical area cranial and caudal to the thyroid lobe(s), is similar to what 
has been described for background correction in renal scintigraphy.21   
The variance components for the T/B ratio were much larger than for the T/S ratio, with a 
marked observer effect. Also, a clear difference was seen between the three different T/B 
ratio ROI placements, with rectangular ROIs in the cervical area (T/Bneck) demonstrating a 
marked lower inter- and  intraobserver variability compared to the other two measurement 
methods (T/Bcircle, T/Bcopy ROI). This was not true for the %TcUT uptake. The reason for this 
unexpected difference is unclear, given that the same ROIs were used for calculation of both 
parameters. Although it has been suggested the T/B ratio or %TcU might be a better 
alternative to the commonly used T/S ratio, as they are independent of potential salivary 
gland disease, this study shows that measuring the T/S ratio shows less variability than 
either of these.7,22 
The variability of the percentage technetium uptake of the salivary glands was close to zero. 
This is first of all due to the fact that none of patients were suspected to have any type of 
salivary gland disease and therefore the salivary glands in this group of hyperthyroid cats can 
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be assumed to be normal and the variance between salivary glands small. Second, normal 
uptake values of salivary glands are generally low and the lower the initial values, the 
smaller the calculated variance will be. Reference values for presumed normal parotid 
salivary gland technetium uptake have been reported in dogs. The normal uptake for healthy 
Beagle dogs was ranging from 1.5 to 3.6 %, with a mean maximum uptake value of 2.62% ± 
0.51 (SD). In a group of hypothyroid Greyhounds the salivary gland uptake was lower at 
0.88% ± 0.33 (SD) with a range of 0.45 to 2.1%.22,23 To our knowledge no similar studies have 
been conducted in cats to estimate the normal range of salivary gland pertechnetate uptake. 
From the present study can be concluded that the percentage technetium uptake for 
presumed normal salivary glands in hyperthyroid cats has an average value of 0.31% 
(median 0.22%; range 0.01 – 2.8%). 
A limitation of this study and of the use of these scintigraphic parameters in general, is the 
error prone to manual drawing and placement of the ROIs. A threshold ROI could have been 
used to eliminate the variability in the size and shape of the ROIs, however the use of this 
type of ROI for the currently used thyroid (semi-)quantification methods has not been 
described in literature and therefore the correct threshold is unknown. The placement of the 
ROIs on the scan is dependent on the operator but also on the image quality. In this regard, 
in case of high uptake in the thyroid glands, difficulties may arise to visualize the patient’s 
silhouette and salivary glands. Even after adjusting grayscale window settings the image may 
be inadequately visible and in our experience, this is mostly true for the ROIs to be placed in 
the axillary region. Another difficulty in placing these axillary ROIs is that in thin cats the 
axillary region may be very narrow, especially if the cat is positioned with the forelimbs fully 
extended. The method of placing background ROIs in the cervical area may therefore be 
more reliable as was demonstrated in this study for the T/B ratio. Finally, every institution 
may have different methods to obtain and manipulate images and technical quality factors 
may differ between equipments. Only hyperthyroid patients were included in the study, and 
whether there is a difference in variabilities between measurements made on scans of 
normal cats compared to scans of hyperthyroid cats remains to be investigated. 
In summary, the findings of this study suggest that the most commonly used and reported 
T/S ratio, even though performed without background correction, shows a good 
repeatability and reproducibility. Both the T/S ratio or %TcU are clearly less operator 
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dependent than the T/B ratio suggesting their preferential use in facilities that are 
accommodating a large or less experienced staff. 
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The effect of scintigraphic (semi-)quantitative factors on 
radioiodine therapy outcome in hyperthyroid cats 
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Summary  
The outcome of radioiodine therapy in hyperthyroid cats is suspected to be influenced by 
multiple factors. The degree of thyroid gland activity, represented by uptake of sodium 
pertechnetate or tracer activities of radioiodine by the thyroid gland on thyroid 
scintigraphy, has been suggested in literature as one of those. Thyroid gland pertechnetate 
uptake can be represented by (semi)-quantitative factors such as the thyroid to salivary 
gland ratio (T/S), the thyroid to background ratio (T/B) and the percentage technetium 
uptake by the thyroid glands (%TcU). In the present study, sodium pertechnetate thyroid 
scans of 75 hyperthyroid cats were retrospectively evaluated and statistical analysis was 
performed with and without correction for injected activity of radioiodine in order to find a 
relationship between scan parameters and radioiodine therapy outcome. Higher T/S ratios 
were found to be significantly related to a persistent hyperthyroid outcome in both 
analyses. For the T/S ratio, a threshold value of 5.4 was determined, with a sensitivity of 
73% and a specificity of 59%. An increased risk for persistent hyperthyroidism compared to 
a final euthyroid outcome with an increased T/Bcircle ratio was only found to be significant 
without correction for the activity of radioiodine administered. Regarding a low total T4 
outcome no significant relationships with any of the investigated parameters were found. 
The findings of this study suggest that semi-quantification of thyroid gland uptake is best 
performed using the T/S ratio. A T/S ratio ≥ 5.4 is a possible indicator of an increased risk of 
persistent hyperthyroidism. 
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1. Introduction 
Hyperthyroidism is a common disease in older cats and radioiodine therapy is an important 
treatment option.1-4 Research for optimization of the treatment protocol or detecting 
factors that may affect or predict therapy outcome is difficult as the therapy shows a 
generally good outcome of 70 to 95%, although the definition of a succesful therapy and 
follow-up times are variable.5-12 However, negative effects associated with a hypothyroid or 
persistent hyperthyroid outcome, such as daily thyroxine supplement pilling, possibly 
decreased renal function or repeated radioiodine treatment, justifies the quest for these 
therapy predicting or influencing factors.13,14 In other work from our department the effect 
of thyroid volume on radioiodine therapy outcome has been investigated. Only an increased 
risk towards a low total T4 (TT4) outcome was seen with the presence of multiple affected 
thyroid foci.15 Aside from thyroid volume or the number of affected foci, thyroid uptake has 
also been suggested as a factor predicting or influencing radioiodine therapy outcome. 
Thyroid gland uptake can be estimated by semi-quantitative ratios: the thyroid to salivary 
gland ratio (T/S) and the thyroid-to-background ratio (T/B) or by a quantitative 
measurement, the percentage technetium uptake (%TcU). Pertechnetate (99mTcO−4) and 
radioiodine are taken up by the thyroid glands by the same receptors and pertechnetate can 
therefore be used in the diagnosis of hyperthyroidism and (semi-)quantification of uptake 
before radioiodine therapy.16 Human literature shows conflicting results regarding the 
predictive effect of radioiodine or pertechnetate uptake in patients with Graves’ 
hyperthyroidism, although the majority of the authors report an increased number of 
persistent hyperthyroid patients with increased uptake of pertechnetate or radioiodine by 
the thyroid gland.17-21 In cats, only few studies have been published. Whereas the T/S ratio 
in cats did not appear to be related to therapy outcome, a relationship was found between 
an increased T/B ratio and persistent hyperthyroidism.10,12 Regarding the predictive value of 
the %TcU, no studies are available today to the authors’ knowledge. The aim of this study 
was to investigate the relationship between pre-therapy (semi-)quantitative thyroid 
parameters and the final outcome of radioiodine therapy. The hypothesis was that higher 
uptake of sodium pertechnetate would result in an increased risk for persistent 
hyperthyroidism, whereas patients with a reduced uptake would show an increased chance 
of a euthyroid or low TT4 outcome. 
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2. Materials and Methods 
Demographics 
The study included 75 hyperthyroid cats. These cats were diagnosed with hyperthyroidism 
by the referring veterinarian, based on a combination of thyroid palpation, clinical signs and 
serum TT4 concentration, and referred to our clinic for radioiodine therapy. The group 
included 36 males and 39 females, all neutered, with a median age of  12 years (range 6 – 18 
years). Inclusion criteria for the current study were that one or more, well-delineated 
hyperactive foci were seen on the pre-therapy pertechnetate scans and that a control serum 
TT4 measurement at 6 months post-therapy was available. 
 
Diagnostic pertechnetate imaging 
The cats were injected intravenously via a catheter with a median activity of 92.5 MBq 
(range 51.8 -  148 MBq) pertechnetate into the cephalic vein. Acquisitions were performed 
30 minutes after the injection on a dual-head gamma camera, with a low-energy high-
resolution (LEHR) collimator positioned underneath the scan bed (GCA 7200A; Toshiba). The 
patients were anesthetized with propofol (4–8 mg/kg to effect, IV, Propovet; Ecuphar, 10 
mg/ml) and positioned in ventral recumbency with the front limbs pulled forward. A 
standard, i.e. a syringe containing a known, small amount of radioactivity, was placed next 
to the cat and scanned simultaneously. Zoomed 25.6 × 25.6 cm field-of-view planar images 
were acquired on counts (200 kcounts), in a 256 × 256 matrix. 
Different regions of interest (ROIs) were placed on the images to calculate the following 
parameters: T/S ratio, T/B ratio and %TcU. ROIs were drawn manually over the thyroid 
lobe(s) and salivary gland(s). Background correction was performed using 3 different 
methods: 2 rectangular, fixed-size ROIs were placed cranial and caudal to the thyroid lobe(s) 
and averaged (background “neck") (1); a fixed-size circular ROI was placed in the ipsilateral 
axillary region of the patient (background “circle") (2) and finally a copy of the thyroid lobe 
ROI was placed in the ipsilateral axillary region (background “copy ROI") (3). To calculate the 
percentage pertechnetate uptake a ROI was drawn manually over the standard activity and 
a copy of this ROI was placed on the scan as far away from the patient and the standard as 
possible to correct for background activity. Both for the T/B ratio and the %TcU the 3 
previously mentioned background ROIs were applied. The scans were processed by three 
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different observers (VV, EV, KP) using multimodality software (Hermes V5.0; Nuclear 
Diagnostics AB).  
 
Radioactive iodine (131I) therapy 
Following the pertechnetate scans the patients received an intravenous injection of 
radioiodine (131I). The amount of radioactive iodine administered depended on the severity 
and duration of clinical signs, serum TT4 and the T/S ratio, similar to a previously reported 
dose scoring method.8 In order to correct for this injected amount of radioiodine in the 
statistical analysis, the patients were divided in 3 dose categories: 1) 74-148 MBq (n=49); 2) 
148-259 MBq (n=19) and 3) >259 MBq (n=7). All patients were taken off antithyroid 
medication before the radioiodine therapy for a minimum of 10 days. 
 
Therapy outcome and influencing factors 
Follow-up clinical examinations and blood work was performed by the referring 
veterinarian. To correlate the calculated factors to radioiodine therapy outcome, the cats 
were categorized in 3 groups according to the 6 month blood result: low TT4, euthyroid or 
hyperthyroid. The cats were categorized as low TT4 and not hypothyroid for the reason that 
these final outcomes were solely based on a single serum TT4 measurement and a diagnosis 
of true hypothyroidism could not be guaranteed.15,22 In patients with 2 or more hyperactive 
foci, only the values of the most active focus was used in the statistical analysis. 
The statistical analysis was based on logistic regression. In separate analyses, the effect of 
different imaging parameters on the odds of a low TT4 versus a euthyroid outcome, 
persistent hyperthyroidism versus a euthyroid outcome and persistent hyperthyroidism 
versus a low TT4 outcome, was assessed and summarized by the odds ratio. Furthermore, 
the different imaging parameters were compared between the thyroid status groups using 
the F-test in a linear effects model and the groups were compared pairwise using Tukey’s 
method to adjust for multiple comparisons. An additional logistic regression analysis was 
performed using dose category as a covariate. To assess the diagnostic accuracy of the T/S 
ratio in detecting the risk of persistent hyperthyroidism, receiver operating characteristic 
(ROC) curve analysis was performed. Tests were performed at the 5% significance level. 
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3. Results 
Of the 75 hyperthyroid patients included, 39 (52%) were euthyroid at 6 months after the 
radioiodine therapy. Eleven cats (14.7%) showed persistent hyperthyroidism and 25 of them 
(33.3%) showed a TT4 below the reference interval (low TT4). Given that the patient scans 
were retrospectively selected based on a clear delineation of the hyperactive foci and 
therefore inclusion was biased, this outcome does not necessarily represent the general 
outcome of radioiodine therapy in our clinic. The scans were subdivided into 3 different 
uptake patterns: 24 patients had a single hyperactive focus (unilateral disease), 46 patients 
showed the presence of 2 hyperactive foci (bilateral disease or unilateral disease with 
ectopic thyroid tissue) and 5 patients showed the presence of >2 hyperactive foci. Although 
imaging features cannot distinguish benign from malignant disease with certainty,  none of 
the thyroid scans suggested the presence of malignant disease, with features such as 
heterogeneous radionuclide uptake, irregular thyroid lobe margins, and very extensive, 
possibly multifocal, radionuclide uptake outside the normal thyroid lobe contours.16 The 
parameters included in the analysis for the complete group of hyperthyroid cats and per 
therapy outcome group are summarized in Table 1. 
 
Without correction for the administered activity of radioiodine 
Significant effects on therapy outcome were only found for the T/S ratio and T/Bcircle ratio, 
with an increasing probability of persistent hyperthyroidism with increasing values for the 
T/S and T/Bcircle ratios. The odds ratio of persistent hyperthyroidism versus a euthyroid 
outcome per unit increase in the T/S ratio equals 1.29 (P=0.010), and the odds ratio of 
persistent hyperthyroidism versus a low TT4 outcome per unit increase in the T/S ratio 
equals 1.28 (P=0.018). The odds ratio of persistent hyperthyroidism versus a euthyroid 
outcome per unit increase in T/Bcircle ratio equals 1.09 (P=0.048), and the odds ratio of 
persistent hyperthyroidism versus a low TT4 outcome per unit increase in the T/Bcircle ratio 
equals 1.08 (P=0.046). Both latter odds ratios are close to 1 and therefore clinically not 
relevant. 
Comparing the different outcome groups, significant differences were found for the T/S 
ratio between persistent hyperthyroid and euthyroid patients (P=0.001) and between 
persistent hyperthyroid cats and cats with a low TT4 outcome (P=0.004). This is similar for 
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the T/Bcircle ratio, between persistent hyperthyroid and euthyroid patients (P=0.003) and 
between persistent hyperthyroid cats and cats with a low TT4 outcome (P=0.003). 
None of the other parameters showed a significant correlation with the therapy outcome. 
Additionally, also the effect of multiple hyperactive foci on the pertechnetate scan versus a 
single affected thyroid lobe, was included in the analysis but no significance was reached. 
The T/S ratio and T/Bcircle ratio values are presented by box plots per therapy outcome group 
in Figure 1. For the T/Bcircle ratio a large overlap is observed between the three outcome 
categories. For the T/S ratio this overlap is also present for the low TT4 and euthyroid 
outcome categories, but to a smaller extent for the persistent hyperthyroid category. The 
median T/S ratio in the persistent hyperthyroid group (10.1) was almost double of the 
median T/S ratio of cats that were euthyroid at 6 months after therapy (5.1). ROC curve 
analysis was done for the best performing parameter, the T/S ratio, and is shown in Figure 
2. When comparing persistent hyperthyroid cats with cats with a low TT4 outcome,  the 
sensitivity equals 73% and the specificity 72% when using a cutt-off of 5.29. When 
comparing persistent hyperthyroid cats with cats with a succesful euthyroid outcome, the 
sensitivity equals 73% and the specificity 59% when using a cutt-off of 5.40. 
 
With correction for the administered activity of radioiodine 
When correction for the injected activity of radioiodine was included, the values slightly 
changed. The odds ratio of persistent hyperthyroidism versus a euthyroid outcome per unit 
increase in the T/S ratio increased to 1.33 (P=0.021), and the odds ratio of persistent 
hyperthyroidism versus a low TT4 outcome per unit increase in the T/S ratio increased to 
1.90 (P=0.018). On the contrary, for the comparison of persistent hyperthyroid cats versus 
those with a final euthyroid outcome, the T/Bcircle ratio showed no longer a significant 
difference (P=0.095). Regarding the comparison of persistent hyperthyroidism versus a low 
TT4 outcome, all three T/B ratio methods were found to be significant. The odds ratio per 
unit increase for the T/Bcircle ratio was 1.21 (P=0.009), for the T/Bneck ratio this was 1.3 
(P=0.015) and for the T/Bcopy ROI ratio this was 1.17 (P=0.015). 
Again comparing the different outcome groups, the differences between persistent 
hyperthyroid and euthyroid patients (P=0.004) and between persistent hyperthyroid cats 
and cats with a low TT4 outcome (P=0.0003) remained significant for the T/S ratio. The 
significant difference in T/Bcircle ratio between persistent hyperthyroid and euthyroid 
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patients was lost in this second analysis (P=0.076), but significance was now reached for the 
3 methods of T/B ratio calculation, between persistent hyperthyroid cats and cats with a low 
TT4 outcome (T/Bcircle ratio: P=0.001; T/Bneck ratio: P=0.003; T/Bcopy ROI ratio: P=0.002).  
None of the other parameters, including the number of hyperactive foci, showed a 
significant correlation with the therapy outcome. 
 
 
 1 
focus 
2 
foci 
3 
foci 
T/S T/Bneck T/BcopyROI T/Bcircle TcUneck TcUcopyROI TcUcircle 
           
Hyperthyroid 
cats (n=75) 
24 46 5 5.1 
(1.6-
18.9) 
9.6 
(0.4-36.3) 
16.5 
(3.3-69.8) 
16.7 
(3.3-
52.3) 
7.9 
(0.8-87.1) 
8.2 
(0.9-90.5) 
8.2 
(0.9-90.3) 
 
           
           
Outcome 
 
          
Low-TT4 
(n=25) 
8 12 5 4.3 
(1.6– 
14.8) 
7.5 
(2.5– 
23.7) 
14.5 
(4- 
44.4) 
12.4 
(3.3– 
40.5) 
6.8 
(1.6– 
87.1) 
7 
(1.7-90.5) 
7 
(1.7-90.3) 
Euthyroid 
(n=39) 
11 28 0 5.1 
(2.2-
14.3) 
9.9 
(0.4– 
20.2) 
16.6 
(5.9– 31.1) 
16.8 
(5.8– 
30.5) 
7.9 
(0.8-64.3) 
8.2 
(0.9- 
6.8) 
8.2 
(0.9-66.7) 
Hyperthyroid 
(n=11) 
5 6 0 10.1 
(2.2-
18.9) 
13 
(2.1-36.3) 
24.9 
(3.3-69.8) 
22.3 
(3.3-
52.3) 
13.3 
(1.8-39.9) 
13.6 
(1.5-40.5) 
13.8 
(1.4-40.3) 
           
 
Table 1. The number of hyperactive foci (1,2,3), median, minimum and maximum values for the semi-
quantitative and quantitative scintigraphic parameters are given for all patients included in the study and for 
each outcome category. 
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Figure 1. Box plot representation of the T/S ratio and T/Bcircle ratio for each therapy outcome group. A large 
overlap is seen between the euthyroid and low-TT4 groups for both the T/S and T/Bcircle ratio. Overlap with the 
persistent hyperthyroid group is also present for both ratios but to a lesser extent for the T/S ratio.  
 
 
Figure 2. ROC curves for the T/S ratio. Comparing persistent hyperthyroid cats with those with a low TT4 
outcome a cutt-off value of 5.29 was associated with a sensitivity of 73% and a specificity of 72%. Comparing 
persistent hyperthyroid cats with those with a final euthyroid outcome a cut-off value of 5.4 was associated 
with a sensitivity of 73% and a specificity of 59%. 
 
 
  CHAPTER 3 
 
107 
 
4. Discussion 
The semi-quantitative and quantitative scintigraphic parameters described in this study 
represent an estimation of thyroid follicular cell activity and the amount of pertechnetate 
uptake in the thyroid gland. Because pertechnetate and radioiodine are taken up by the 
same receptors, the diagnostic pertechnetate scan allows a safe and fast estimation of 
thyroid gland activity that can also be used for the therapeutic radioiodine activity 
determination.7,8,16,23 The uptake of pertechnetate and radiodine is variable between 
patients and can be influenced by a number of external factors such as the use of iodinated 
contrast media prior to the procedure, the amount of dietary iodine intake or the use of 
antithyroid medication.16,24-29 None of the cats in this study had recently received iodinated 
contrast media and all cats were off antithyroid medication for a minimum of 10 days 
before radioiodine treatment. Neither of these factors were therefore suspected to play a 
role in our group of hyperthyroid cats. However a limitation of the study is that the 
nutritional iodine intake of these cats is unknown. All cats were on commercial diets prior to 
the study and these may vary in iodine content and bioavailability of this nutritional 
iodine.30,31 Due to the retrospective nature of this study, another limitation is that both the 
diagnostic and follow-up TT4 measurements were performed by the referring veterinarian. 
Therefore the methods and reference intervals used for the serum TT4 measurements were 
not uniform across this group and these may vary between different laboratories.  
(Semi-)quantifications using sodium pertechnetate remain of course an estimation of the 
amount of radioiodine activity that will be taken up by the thyroid gland and opposite to 
radioiodine, pertechnetate will not be incorporated in thyroid hormones. However, using 
131I in pre-therapy studies is not only less safe from a radioprotective point of view, but 
tracer studies intended to calculate the therapeutic radioiodine activity are also associated 
with limitations such as differences between the delivered radioiodine thyroid dose and the 
intended dose.17,19,23,32 Conform to what has been reported by most authors in humans with 
Graves’ disease, the results of this study show a high T/S ratio, representative of high 
thyroid gland uptake, to increase the risk of persistent hyperthyroidism.17,18,20,21 A higher 
uptake of pertechnetate suggests there will be a higher uptake of radioiodine by the thyroid 
gland, and therefore more destruction of the hyperfunctional thyroid tissue could be 
expected. However, hyperthyroid cats have not only been observed to show an increased 
radioiodine uptake compared to euthyroid cats, but also showed an increased turnover of 
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radioiodine.33 An increased turnover will reduce the residence time of radioiodine within 
the thyroid gland to cause tissue destruction. de Jong et al. (2013) already demonstrated in 
humans with Graves’ disease that an increased turnover of radioiodine resulted in more 
patients with a persistent hyperthyroid outcome.21 At the same time they found patients 
with a persistent hyperthyroid outcome to also show higher levels of radioiodine uptake. 
Although it has not been proven, the increased radioiodine uptake and increased turnover 
in hyperthyroid patients could be related and might explain the findings in this study where 
a higher T/S ratio will increase the chance of persistent hyperthyroidism.  
Wallack et al. (2010) described a significant relationship between an increased T/Bcircle ratio 
and a persistent hyperthyroid outcome and suggested an increased radioiodine dose for 
patients with a T/B ratio ≥ 11.12 The T/Bcircle ratio in this study showed no longer a significant 
effect on therapy outcome between persistent hyperthyroid and final euthyroid cats when 
correction for the amount of injected radioiodine was included in the analysis. Even without 
dose correction the amount of overlap between the outcome categories was large and ROC 
curve analysis was therefore not performed for this parameter. 
Although the T/S ratio, T/B ratio and %TcU all represent thyroid gland uptake, and in 
contrast to what has previously been reported in veterinary literature, the results of this 
study only showed the T/S ratio to have a significant relationship to the outcome of 
radioiodine therapy in cats.10,12 Whereas these latter two studies used a fixed amount of 
radioiodine, the amount of injected radioiodine was determined using a scoring system in 
the current study. A second analysis correcting for this protocol was performed however 
and confirmed, with an increased odds ratio, the significant relationship of an increased T/S 
ratio with a persistent hyperthyroid outcome. ROC curve analysis suggested a T/S ratio cut-
off value of 5.4 to represent an increased risk of persistent hyperthyroidism after therapy. 
The sensitivity (73%) of this threshold was acceptable, and could be interpreted as a 
suggestion to increase the activity of radioiodine administered to patients with a T/S ratio 
≥5.4. However the specificity (59%) was only modest and increased radioiodine activity 
could consequently lead to a significant number of patients being relatively overdosed. The 
use of this cut-off value to alter treatment protocols therefore needs a careful approach and 
future prospective studies are needed to confirm or refute its value.  
Using the T/S ratio remains an operator dependent  procedure. No fixed-size ROIs can be 
used as the size and shape of thyroid and salivary glands vary from patient to patient. 
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However, in a previous study we reported that the T/S ratio shows little inter- and 
intraobserver variability, and its use in practice is preferred compared to the T/B ratio or 
%TcU.34 
Not only thyroid gland uptake but also salivary gland uptake, the denominator in the T/S 
ratio, might influence its value. The salivary gland percentage technetium uptake in a group 
of healthy, euthyroid cats showed no relevant week-to-week variation and the amount of 
uptake was similar to the uptake observed in a study with hyperthyroid cats. It could  
therefore be assumed that hyperthyroidism as such has little or no effect on the uptake of 
pertechnetate by the salivary glands.34,35 Moreover, salivary gland disease is rare in cats and 
its active uptake of pertechnetate may results in a less variable uptake compared to the 
peripheral soft tissues used in the calculation of the T/B ratio.16,26,36,37 This active salivary 
gland uptake will also aid in the delineation of the salivary glands for drawing ROIs when 
uptake by the thyroid gland is high and the silhouette of the patient formed mainly by soft 
tissue uptake, may become difficult to visualize.  
For patients with a low TT4 outcome no significant relationships with any of the (semi-) 
quantitative parameters in this study were observed. To the author’s knowledge there are 
no previous reports on this subject in cats. In human literature there is a study that, in 
contrast to most literature, reported a faster progression towards or an increased risk of 
hypothyroidism with an increased radioiodine uptake. However, turn-over of the 
radioiodine was also not investigated in that study and with a follow-up period of 20 years 
the outcome is difficult to compare to the group of cats in this study.38  
The therapeutic effect of radioiodine is not only dependent on the uptake of radioiodine or 
its residence time within the thyroid gland tissue but also on the excretion from the body. 
The elimination of radioiodine from the body happens primarily through the kidneys.26 
Thyroid and renal function are closely connected  and although renal function was not 
included as a parameter in this study, chronic kidney disease is a commonly occuring disease 
in older cats.39,40 The effect of patient renal function on radioiodine therapy outcome could 
therefore be an interesting topic of future research. 
In contrast to previous studies there was no significant relationship between cats affected 
by multiple affected foci, either bilaterally or bilaterally with additional ectopic thyroid 
tissue, and a low TT4 outcome.
11,15 These latter studies included a similar number of cats and 
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both had more than twice the number of patients in this study, possibly explaining the 
difference in results. 
Aside from the aforementioned factors, the outcome of radioiodine therapy is suspected to 
be influenced by multiple factors, e.g. thyroid volume, the occurrence of multifocal disease, 
the pre-therapy TT4 and potentially the previous use of antithyroid medication. This 
complicates the research on this topic and possibly explaines some of the contradicting 
results in different studies.8-11,15,24  
Performing a pertechnetate thyroid scan prior to the radioiodine treatment and processing 
of the images is fast and easy. The results from this study suggest that the T/S ratio is the 
preferential method of semi-quantifying thyroid gland uptake and a threshold value of ≥ 5.4 
is a possible indicator of an increased risk of persistent hyperthyroidism. No significant 
relationships were found in this study for patients with a low TT4 outcome. Future, ideally 
prosepective studies are needed to confirm these findings and assess other factors such as 
renal function that might play an important influencing role on radioiodine therapy 
outcome. 
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Summary 
A successful, euthyroid outcome after radioiodine therapy in hyperthyroid cats ranges from 
83% to 95%. Thyroid volume has been reported as one of the factors influencing radioiodine 
therapy outcome in humans and cats. The goal of this study was to describe the most 
reliable and practically applicable formula to determine thyroid volume using scintigraphy. 
The volume of each thyroid lobe of 32 hyperthyroid cats was determined using ultrasound 
and scintigraphy. The ultrasonographically determined volume (ellipsoid formula) for each 
thyroid lobe was compared to the volume calculated on scintigraphy, using eight different 
formulas: F1 ((π/6) x L x H x W), F2 ((π /2) x L x W²), F3 (0.33 x (area cm²)3/2), F4 (1.08 x  (π 
/6)  x L x W²), F5 (area x H), F6 (0.27 x area x L), F7 (π x L x W²) and F8 (π x (4/3) x W³). F1, F3, 
F4 and F6 did not statistically differ from the volumes measured on ultrasound, while F2, F5, 
F7 and F8 did. Subjective shape assessment of the thyroid lobes, assigned as cylindrical or 
spherical, and the use of corresponding formulas did not appear to be useful.  
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1. Introduction 
Treatment of hyperthyroidism in cats with radioactive iodine is the therapy of choice 
whenever this technique is available and the patient is a suitable candidate. Medicinal and 
surgical treatment have considerable disadvantages, e.g. adverse side effects, daily pilling, 
the risk of anesthesia in older cats and post-surgical complications.1,2 A disadvantage of 
radioactive iodine treatment is that it requires patient isolation and specialized 
infrastructure. Whether a fixed dose, a scoring system or individual dose calculations using 
kinetic studies are applied seems to have no effect on radioiodine therapy outcome. In most 
cases therapy success or failure is determined based on a combination of the serum total T4 
(TT4) concentration and the presence of clinical signs. Some patients show a TT4 value just 
outside the normal reference interval, but without any clinical signs of hypo- or 
hyperthyroidism. A euthyroid outcome varies in literature between 83% and 95%.3-10 The 
precise causes for therapy failure, either resulting in hypothyroidism or persistent 
hyperthyroidism remain unclear to this day. In human medicine a large thyroid volume has 
been suggested to be one of the predisposing factors for persistent hyperthyroidism 
although no consensus exists.11-14,15 Extrapolation of data from human medicine has to be 
considered with care since the etiology of hyperthyroidism in humans is often different from 
that in cats. Furthermore, hypothyroidism is often accepted as a successful outcome in 
human medicine.11,13,15 The influence of thyroid volume on a hypothyroid outcome has also 
been reported on in humans, as well as argued.16,17,18 An autoimmune cause may however 
also be responsible for post-therapy hypothyroidism.17 Follow-up ultrasound volume 
estimation after radioiodine therapy has also been reported to be a reliable prognostic 
factor of therapy outcome in human medical literature.12 In veterinary medicine, one study 
reported the possible influence of a large thyroid volume on persistent hyperthyroidism 
following radioiodine treatment in cats.8 Determination of predisposing factors for therapy 
failure (persistent hyperthyroidism or hypothyroidism necessitating thyroid hormone 
replacement) may lead to new protocols and individual dose calculations to improve 
radioiodine therapy outcome. If thyroid volume influences therapy results, this may be a 
parameter to be taken into account. Calculation of thyroid volume on a planar scintigram 
could easily be incorporated in the existing diagnostic procedure prior to radioiodine 
therapy, requiring no additional handling of the patient.  The aim of this study was to test 
different formulas for scintigraphic thyroid volume determination, based on the planar 
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scintigraphic acquisition used for diagnosis of hyperthyroidism in cats and determine the 
most applicable formula to determine thyroid volume. Because of its accessibility and non-
invasiveness, ultrasound was chosen as reference method.19,20 
 
2. Materials and Methods 
Patients 
Data from 32 cats, presented at our clinic between October 2010 and October 2011 for a 
diagnostic pertechnetate (99mTcO4
-) scan and radioiodine treatment, were collected (mean 
age 12.2 years (range 8.9 – 17.6 years); 18 female/14 male). The cats were diagnosed with 
hyperthyroidism by referring veterinarian based on clinical signs and serum total thyroxine 
levels (TT4). Inclusion criteria were unilateral disease or bilateral disease where one lobe 
was obviously larger than the other one and so overlap of lobes on both ventral and lateral 
planar scans was not an issue. In case of bilateral disease, only the measurements of the 
largest lobe were used, as the smaller focus could not be recognized on the lateral scan. 
Overlapping lobes and ectopic intrathoracic thyroid tissue, which was not reachable with 
ultrasound, were excluded as this could interfere with making correct measurements. Cats 
that received antithyroid medication were off this medication for a minimum of three days 
prior to radioiodine treatment.  
 
Scintigraphy 
A catheter was placed in one of the cephalic veins and each cat was injected intravenously 
with pertechnetate (mean activity 97.68  28.49 MBq). Approximately 40 minutes after 
injection the diagnostic scans were performed on the gamma camera (Toshiba, GCA 7200 A, 
Japan) equipped with a low energy high resolution (LEHR) collimator. For this procedure 
patients were anesthetized with propofol IV (4 – 8 mg/kg to effect, Propovet®, Ecuphar, 10 
mg/ml).  Two planar static images were made, one in ventral recumbency and one in right 
or left lateral recumbency, depending on the side of the affected thyroid lobe (e.g. unilateral 
left sided affected animals would be positioned in left lateral recumbency). The acquisition 
parameters were 200 kcounts, a 256 x 256 matrix size and 0.1 cm pixel size yielding a 25.6 x 
25.6 cm field-of-view. All images were processed using multimodality software (Hermes 
V5.0, Nuclear Diagnostics AB, Stockholm, Sweden). Regions of interest (ROI) were drawn 
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over the affected thyroid lobes, using a 30% threshold ROI. This threshold value was 
established previously using 99mTc-labelled phantoms with a known volume and known 
dimensions (mimicking an enlarged thyroid gland), scanned with the same protocol as the 
patients. A 30% threshold ROI was found to give measurements most comparable with the 
phantom’s real dimensions. Length, height and width of each thyroid lobe were manually 
measured using this ROI delineation. The area (cm²) of each lobe was calculated 
automatically by the thyroid volume function of the Hermes software.  
For volume estimation, eight formulas that were previously described in human and 
veterinary literature or incorporated in the Hermes software were tested using these four 
parameters.8,21-25 The following formulas were tested. Formula 1 to calculate the volume of 
an ellipsoid (F1 = (π/6) x L x H x W), formula 2 (F2 = (π /2) x L x W²), formula 3 (F3 = 0.33 x 
(area cm²)3/2), formula 4 (F4 = 1.08 x (π /6) x L x W²), formula 5 (F5 = area x H) and formula 6 
(F6 = 0.27 x area x L). Formula 2 and 4 are incorporated in the Hermes software. Formula 7 
is the formula of the volume of a cylinder (F7 = π x L x W²) and formula 8 the formula of the 
volume of a sphere (F8 = π x (4/3) x W³). Additional to the application of both formulas to all 
thyroid lobes, formulas 7 and 8 were also tested on the respective shapes (F7 to cylindrical 
shaped thyroid lobes and F8 to spherical shaped) to examine a potential influence of the 
shape on the usefulness of these formulas. All measurements and shape evaluations were 
performed by the same clinician (VV).  
 
Ultrasound 
Ultrasound was performed immediately following scintigraphy while the patients were still 
sedated. The cats were placed in dorsal recumbency in a cushion with the head extended, 
and B-mode ultrasound was performed using a 10 – 15 MHz, multifrequency, linear array 
probe (CnTI Mylab 30, Esaote, Firenze, Italy). The highest frequency (15 MHz) was used for 
all patients; gain and position of the focal zone were optimized for each patient individually.  
The presence of any cystic lesions that could interfere with therapy efficacy was evaluated, 
as well as the appearance of the thyroid parenchyma, and measurements were made for 
volume determination. For this purpose the thyroid lobes were scanned in three planes 
(transverse, sagittal and dorsal) (Figure 1). Maximum dimensions in each plane were 
searched for before freezing the image and making measurements with the electronic 
caliper. The sagittal view provided length and height, the transverse view provided height 
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and width and the dorsal view provided length and width parameters. Of these six 
measurements the maximum length (L), height (H) and width (W) values were chosen and 
thyroid volume was calculated by the ellipsoid formula (volume = π/6 x length x height x 
width).19,20 Ultrasounds were performed by two of the authors (AC, VV).  
 
Statistics 
A paired t–test was used to compare the volume measured on ultrasound with the volume 
obtained by scintigraphy for each thyroid lobe using the different formulas. Thyroid shapes 
on planar scintigraphy were divided in 2 groups: cylinder and sphere shaped. Both groups 
were tested separately for applicability of the cylinder and sphere formula, again using a 
paired t–test. 
 
  
 
Figure 1. Transverse (A), sagittal (B) and dorsal (C) plane ultrasound images of the left thyroid lobe of a 
unilaterally affected hyperthyroid cat. A height measurement is made in A and B, a length measurement is 
made in C (white arrow: common carotid artery, star: trachea). 
 
3. Results 
Table 1 summarizes the mean L, H and W, as measured on the scintigram as well as the 
same measurements on ultrasound. The mean area on the scintigram was 2.56 cm² (SD = 
1.26; range 0.61 – 4.92 cm²). The mean thyroid volumes calculated on ultrasound and 
scintigraphy are summarized in Table 2. Thirteen cats (40.6%) had cystic lesions in their 
  CHAPTER 4 
 
122 
 
affected thyroid lobes. The size of these lesions was variable and ranged from very small 
lesions to cystic lesions that occupied nearly the entire thyroid lobe in 2 cats. In one cat both 
thyroid lobes had an abnormal ultrasonographic appearance, although on scintigraphy only 
one lobe showed pertechnetate uptake. 
Thyroid volumes calculated using F1 (p = 0.426), F3 (p = 0.072), F4 (p = 0.142) and F6 (p = 
0.220) showed no significant difference with the volumes calculated on ultrasonography. F2 
(p < 0.00001), F5 (p = 0.00002), F7 (p = 0.0004) and F8 (p = 0.021) on the contrary did show 
a significant difference. F4, F6 and F1 in particular, showed the best agreement with 
ultrasonographically determined volumes (Figure 2). Twenty-three of the 32 thyroid lobes 
(72%) were defined as being cylinder shaped, 9/32 lobes (28%) were defined as sphere 
shaped (Figure 3). Small variations in shape such as bean shaped or bilobed were 
recognized. Overall, the differences between the volumes measured on ultrasound and 
scintigraphy were smaller for both shapes when F8 was used, making this formula more 
applicable than F7. F8 performed significantly (p = 0.003) better to calculate the volume of a 
cylinder-shaped lobe, i.e. it differed less from the ultrasonographically determined volume. 
 
 Length Height Width 
Ultrasound 26.7 (13.3 – 46; ±6.6) 10.5 (5.4 – 25.4; ±4.2) 13.3 (5.1 – 35.1; ±5.6) 
Scintigraphy 20.7 (8 – 35; ±6.3) 13.2 (6 – 21.9; ±3.8) 13.1 (6 – 25.8; ±3.7) 
Table 1. Mean length, height and width (mm), range and standard deviation, measured on ultrasound and 
scintigraphy. 
 
Ultrasound F1 F2 F3 F4 F5 F6 F7 F8 
(π/6) x L x 
H x W 
(π/6) x L x 
H x W 
(π /2) x L x 
W² 
0.33 x 
(area 
cm²)3/2 
1.08 x 
0.523 x L x 
W² 
Area x H 0.27 x area 
x L 
π x L x W² π x (4/3) x 
W³ 
2012 
(191.8 – 
10550; ± 
2116.6) 
2223 
(188 – 
8250; 
± 1753) 
6680 
(565 – 
29157; 
± 5707) 
1472 
(157 – 
4705; 
± 1059) 
2403 
(203 – 
10490; 
± 2053) 
3771 
(366 – 
12877; 
± 2794) 
1622 
(160 – 
4429; 
± 1171) 
3340 
(283 – 
14579; 
± 2854) 
1482 
(113 – 
8987; 
± 1615) 
Table 2. Mean thyroid volume (mm³), range and standard deviation as determined on ultrasonography and 
scintigraphy, using the 8 different formulas, F1 – F8 (L = length, H = height, W = width).  
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Figure 2. The mean difference between volumes (in mm
3
) measured on ultrasound (Y-axis) and on scintigraphy 
(X-axis), for each of the eight formulas (F1 – F8). The full line is the 95% confidence interval, the dotted line is 
the 95% reference range.  
 
 
                           
Figure 3. A cylinder shaped (A) and a sphere shaped (B) thyroid lobe with a 30% threshold ROI in two 
unilaterally affected hyperthyroid cats.  
 
4. Discussion 
Although little is known about the influence of thyroid volume on radioiodine therapy 
outcome in veterinary medicine, nor about the most suitable method to determine this 
volume, it is one of the parameters that has been implicated in therapy failure both in 
humans and in cats.8,11-14 In this study threshold dependent automatic ROI drawing (i.e. 
exclusion of pixels containing activity below a preset threshold) on planar thyroid 
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scintigraphy was used to minimize operator dependent inaccuracies. The threshold however 
has an inevitable influence on the size of the ROI and consequently on the calculated 
volumes. The ROI threshold for thyroid volume calculation in humans varies from 5% to 
30%.24-26 This is comparable to the 30 % threshold value we found most suitable for scan 
processing.  
Forrest et al. (1996) calculated thyroid volume with the sphere and cylinder formula 
(applied according to the visual evaluation of the lobes) in 80 cats and found a mean thyroid 
volume of 10400 mm³ (range 2100 – 28400 mm³).8 This volume is more than five times the 
mean volume determined by the formulas with best agreement with ultrasound in this 
study. However, in the study of Forrest et al. (1996) measurements of multiple thyroid foci 
were added up, to calculate total active thyroid volume for dosimetric purposes. This does 
not allow a direct comparison with our results as volumes were calculated only for well-
delineated single thyroid lobes. Moreover, Forrest et al. (1996) did not compare the thyroid 
volume to the real volume or a volume measured with other imaging modalities and no ROI 
threshold was mentioned.  
Inevitably, differences in shape will have a considerable influence on the volume 
calculations and the formulas to be used. For this reason the volumetric formulas of a 
sphere and a cylinder were tested in this study for the respective shapes. Surprisingly, the 
agreement between volume measurements using ultrasound and F8 for cylinder-shaped 
thyroid lobes was higher than for sphere-shaped lobes, while for sphere-shaped thyroid 
lobes F8 was not superior to F7. The reason for this is unclear. 
A limitation of this study is that most formulas that were tested are derived from human 
literature; therefore the correction factors may not be applicable to cats. Even in human 
medicine, there is a discrepancy between different publications concerning the formulas for 
volumetric calculations. Human medicine also faces the additional difficulty that thyroid 
pathology is more diverse compared to cats, with an inevitable influence on shape and 
volume calculations. F1 has been reported to be applicable for the volume calculation of 
diffuse goiters in man.24 F3 was found to be an acceptable formula to estimate thyroid gland 
volume in patients with non-specified thyrotoxicosis, especially in combination with 
ultrasound and the use of the correction factor 0.419 instead of 0.33.22 Other authors 
reported F3 and a formula similar to F3 (0.326 x area3/2) not to be useful in multinodular 
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goiters nor Graves’ disease.23-25 A formula very similar to F6 (0.323 x area x length) showed a 
reasonable correlation to ultrasound in patients with Graves’ disease.26 
In this study scintigraphic volume calculations were compared with ultrasound. However, in 
human medicine has been reported that the volume as measured ultrasonographically prior 
to thyroidectomy was underestimated in comparison to the real volume (after thyroid 
excision) for all pathologies.27 Despite this the standard technique in human and veterinary 
medicine to determine thyroid volume is the use of ultrasound and the ellipsoid 
formula.8,19,20,22,26,28 To our knowledge no formulas other than the ellipsoid formula have 
been used for routine ultrasonographic thyroid volume determination. 
Ideally CT or MRI should be performed for volume calculations. Measurements and volumes 
calculated on CT data have already been reported for clinically healthy cats but not yet in 
hyperthyroid cats.29 The need for prolonged anesthesia in a geriatric population often 
suffering from concurrent cardiac and/or renal disease and the additional cost hamper the 
use of these modalities in clinical settings. Moreover, studies in human medicine comparing 
MRI and ultrasound proposed ultrasound to be a reliable alternative technique, provided 
that a correction factor is used.25,30 
The mean volume of 2012 mm³ per hyperthyroid lobe was remarkably larger than the 
volume reported in previous studies. Some thyroid lobes were ill-defined on ultrasound 
which possibly impeded reliable measurements. Barberet et al. (2010) described a mean 
volume of 572 mm³ for the left lobe and 552 mm³ for the right lobe, while Wisner et al. 
(1994) described a mean lobe volume of 578 mm³.19,20 When we have a closer look at the 
separate parameters we can conclude that the mean length of 26.7 mm is rather 
comparable to the mean length of Barberet et al. (2010) and Wisner et al. (1994) with 21.4 
mm for the left lobe and 19.7 mm for the right lobe; and 20.2 ± 3.6 mm for the left lobe and 
21.9 ± 4.4 mm for the right lobe respectively. However, the mean height (10.5 mm) and 
width (13.3 mm) in this study are approximately double of those measured by Wisner et al. 
(1994) who determined the mean height for the left lobe to be 5.5 ± 2.4 mm and the mean 
height for the right lobe to be 8.1 ± 3.0 mm. The mean width was 5.7 ± 2.1 mm for the left 
lobe and 7.7 ± 2.4 mm for the right lobe. Mean values for height and width were not 
mentioned in the study of Barberet et al. (2010). The reason for this difference is unclear. 
Most likely the discrepancy between this study and the two others is due to simple 
coincidence, as the degree of clinical hyperthyroidism in cats is also very variable.19,20  
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Furthermore, the group of cats in this study was approximately double as large as in the 
other two studies.19,20  
Our aim was to define the most reliable formula to determine thyroid volume on 
scintigraphy. Given that thyroid volume has been suggested to be a factor influencing 
therapy outcome, the determination of volume on planar scintigraphy may provide an easy 
method in clinical surroundings where a scintigram is often used as a diagnostic tool prior to 
radioiodine therapy. Statistical analysis showed three formulas to be promising. F1, showing 
the best agreement with ultrasound, has the disadvantage however that two scans, one in 
ventral and one in lateral recumbency, are necessary to obtain all parameters needed. On 
the contrary F4 only requires one image. F6 requires determination of the thyroid area, 
which is a function specific to the Hermes software and may not be available on all systems. 
Applying specific formulas based on a subjective assessment of thyroid shape on the planar 
scintigram did not appear to be of any use since the shape of the thyroid lobe and its 
corresponding formula did not improve the accuracy of volume calculations. The advantage 
of volume measurements on scintigraphy is that only one examination has to be performed 
for information on thyroid activity and volume. Additional studies are needed to determine 
whether a correction factor more applicable to cats, should be introduced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 4 
 
127 
 
References 
1. Kintzer P.P. (1994). Considerations in the treatment of feline hyperthyroidism. Veterinary 
Clinics of North America: Small Animal Practice 24, 577 – 585. 
2. Van Hoek I., Peremans K., Waelbers T., Vandermeulen E., Daminet S. (2007). Non-surgical 
treatment of feline hyperthyroidism: options and considerations. Flemish Veterinary Journal 
76, 69 – 80. 
3. Meric S.M., Hawkins E.C., Washabau R.J., Turrel J.M., Feldman E.C. (1986). Serum 
thyroxine concentrations after radioactive iodine therapy in cats with hyperthyroidism. 
Journal of the American Veterinary Medical Association 188, 1038 – 1040. 
4. Meric S.M., Rubin S.I. (1990). Serum thyroxine concentrations following fixed-dose 
radioactive iodine treatment in hyperthyroid cats: 62 cases (1986 – 1989). Journal of the 
American Veterinary Medical Association 197, 621 – 623. 
5. Slater M.R., Komkov A., Robinson L.E., Hightower D. (1994). Long-term follow-up of 
hyperthyroid cats treated with iodine-131. Veterinary Radiology and Ultrasound 35, 204 – 
209. 
6. Théon A.P., Van Vechten M.K., Feldman E. (1994). Prospective randomized comparison of 
intravenous versus subcutaneous administration of radioiodine for treatment of 
hyperthyroidism in cats. American Journal of Veterinary Research 55, 1734 – 1738. 
7. Peterson M.E., Becker D.V. (1995). Radioiodine treatment of 524 cats with 
hyperthyroidism. Journal of the American Veterinary Medical Association 207, 1422 – 1428. 
8. Forrest L.J., Baty C.J., Metcalf M.R., Thrall D.E. (1996). Feline hyperthyroidism: efficacy of 
treatment using volumetric analysis for radioiodine dose calculation. Veterinary Radiology & 
Ultrasound 37, 141–145. 
9. Chun R., Garrett L.D., Sargeant J., Sherman A., Hoskinson J.J. (2002). Predictors of 
response to radioiodine therapy in hyperthyroid cats. Veterinary Radiology and Ultrasound 
43, 587 – 591. 
10. Wallack S., Metcalf M., Skidmore A., Lamb C.R. (2010). Calculation and usage of the 
thyroid to background ratio on the pertechnetate thyroid scan. Veterinary Radiology and 
Ultrasound 51, 554 – 560. 
11. Andrade V.A., Gross J.L., Luiza Maia A. (2001). The effect of methimazole pretreatment 
on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up 
  CHAPTER 4 
 
128 
 
of a prospective randomized study. Journal of Clinical Endocrinology & Metabolism 86, 3488 
– 3493. 
12. Gomez-Arnaiz N., Andia E., Guma A., Abós R., Soler J., Gómez J.M. (2003). 
Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment 
outcome in Graves’ disease hyperthyroidism. Hormone and Metabolic Research 35, 492 – 
497. 
13. Zantut-Wittmann D.E., Ramos C.D., Santos A.O., Lima M.M., Panzan A.D., Facuri F.V., 
Etchebehere E.C., Lima M.C., Tambascia M.A., Camargo E.E. (2005). High pre-therapy 
[99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors 
of failure in [131I]iodide therapy in Graves' disease. Nuclear Medicine Communications 26, 
957 – 963. 
14. Markovic V., Eterovic D. (2007). Thyroid echogenicity predicts outcome of radioiodine 
therapy in patients with Graves’ disease. Journal of Clinical Endocrinology & Metabolism 92, 
3547 – 3552.  
15. Sabri O., Zimny M., Schulz G., Schreckenberger M., Reinartz P., Willmes K., Buell U. 
(1999). Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic 
medication. Journal of Clinical Endocrinology & Metabolism 84, 1229 – 1233. 
16. Reinhardt M.J., Brink I., Joe A.Y., von Mallek D., Ezziddin S., Palmedo H., Krause T.M. 
(2002). Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: 
effect of pre-treatment thyroid volume on clinical outcome. European Journal of Nuclear 
Medicine 29, 1118 – 1124. 
17. Tsuruta M., Nagayama Y., Yokoyama N.,  Izumi M., Nagataki S. (1993). Long-term follow-
up studies on iodine-131 treatment of hyperthyroid Graves’ disease based on the 
measurement of thyroid volume by ultrasonography. Annals of Nuclear Medicine 7, 193 – 
197. 
18. Ceccarelli C., Bencivelli W., Vitti P., Grasso L., Pinchera A. (2005). Outcome of 
radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective 
study. Clinical Endocrinology 62, 331 – 335. 
19. Wisner E.R., Théon A.P., Nyland T.G., Hornof W.J. (1994). Ultrasonographic examination 
of the thyroid gland of hyperthyroid cats: comparison to 99mTcO4
- scintigraphy. Veterinary 
Radiology and Ultrasound 35, 53 – 58. 
  CHAPTER 4 
 
129 
 
20. Barberet V., Baeumlin Y., Taeymans O., Duchateau L., Peremans K., van Hoek I., Daminet 
S., Saunders J.H. (2010). Pre- and posttreatment ultrasonography of the thyroid gland in 
hyperthyroid cats. Veterinary Radiology and Ultrasound 51, 324 – 330. 
21. Himanka E., Larsson L.G. (1955). Estimation of thyroid volume: an anatomic study of the 
correlation between the frontal silhouette and the volume of the gland. Acta Radiologica 43, 
125 – 131. 
22. Brown M.C., Spencer R. (1978). Thyroid gland volume estimated by use of ultrasound in 
addition to scintigraphy. Acta Radiologica Oncology 17, 337 – 341. 
23. Huysmans D.A.K.C., De Haas M.M., Van Den Broeck W.J.M., Hermus A.R., Barentsz J.O., 
Corstens F.H., Ruijs S.H. (1994). Magnetic resonance imaging for volume estimation of large 
multinodular goiters: a comparison with scintigraphy. British Journal of Radiology 67, 519 – 
523. 
24. Wesche M.F.T., Tiel-v.Buul M.M., Smits N.J., Wiersinga W.M. (1998). Ultrasonographic 
versus scintigraphic measurement of thyroid volume in patients referred for 131I therapy. 
Nuclear Medicine Communications 19, 341 – 346. 
25. Van Isselt J.W., de Klerk J.M.H., van Rijk P.P., van Gils A.P., Polman L.J., Kamphuis C., 
Meijer R., Beekman F.J. (2003). Comparison of methods for thyroid volume estimation in 
patients with Graves’ disease. European Journal of Nuclear Medicine and Molecular Imaging 
30, 525 – 531. 
26. Pant G.S., Kumar R., Gupta A.K., Sharma S.K., Pandey A.K. (2003). Estimation of thyroid 
mass in Graves’ disease by a scintigraphic method. Nuclear Medicine Communications 24, 
743 – 748. 
27. Miccoli P., Minuto M.N., Orlandini C., Galleri D., Massi M., Berti P. (2006). 
Ultrasonography estimated thyroid volume: a prospective study about its reliability. Thyroid 
16, 37 – 39. 
28. Stokkel M.P.M., Handkiewicz Junak D., Lassmann M., Dietlein M., Luster M. (2010). 
EANM procedure guidelines for therapy of benign thyroid disease. European Journal of 
Nuclear Medicine and Molecular Imaging 37, 2218 – 2228. 
29. Drost W.T., Mattoon J.S., Weisbrode S.E. (2006). Use of helical computed tomography 
for measurement of thyroid glands in clinically normal cats. American Journal of Veterinary 
Research 67, 467 – 471. 
  CHAPTER 4 
 
130 
 
30. Reinartz P., Sabri O., Zimny M., Nowak B., Cremerius U., Setani K., Büll U. (2002). Thyroid 
volume measurement in patients prior to radioiodine therapy: comparison between three-
dimensional magnetic resonance imaging and ultrasonography. Thyroid 122, 713 – 717.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 5 
 
131 
 
 
 
 
 
 
 
 
CHAPTER 5 
The effect of thyroid volume on radioiodine therapy outcome in 
hyperthyroid cats 
 
 
 
 
 
 
 
 
Adapted from:  
Volckaert V, Vandermeulen E, Dobbeleir A, Duchateau L, Saunders JH, Peremans K. Effect of thyroid 
volume on radioiodine therapy outcome in hyperthyroid cats (2016). Journal of Feline Medicine 
and Surgery, 18: 144 – 149. 
 
  CHAPTER 5 
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 5 
 
133 
 
Summary 
Radioiodine therapy is commonly used in hyperthyroid cats and has a high success rate, 
ranging from 85% to 95%. Similar to human medicine, thyroid volume has also been 
reported to influence radioiodine therapy outcome in hyperthyroid cats. The purpose of this 
study was to relate total thyroid volume, calculated by a newly constructed formula for 
feline patients (volume = 0.438 × length × width²), to the outcome of radioiodine therapy. 
To search for a correlation between total thyroid volume and therapy outcome, 167 
hyperthyroid cats were included. Patients were categorized according to the administered 
radioiodine dose and therapy outcome. Our analysis did not show a significant relationship 
between an increased total thyroid volume and the odds for a final low total T4 
concentration (p = 0.3930) or a persistent hyperthyroid outcome (p = 0.0901). A significant 
relationship was found for an increase in the odds for a final low TT4 outcome with an 
increase in the number of hyperfunctional foci detected on the pertechnetate thyroid scan 
(p = 0.0238). This was not true for a persistent hyperthyroid outcome (p = 0.7435). The 
number of detected foci was also significantly associated with the total thyroid volume (p = 
0.0006). Findings indicated that the presence of multiple affected foci influences therapy 
outcome towards a low TT4 outcome. Bilateral hyperthyroidism and its potential effect on a 
final low TT4 outcome should therefore be addressed when informing owners of the 
possible outcomes of radioiodine therapy for their cat. 
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1. Introduction 
Radioiodine therapy in hyperthyroid cats has a high success rate, reported in literature as 
hypo- or euthyroid, ranging from 85% to 95%.1–6 In this study therapy failure is described as 
a hyperthyroid or low total thyroxine concentration (TT4) outcome. The term ‘low TT4’ 
rather than hypothyroid was chosen for patients with a serum TT4 below the reference 
range, given the difficult diagnosis of hypothyroidism in cats and the lack of extensive 
diagnostic work-up in the patient follow-up in this study. Therapy failure is accompanied by 
considerable drawbacks, justifying further research on possible causes. A final low TT4 
outcome has a potentially negative effect on renal function and may create the need for 
thyroxine supplementation, meaning daily medication and an additional cost for the 
owner.7–11 Persistent hyperthyroidism results in the need for a second radioiodine therapy 
or another form of treatment. The relationship between a large thyroid volume and a 
persistent hyperthyroid outcome has been reported in human medicine by different 
authors, although this has been disputed by others.12-21 Total thyroid volume in 
hyperthyroid cats, determined ultrasonographically, was reported to be significantly 
different from the total thyroid volume in normal, euthyroid cats.22 Therefore, it is 
reasonable to consider an effect of thyroid volume on radioiodine therapy outcome. Most 
studies in people have not found a relationship between thyroid gland size and a 
hypothyroid outcome, although one study reported that smaller goitres were a risk factor 
for developing hypothyroidism.23-26 Thyroid size estimation by palpation, as a scoring factor 
for dose determination, has been used in hyperthyroid cats treated with radioiodine.1,4 In 
two other studies, thyroid volume estimation was taken into account for dose calculations 
in hyperthyroid cats; however, the method of volume estimation was not mentioned.2,27 
Only a single study described the effect of thyroid volume on therapy outcome in 
hyperthyroid cats, concluding that persistent hyperthyroidism after a single treatment was 
seen more often in cats with larger total thyroid volumes, as estimated by scintigraphy.5 In a 
previous study by our group, eight different formulas to estimate thyroid volume on 
scintigraphy were compared.28 One formula, derived from human medicine, showed no 
statistical difference between the volume estimated using ultrasonography and the volume 
estimated on scintigraphy (volume = 1.08 × [π /6] × length × width² or volume = 0.565 × 
length × width²). Furthermore, this formula was based on a single scintigraphic acquisition 
and was therefore selected for volume estimation in this study. Further optimization of this 
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formula led to the determination of a correction factor of 0.438 for feline use (volume = 
0.438 × length × width²). The goal of this study was to relate the total thyroid volume to the 
outcome of the subsequent radioiodine therapy. We hypothesized that larger volumes 
would result in a higher percentage of persistent hyperthyroidism and smaller volumes 
would be at risk of receiving too much radioactive iodine thus resulting in a low TT4 
outcome. 
 
2. Materials and methods 
Demographics 
The study consisted of 167 hyperthyroid cats (81 males, 86 females), with a mean age of 12 
years and 5 months (range 7 – 18 years). All cats were diagnosed with hyperthyroidism 
based on their clinical signs and measurement of the serum TT4 by the referring 
veterinarian. The first group of 39 cats was presented at our facility between December 
2003 and October 2008, and these patients were retrospectively included. The second 
prospective group of 128 cats was presented between October 2011 and November 2012. 
As a first inclusion criterion, a control TT4 measurement 6 months after the radioiodine 
therapy was required. These final outcomes, solely based on the control TT4 value, were 
categorized as low TT4, euthyroid or hyperthyroid. Only those cats with scans that showed 
unilateral disease or clearly discernible hyperactive thyroid tissue foci in cases of bilateral 
disease, or the presence of additional ectopic thyroid tissue, were included. 
 
Thyroid scintigraphy 
All cats underwent a diagnostic thyroid pertechnetate scan. The cats were scanned on a 
dual-head camera (GCA 7200A; Toshiba) with a low-energy high-resolution (LEHR) 
collimator. The average pertechnetate activity injected into the cephalic vein was 95.3 MBq 
and acquisitions were performed 30 minutes after injection. The cats were anaesthetized 
with propofol (4–8 mg/kg to effect, IV, Propovet, 10 mg/ml; Ecuphar) and were positioned 
in ventral recumbency with the gamma camera located underneath the table. Zoomed 25.6 
× 25.6 cm field-of-view planar images were acquired on counts (200 kcounts), in a 256 × 256 
matrix, with a 0.1 cm pixel size. All scans were processed using multimodality software 
(Hermes V5.0; Nuclear Diagnostics AB). After the diagnostic scan, patients were treated by 
intravenous injection of an individually adapted dose of radioiodine (131I), depending on the 
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severity of clinical signs, the serum TT4 concentration and the thyroid-to-salivary gland ratio 
as determined on the pertechnetate scan. This dose scoring method is similar to what has 
been reported previously.4 The median dose of radioiodine administered was 117.71 MBq 
(range 69.56 – 372.22 MBq). Patients that were on prior medicinal treatment were taken off 
antithyroid medication for a minimum of 10 days before the radioiodine therapy.  
 
Thyroid volume 
To quantify thyroid volume, a formula based solely on the length and width of each thyroid 
lobe (volume = 1.08 × [π /6] × length × width²) was elected as the most suitable.28 This 
formula assumes an ellipsoid shape of the thyroid gland and equates height (i.e. the 
dorsoventral dimension) to width (i.e. the mediolateral dimension), and a correction factor 
of 1.08 was applied. The formula did not show a significant difference between the 
ultrasonographically and scintigraphically estimated volumes and has the additional 
advantage that only a single ventral planar image is needed. As the correction factor was 
derived for human patients, we first determined a factor for feline use. The assumption of 
an ellipsoid shape was dismissed, and a correction factor of 0.438 was calculated based on a 
mathematical comparison of thyroid length and width measurements that were made using 
ultrasonography and planar thyroid scintigraphy for a group of 28 cats (unpublished data). 
The correction factor was introduced in the formula as follows: thyroid volume = 0.438 × 
length × width². The thyroid volumes of 167 hyperthyroid cats were then calculated using 
this new formula. Length (i.e. the craniocaudal dimension) and width (i.e. the mediolateral 
dimension) measurements were made with an automatically applied region of interest 
(ROI), based on a 30% threshold of the activity of the lobe considered (Figure 1).28 All 
measurements were made by the same author (VV). The volume of each thyroid focus was 
calculated and summed in case of bilateral disease or the presence of ectopic thyroid tissue. 
Next, a correlation between the total thyroid volume and therapy outcome was 
investigated. Given that the activity of radioiodine used in our facility was individually 
adapted, a dose correction was needed to model the relationship between total thyroid 
volume and therapy outcome. To correct for the administered dose, the cats were divided 
into three groups: group 1 (low dose, 74 – 148 MBq, n = 114), group 2 (medium dose, 148 –
259 MBq, n = 41) and group 3 (high dose, >259 MBq, n = 12). The effect of total thyroid 
volume and the number of affected foci on therapy outcome was modeled by a logistic 
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regression model using the euthyroid group as a reference category, and using dose as 
categorical and volume and the number of foci as continuous fixed effects. Additionally, a 
linear regression model was fitted to assess the effect of the number of foci on total thyroid 
volume. 
 
3. Results 
The findings for each of the different dose categories are summarized in Table 1. Of the 167 
cats treated with radioiodine, 111 (66.5%) demonstrated a TT4 value within the normal 
reference range at 6 months after therapy. Forty cats (24.0%) showed a TT4 value below, 
and 16 cats (9.5%) showed a TT4 value above the normal reference range. Ninety-six (57.5%) 
cats had bilateral thyroid disease, 52 (31.1%) were unilaterally affected and 19 (11.4%) had 
unilateral or bilateral disease with additional ectopic foci. Of the 111 euthyroid cats, 62 
(55.9%) were bilaterally affected, 40 (36.0%) were unilaterally affected and 9 (8.1%) showed 
the presence of additional ectopic thyroid tissue. Two of these cats showed a single focus in 
the cervical region and two intrathoracic foci. They were classified as bilateral with ectopic 
tissue, although the question remains if both intrathoracic foci were ectopic tissue or if one 
of them was an enlarged, descended thyroid lobe. The 7 other cats all showed bilateral 
disease with additional ectopic thyroid tissue. Of the 40 cats with a low TT4 outcome, 24 
(60.0%) were bilaterally affected, 8 (20.0%) were unilaterally affected and 8 (20%) were 
bilaterally affected with additional ectopic thyroid tissue. Of the 16 persistent hyperthyroid 
cats, 9 (56.25%) were bilaterally affected, 5 (31.25%) were unilaterally affected and 2 
(12.5%) showed ectopic foci. One of the latter showed an enlarged thyroid focus in the 
cervical region and a smaller focus intrathoracically; this cat was classified as unilaterally 
affected with additional ectopic thyroid tissue. Again, whether this should be defined as 
bilateral disease with one descended lobe or as unilateral disease with additional ectopic 
tissue is not certain. The other cat with ectopic thyroid tissue was bilaterally affected with 
an additional ectopic focus. The mean thyroid volume of unilaterally affected cats was 
1130.4 mm³ ± 748 mm³; the mean total thyroid volume of bilaterally affected cats was 
1418.1 mm³ ± 1044.5 mm³; patients either unilaterally or bilaterally affected, but with 
additional thyroid tissue, showed a mean total thyroid volume of 1742.28 ± 1486.8 mm³. 
The median dose of radioiodine activities for the final euthyroid group was 116.81 MBq 
(range 69.56 – 372.22 MBq); for the final low TT4 group this was 129.5 MBq (range 79.40 –
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346.76 MBq); and for the persistent hyperthyroid group this was 110.63 MBq (range 82.14 –
319.20 MBq). The median dosages of radioiodine for each dose category were as follows: 
group 1 (102.12 MBq; range 69.56 – 142.3 MBq), group 2 (179.04 MBq; range 148.74 –
255.67 MBq), group 3 (318.07 MBq; range 262.7 – 372.22 MBq). A possible influence of the 
calculated total thyroid volume on therapy outcome was investigated. The odds ratio (OR) 
per 100 mm³ increase in thyroid volume for persistent hyperthyroidism, relative to a final 
euthyroid outcome, was 1.04257 (95% confidence interval (CI): 0.99252 – 1.09514), thus not 
significantly different from 1 and clinically not relevant (p = 0.0901). The OR per 100 mm³ 
increase in thyroid volume for a final low TT4 outcome, relative to a final euthyroid 
outcome, was 1.01628 (95% CI: 0.97857 – 1.05544), which is even closer to, and not 
significantly different from 1 (p = 0.3930). Regarding the effect of the number of affected 
foci on therapy outcome an OR of 1.9906 (95% CI: 1.08288 – 3.67914) was observed for the 
odds of a low TT4 outcome relative to the odds of a final euthyroid outcome. This means 
that an increase of 1 unit for the number of foci doubles the odds of a final low TT4 outcome 
relative to a euthyroid outcome (p = 0.0238). However, the number of foci did not 
significantly increase the odds for a final hyperthyroid outcome relative to a euthyroid 
outcome (OR = 1.16216; 95% CI: 0.46381 – 2.91197; p = 0.7435). Finally, the relationship 
between the number of foci counted on the pertechnetate  scan and the total thyroid 
volume was fitted by a linear regression model, and this analysis demonstrated a significant 
effect of an increasing number of foci on the total thyroid volume (p = 0.0006).  
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Dose 
category 
Number 
of cats 
Mean 
total 
thyroid 
volume 
(mm³) 
Standard 
deviation 
(mm³) 
Outcome UL BL UL + E BL + E 
1 23 1089.66     575.41    Hypo 3 17 0 3 
1 78 1115.61     698.89     Eu 31 41 0 6 
1 13 1396.18     907.83    Hyper 5 6 1 1 
2 12 1903.68    1294.92    Hypo 3 7 0 2 
2 28 1645.31    1268.60    Eu 7 18 0 3 
2 1 2890.97          Unknown* Hyper 0 1 0 0 
3 5 2103.48    1989.21    Hypo 2 0 0 3 
3 5 1732.91      565.65    Eu 2 3 0 0 
3 2 3401.26    4207.41   Hyper 0 2 0 0 
Table 1. Summary of the findings for each dose and outcome category. 
*The SD could not be calculated as data from only one cat was available. 
Category 1 = low dose; category 2 = medium dose; category 3 = high dose; UL = unilateral, BL = bilateral, E = 
ectopic thyroid tissue. 
 
 
Figure 1. Pertechnetate scan demonstrating length (A) and width (B) measurements based on a 30% threshold 
ROI in a unilaterally affected hyperthyroid cat. 
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4. Discussion 
Although full agreement has not been reached, the majority of studies in people found 
indications for a relationship between a large thyroid volume and persistent 
hyperthyroidism.12–20 The largest volumes in our study were observed in the persistent 
hyperthyroid outcome group (Table 1). However, no significance was reached regarding the 
odds of persistent hyperthyroidism, relative to a final euthyroid outcome, with an increasing 
thyroid volume. In a study by Forrest et al. (1996), 11% of the hyperthyroid cats treated with 
radioiodine remained hyperthyroid, an outcome comparable to ours (9.5%).5 The persistent 
hyperthyroid cats in this study all showed significantly larger thyroid volumes; however, the 
method of volume calculation was different from our study and the number of cats included 
was much lower (n = 80).5 A possible reason for the lack of statistical significance in our 
study may be the small number of cats in the final hyperthyroid group (n = 16). The formula 
that was designed to estimate thyroid volume might also not have been accurate enough in 
estimating the true total thyroid volume. One other reason for persistent hyperthyroidism is 
the possibility of malignant disease. Thyroid carcinomas are considered uncommon in 
hyperthyroid cats, occurring in only 1 – 5% of cases. The scintigraphic imaging features that 
have been described for thyroid carcinomas are a heterogeneous uptake pattern with 
irregular, spiculated margins, a multifocal pattern with uptake outside the normal thyroid 
lobe margins, and a linear multifocal uptake pattern secondary to tumor extension along the 
fascial planes.29,30 Although these imaging features are not highly reliable in differentiating 
malignant from benign disease, none of the 16 persistent hyperthyroid cats in our study 
were suspected of having malignant disease, based on their scans and follow-up.30 However, 
as no biopsies or fine-needle aspirates were taken, no final conclusions can be drawn. Aside 
from the obvious limitations of this study, it must be borne in mind that other factors may 
play a role in defining the final outcome after therapy. Both in human and feline studies, 
multiple factors influencing radioiodine therapy outcome, for example the administration of 
antithyroid drugs and disease severity, have been proposed and argued.6,12,13,16,19,20,24,26,31,32 
An interesting finding was the larger total thyroid volume in cats with a low TT4 outcome 
compared with those with a euthyroid outcome in dose categories 2 and 3 (Table 1). The 
majority (32/40 [80%]) of these final low TT4 cats were either bilaterally affected or 
bilaterally affected with additional ectopic thyroid tissue. This was confirmed in our 
statistical analysis demonstrating a significant relationship between the number of affected 
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foci and the total thyroid volume, and a doubling of the odds for a final low TT4 outcome 
when one extra focus was observed on the pertechnetate thyroid scan. Nykamp et al. 
(2005) reported a two-fold higher chance of final hypothyroidism in cats with bilateral 
disease, similar to our results.27 Seventy-eight percent of their final hypothyroid patients 
had bilateral disease, whereas 1/6 cats with multifocal disease became hypothyroid.27 The 
idea behind these findings is that the more thyroid tissue is destroyed, the less normal 
functioning tissue remains after therapy. Although a large overlap was observed, the mean 
thyroid volume of all unilaterally affected cats in our study was smaller (1130.4 mm³ ± 748 
mm³) than the mean total thyroid volume of bilaterally affected cats (1418.1 mm³ ± 1044.5 
mm³). Patients either unilaterally or bilaterally affected, but with additional ectopic thyroid 
tissue, showed a mean total thyroid volume of 1742.28 ± 1486.8 mm³. In human medicine 
this effect of large thyroid volume on hypothyroidism has not been reported.23–25 As far as 
the patients with a low TT4 outcome in dose category 1 of this study are concerned, a 
possible explanation could be that their smaller volumes increase the risk of radioiodine 
overdose and therefore the risk of a low TT4 outcome. However, this is only a hypothesis 
and, to our knowledge, there are no previous reports of this phenomenon in the literature. 
In three cats, two with a final euthyroid and one with a persistent hyperthyroid outcome, 
there was a doubt about whether to define a high uptake focus in the thorax as a descended 
thyroid lobe or as ectopic thyroid tissue. In all three cats it was subjectively decided, based 
on the position of the focus, to define it as ectopic tissue. Although the possibility exists that 
these cats were categorized erroneously, the influence on our results was considered 
negligible. The percentage of cats with a successful euthyroid outcome (66.5%) in our study 
was substantially lower than what is commonly reported in literature.1–6 However, some 
studies only considered persistent hyperthyroidism as therapy failure, or included clinical 
signs alone or along with the serum TT4 as a factor to categorize the patient’s thyroid 
disease status.1–5 Moreover, the time of follow-up after therapy varies among studies. In our 
study, a serum TT4 value from 6 months after therapy was chosen as a reliable outcome. Not 
all cats with a low TT4 outcome in this study demonstrated clinical signs of hypothyroidism 
and therefore could potentially have been categorized as successful. As the majority of our 
clients originates from neighboring countries and often has to travel far, follow-up of 
patients was performed by the initially referring veterinarian. Six months after the 
radioiodine therapy, veterinarians and owners were consulted by phone or by e-mail to 
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obtain the results from the blood test and to provide an update on the condition of the 
patients. Unfortunately, not all data obtained from these enquiries proved to be reliable to 
evaluate potential clinical signs related to hypothyroidism. We therefore decided not to 
include clinical signs as a factor to define therapy success. A second drawback of these 
follow-ups by the referring veterinarians is the lack of consistency among laboratory 
reference values. This might raise questions concerning the significance of these 
measurements, particularly for values near the reference range. Moreover, TT4 fluctuations 
have been reported in hyperthyroid cats before and after treatment, and could possibly also 
account for the borderline subnormal TT4 values in clinically normal cats after therapy.
4,33–36 
However, given the potentially negative effect of a decreased thyroid function on renal 
function, as described in both humans and cats, we chose to consider this low TT4 outcome 
as not successful.9-11 A low TT4 concentration can exacerbate renal disease and shorten the 
patient’s life span, especially in cats with underlying chronic kidney disease, which may not 
have been detected before therapy.9,10,37,38 Furthermore, the diagnosis of true 
hypothyroidism in cats is difficult and requires more than a single serum TT4 measurement, 
as was available in our study.39 The fact that only a single blood sample was evaluated in this 
study could therefore also account for low values in some clinically normal cats. Finally, the 
effect of non-thyroidal illness creating an artificially low TT4 is a considerable contributing 
factor in this population, consisting mostly of older patients, and given the lack of a 
thorough clinical and complete biochemical follow-up.  
In summary, although the largest total thyroid volumes were observed in the persistent 
hyperthyroid group, no statistical significance was reached. Remarkably, the majority of 
patients with a low TT4 outcome also presented larger total thyroid volumes compared with 
the final euthyroid group and the odds for a final low TT4 outcome were significantly 
increased in case of multifocal disease. Therefore, the presence of multiple foci and its 
effect on a final low TT4 outcome should be taken into consideration when informing 
owners about the possible outcomes for their cat. Finally, it has to be borne in mind that the 
influence on therapy outcome is most likely multifactorial, with different degrees of 
contribution and likely mutual interactions between several contributing factors. This could 
explain the disagreement present in literature and the lack of significance in our study, and 
justifies further research on this subject as data regarding factors influencing radioiodine 
therapy outcome in cats are severely lacking. 
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Hyperthyroidism is the most common thyroid disorder in cats and mostly diagnosed in older 
cats.1,2 A large study performed in the United Kingdom reported a prevalence of 
hyperthyroidism in 8.7% of cats ≥ 10 years.3 The precise etiology of this disease is unknown 
to this day and therefore it is unclear which preventative measures could be taken. The 
disease usually presents with a typical clinical appearance, including polyuria/polydipsia, 
polyphagia, weight loss and altered behavior. The first step in diagnosing hyperthyroidism is 
the palpation of a cervical thyroid nodule(s) on physical examination and a blood test 
showing an increased serum total thyroxine (TT4). When these tests are inconclusive, other 
circulating thyroid hormones such as thyroid stimulating hormone (TSH) or free thyroxine 
(fT4) can be measured. These values should however not be interpreted as sole values but 
combined they may assist in making the diagnosis. In cases where blood results are 
inconclusive or to plan further treatment, thyroid scintigraphy can be performed.1,4-6 
Radioiodine therapy is the therapy of choice in most cats whenever it is available.1,6,7 This 
therapy is known to be safe and has a generally good outcome. However, there is room for 
improvement and several factors such as a high pre-therapy serum T4 concentration, thyroid 
gland volume, the T/B ratio, the presence of bilateral disease or the route of radioiodine 
administration, have been proposed in literature to influence or predict therapy outcome in 
cats.8-11 As pertechnetate thyroid scintigraphy is routinely performed as part of the 
diagnosis and treatment planning of hyperthyroidism in our institution, parameters that can 
be calculated on these scans became of primary interest. The main goal of this research was 
to optimize quantification and assess reliability and possible relationships of those 
parameters that may potentially affect radioiodine therapy outcome.    
In human medicine the combination of serum fT4 and TSH is standard protocol when 
evaluating thyroid disease.12 TT4 rather than fT4 is the most commonly used parameter in 
cats. TSH on the other hand is less commonly used; especially since there is still no feline 
specific TSH assay available. Other thyroid hormone assays are available, e.g. free T4 or T3, 
but these are not routinely used.4,5 
The diagnosis of hyperthyroidism is not always straight forward and false positive or 
negative diagnoses may occur.4,5 When measurements are doubtful, a control blood test 
after several weeks to months is therefore often advised, and the use of a different 
laboratory technique may also be preferred in these cases.4,5 The aim of the first study 
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(Chapter 1) was to evaluate the week-to-week variation of a wide range of thyroid-related 
parameters used in the diagnosis of hyperthyroidism in cats, as large fluctuations of these 
parameters in healthy cats could falsely influence the diagnosis of thyroid disease. 
Variations of TT4 and T3 on a daily base have been described in healthy and hyperthyroid 
cats.13-15 These variations in hyperthyroid cats have been found to be clinically relevant, and 
suggested that the diagnosis of hyperthyroidism should not be excluded based on a single 
blood exam.13 In healthy cats, non-significant episodic variations were seen over 3-hour 
periods, but no circadian or fixed periodicity was observed over a study length of 72 hours.15  
None of the cats in our study showed a TT4 value in the upper reference range over the 3-
week period, making it very unlikely that they suffered from a subclinical or early form of 
hyperthyroidism. Also, no relevant week-to-week variation of the TT4 was observed. This 
result provides evidence that the chance of a false positive diagnosis of hyperthyroidism 
during routine health checks or in patients with a differential diagnosis including 
hyperthyroidism is not high. Concerning the TSH values, a few measurements below and a 
single measurement above the reported reference range were found over the 3-week 
period. As these values were accompanied by a normal TT4, these might represent an 
incidental fluctuation. Another, more likely possibility is that the normal reference ranges 
are not yet optimized for a feline population. Only one study reported on the normal upper 
reference value.16 Moreover, only canine assays are available and are being used as long as 
no feline assays have been developed. The main problem of this canine assays is the lack of 
distinguishing normal from abnormal cats with low values, with the  
quantification of the canine assay being limited to a lower reference of 0.03 ng/mL. It is 
likely that a lower normal reference range is required for cats. The first step in refining these 
reference values and their diagnostic value is of course the development of a feline TSH 
assay. 
Simultaneously, several scintigraphic parameters commonly used in thyroid function 
evaluation were calculated to assess their week-to-week variation. Whether a certain 
degree of variation exists had not been described before. The scintigraphic parameters that 
were obtained were the thyroid to salivary gland (T/S) ratio, the thyroid to background (T/B) 
ratio and the percentage technetium uptake of the thyroid glands (%TcUT). Additionally and 
only indirectly related to the thyroid function with a possible influence on the T/S ratio, we 
looked into the variation of the percentage technetium uptake of the salivary glands 
  GENERAL DISCUSSION 
 
151 
 
(%TcUSG). No clinically relevant week-to-week variation was observed for any of them. In 
this study different regions of interest (ROI) were delineated to correct for background 
activity. Using background ROIs in the cervical area has been described before, however the 
background ROIs were placed lateral to the thyroid lobe(s) or at the level of the thoracic 
inlet.17-20 Our method of using the mean of two fixed-size ROIs, one cranial and one caudal 
to the thyroid lobe(s) has not been reported before, which might explain the lower values of 
the %TcU and T/B ratio obtained with this method compared to the reported reference 
range using other background ROIs. We did discover in chapter 2 that inter- and 
intraobserver variability of this novel method for the T/B ratio was substantially less than 
the other two described methods. Using ROIs in the axillary region, as it has been described 
for the calculation of the T/B ratio, also showed %TcU values below the reported reference 
range.10,21 The reason for these lower values is unclear but is most likely related to 
differences in study set up, e.g. scan time after injection, and individual differences between 
cats, variation in renal clearance, or variation in the body fat/muscle percentages.  
This study was also the first to describe the %TcU of the salivary glands in healthy, adult cats 
with a mean value of 0.22%. Although the results are based on a group of only 14 cats, the 
values are consistent with the values described in chapter 4, where the %TcUSG was 
obtained from a group of 167 hyperthyroid cats, all with absence of overt salivary gland 
pathology. Salivary gland disease in cats is rare, and there are no known reports on altered 
pertechnetate uptake in case of salivary gland disease.  
In Chapter 2 we assessed inter- and intraobserver variability of several semi-quantitative 
and quantitative parameters calculated in hyperthyroid cats using scintigraphy. Although 
these parameters have been extensively described in literature and are routinely used in 
clinical surroundings, their reliability and reproducibility has never been reported on. Even 
though a visual evaluation is easily made on scintigraphy, quantification is preferred for 
assessment of disease severity, dose determination and the correlation with radioiodine 
therapy outcome.2,10,11,18,22-24 Ideally, measurements should be easy to perform, fast and 
reproducible between different operators. When delineating areas of interest, ROIs can be 
placed on the image and these ROIs can be either fixed, threshold based or manually drawn. 
Fixed-size ROIs are not possible to use for the individual thyroid or salivary gland lobes and 
the standard. The use of a threshold ROI has not been described for these (semi-) 
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quantifications to this day and the threshold to be used is therefore unknown. Usually, 
manually drawn ROIs are therefore preferred. However, scintigraphy is a modality that 
produces images with a poor resolution making it difficult to determine the edges of an area 
of interest, creating inevitably inter-operator differences with manually drawn ROIs.  
Another inevitable operator dependent factor is the placement of the ROIs. This might be 
hindered by poor visualization of the patient’s silhouette in cats with high thyroid gland 
uptake, resulting in count stealing in other areas. Certain body landmarks are therefore 
used. However, again given the poor resolution in scintigraphy this is often more an 
estimation. Other difficulties encountered are the possible overlap between lobes or ectopic 
tissue hindering delineation of the separate hyperactive foci and consequently the ROI 
placement. We reported for the first time inter- and intraobserver variability of the %TcUSG 
and low inter- and intraobserver variabilities were observed. We calculated the percentage 
technetium uptake in presumed normal salivary glands in hyperthyroid cats and an average 
of 0.31% with a range of 0.01% to 2.8% was determined. These values are similar to those 
measured in our group of healthy cats in chapter 1, suggesting that hyperthyroidism does 
not affect salivary gland uptake. Also, the most commonly used parameter in the evaluation 
of feline thyroid disease, the T/S ratio, showed good inter- and intra-operator 
reproducibility. The T/B ratio, reported as an alternative to the T/S ratio, showed clearly 
larger inter- and intraobserver variabilities. Whereas for the T/B ratio a difference in inter- 
and intraobserver variabilities between the different background ROIs was noted, this was 
not observed for the %TcUT. The reason behind this difference is unclear. The results of our 
study showed that the %TcUT and especially the most commonly used T/S ratio, showed 
acceptable to good repeatability and reproducibility respectively, approving their use in 
clinical circumstances with different or less experienced operators.   
In Chapter 3 these (semi-)quantitative thyroid parameters were assessed for their 
relationship with radioiodine therapy outcome. Two of these parameters, the T/S ratio and 
the T/B ratio had already been reported on in cats, whereas the %TcU had not. In previous 
reports only an increased T/B ratio was found to increase the risk of persistent 
hyperthyroidism, for the T/S ratio an effect on therapy outcome was not observed.10,25 
Similar to these studies the radionuclide used in this study was pertechnetate. Although two 
very different radionuclides, the use of pertechnetate rather than radioiodine is a justified 
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alternative to estimate radioiodine uptake by the thyroid gland as both are taken up by the 
same receptors.26 Moreover, pertechnetate is a radioactive substance that is safer to use, 
decaying only by γ-ray emission and with a shorter physical half-life than radioiodine.27 The 
disadvantage of using pertechnetate is that apart from the uptake, pertechnetate will 
behave differently from radioiodine and will not be incorporated in thyroid hormones. This 
will therefore not allow us to assess for example the effective half-life of  radioiodine prior 
to the treatment.  
In contrast to the two previously mentioned studies reported in cats, we did not use a fixed 
radioiodine activity for the treatment of hyperthyroidism. Dividing the patients in three 
different categories depending on the injected activity of radioiodine was based on a scoring 
method using different parameters: the severity of the clinical signs, the serum TT4 and the 
T/S ratio. Especially the use of the latter parameter could affect the results of this study and 
therefore a second statistical analysis was included, correcting for the administered 
radioiodine activity. The T/B ratio and %TcU were again calculated using the same three 
different background ROIs as in chapter 2. Although the T/S ratio, T/B ratio and %TcU all 
represent thyroid gland uptake, the results were different both before and after correction 
for the administered activity of radioiodine. For the %TcU no statistical significance was 
reached in both analyses. Of the three different methods of background correction, the 
T/Bcircle ratio, the same method used in the study of Wallack et al. (2010), showed the most 
promising results in the first analysis, although this was not confirmed after correction for 
the administered activity of radioiodine.10 Only the T/S ratio showed a significant 
relationship with radioiodine therapy outcome, which was confirmed and reinforced after 
correction for the administered activity of radioiodine. The differences between the two 
analyses were present but small. Overall, the majority of patients received an amount of 
radioiodine activity that was near the commonly used fixed amount of 148 MBq 
(4mCi)10,25,28: 49/75 patients received 74 - 148MBq (2 - 4mCi), 19/75 received 148 - 259 MBq 
(4 - 7mCi) and only 7/75 cats received >259 MBq (7mCi).  
Although it has been suggested that the T/B ratio would be more reliable than the T/S ratio 
as it is independent of salivary gland uptake, we have found the opposite to be true. The 
uptake in the soft tissues will depend on blood flow, the proportion of muscle and 
connective tissue and their vascularization, and the amount of pertechnetate that is not 
taken up by any of the other organs. We suspect that the active uptake of pertechnetate by 
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the salivary glands is responsible for less variability in uptake. Already in chapter 1 and 
chapter 2,  the %TcUSG and T/S ratio have been found to show little week-to-week variation 
in healthy animals and both parameters showed a good repeatability and reproducibility in 
hyperthyroid cats compared to the different T/B ratios, supporting their preferential use 
over the T/B ratio.  
In two recent studies, different, newly defined ROIs for background activity were 
introduced. The T/B ratio using a background ROI drawn over the heart was found to be the 
best T/B ratio for diagnosing hyperthyroidism and showed the best correlation with serum 
thyroid hormone concentrations. However, the T/B ratio was still performing slightly less 
good than the T/S ratio and the %TcU. Inter- or intraobserver variability was not assessed in 
these studies, nor was the relationship with therapy outcome. The value of this T/B ratio, 
using a background ROI over the heart, to our research is unknown. However, although the 
aims of these two recent studies were different to ours, it is important to notice that once 
again the T/B ratio was performing slightly less good than the T/S ratio and the %TcU.29,30 
All parameters included in our study represent thyroid gland uptake of pertechnetate and 
radioiodine. However, apart from the amount of radioiodine taken up by the thyroid gland, 
there are multiple other factors that may play a role in determining the efficacy and 
outcome of the radioiodine treatment, many of which would be difficult to evaluate. For 
example, the radionuclide’s residence time within the thyroid gland or the radiosensitivity 
of the hyperfunctional tissue will be contributing factors. The longer radioiodine resides 
within the thyroid gland, the more destruction of hyperfunctional thyroid tissue will be able 
to take place. Radioiodine has a long physical half-life of 8 days but the biological half-life 
will be dependent on the patient’s metabolism and therefore will be variable. The biological 
half-life is a factor that could not be integrated in this study as we used pertechnetate 
which, as mentioned before, is not incorporated in thyroid hormones like radioiodine is, and 
therefore does not follow the same biological pathway. Also regarding the radiosensitivity of 
hyperfunctional thyroid tissue, nothing has been reported in cats to this day.   
 
Considering other scintigraphic factors that could affect or predict radioiodine therapy 
outcome, we focused on thyroid volume in Chapter 4, as thyroid volume has been reported 
both in people and in cats as one of the factors that might affect radioiodine therapy 
outcome.11,31-35 Different imaging modalities are available for evaluation of the thyroid 
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gland but pertechnetate scintigraphy is the only modality that allows evaluation of thyroid 
gland function. It is therefore routinely used for thyroid gland evaluation whenever it is 
available. In literature several formulas have been proposed for thyroid volume calculation 
but none are specifically designed for the calculation of feline thyroid volume using 
scintigraphy. Our goal in this study was to find an easy method of estimating thyroid volume 
on planar diagnostic scintigraphy that was as accurate as possible, requiring little or no extra 
scan time and was easy to perform by different operators and in different institutions. A 
first step was to define the best suitable ROI. Based on phantom scans, we defined an 
automatically drawn ROI with a 30% threshold as being the most reliable. This method 
reduces interoperator variability as opposed to manually drawn ROIs. This last method 
could introduce variability due to the inherent suboptimal resolution of scintigraphy. 
The second step was to determine a suitable formula for feline thyroid volume calculations 
based on pertechnetate scintigraphy. Normal thyroid lobes are described as ellipsoid shaped 
but with hyperthyroidism thyroid lobes are known to become more rounded or tubular in 
shape.36-39 Little information on feline thyroid volume measurements based on scintigraphy 
is available in literature. One previous study determined thyroid lobe volume in cats using 
the formulas for the volume of a sphere and cylinder.11 We used 8 formulas, mainly derived 
from human literature and the software that is used in our clinic, and compared them to 
ultrasonographically determined volumes as a gold standard. The disadvantage of using 
these formulas is that the incorporated correction factors have been developed for use in 
people. Because so little information is present on feline thyroid volume calculations, the 
testing of these 8 different formulas was mostly considered a first attempt and a guide to 
optimize a formula for feline use. Analyses showed only 3 of the 8 formulas to be promising. 
Nevertheless, the correlation with the ultrasonographically determined volume was not 
high for all of them, leaving space for further optimization. For the ease of patient handling 
and scan processing, ideally only a single ventral scan should be performed, which was 
offered by formula 4 and 6. Formula 6 is based on a parameter (area calculation) that may 
not be provided by all image processing software and this formula was therefore considered 
less desirable to work with. Offering the best agreement with ultrasonography, formula 1 
requires the acquisition of a second lateral scan to measure thyroid lobe height. The only 
feline study on scintigraphic thyroid volume calculations used the formula for spheres and 
cylinders.11 We also explored these formulas (formula 7 and 8), as affected thyroid lobes will 
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become more rounded rather than ellipsoid, but the analysis showed no benefit of this 
subjective shape assessment and neither formula was found to correlate with the 
ultrasonographically determined volume. 
Several factors could explain the fact that the correlation between both imaging modalities 
was low. First, ultrasonography was chosen as the technique to represent the real thyroid 
lobe volume in this study. However, considering all imaging modalities the best method to 
determine thyroid lobe volume would have been the use of CT or MRI.  Given the longer 
anesthesia times related with these modalities, and the radiation exposure associated with 
CT, the choice for ultrasonography was made, a method also accepted and commonly used 
in human medicine.40,41 None of these three modalities is appropriate or necessary though 
for the diagnosis and evaluation of hyperthyroidism.42 Second, thyroid lobe volume 
calculations on ultrasonography were based on the commonly used ellipsoid 
formula.36,38,40,41,43 It may be questioned whether the ellipsoid formula is the best one to use 
in case of hyperthyroidism because of the more rounded thyroid lobes. Thirdly, 
ultrasonographic measurements are considered operator dependent. However, where a 
normal thyroid gland is small and may be difficult to find and acquire the correct planes for 
taking measurements by inexperienced operators, the opposite is true in hyperthyroid cats. 
The thyroid glands are usually markedly increased in size and this therefore facilitates the 
scanning and acquiring of measurements. Fourthly, most formulas used for the scintigraphic 
volume calculations incorporated correction factors for human use and little information 
was present on how these factors were determined. Finally, the anatomical volume of a 
thyroid lobe may differ from the volume of the autonomously functioning thyroid tissue 
present in the thyroid gland. A remarkable finding from the ultrasonographic examinations 
was the number of cats with cystic lesions in their enlarged thyroid lobes. Although the 
cystic lesions were usually small, they were present in 40.6% of the cats. Cystic thyroid 
lesions in hyperthyroid cats have been described and although the precise relationship with 
therapy outcome is unknown, a recently published abstract reported that in cats with cystic 
thyroid lesions, the lesions resolved better using higher activities of radioiodine compared 
to smaller activities.44-46 Where larger thyroid volumes are hypothesized to suffer from 
inadequate amounts of radioiodine radiation leading to therapy failure, radiation of this 
cystic fluid content could be imagined as radiation lost to otherwise target hyperfunctional 
thyroid tissue. On the other hand, it could also be hypothesized that the cystic lesions lead 
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to an overestimation of the size of the hyperfunctional thyroid lobe(s), which may 
potentially lead to overestimating the activity of radioiodine required for the treatment. 
Unfortunately, most cystic lesions are not detectable on planar scintigraphy and the 
deduction of their volume from the total volume is therefore not possible.  Therefore, the 
presence of multiple or large cystic thyroid lesions could be thought of as another factor 
that may possibly affect radioiodine therapy outcome and should be considered for further 
research given the high prevalence of lesions in this relatively small group of cats.  
 
In Chapter 5, we first aimed at optimizing formula 4 from chapter 4 (volume = 1.08 × [π /6] × 
length × width²). This formula is incorporated in the Hermes software that is used in our 
department and allows thyroid volume to be calculated with a single ventral planar 
acquisition, as width and height are equalized. This is a reasonable assumption for thyroid 
lobes as they are described to be rounded to ovoid in cross-section, and become more 
rounded in shape in the longitudinal plane with hyperthyroidism.37,38,47 This rounded shape 
of affected thyroid lobes was confirmed in the cats included in our study. Apart from 
reducing scan time by avoiding an extra lateral scan, it reduces the number of 
measurements to be taken, measurements that are prone to possible error due to operator 
dependency. Formula 4 is a formula developed for human purposes and included a 
correction factor of 1.08 of unknown origin. Therefore, we decided to adapt it for feline use. 
We measured thyroid length and width of 28 cats, both on ultrasonography and 
scintigraphy. These values were compared and a correction factor of 0.438 was calculated 
and introduced in the following formula: thyroid lobe volume = 0.438 × length × width². We 
hypothesized that larger volumes would more likely result in persistent hyperthyroidism due 
to insufficient radiation of larger amounts of hyperfunctional tissue, but no statistically 
significant difference in outcome was reached. The low number of persistent hyperthyroid 
cats in this study (16/167, 9.5%) or a suboptimal formula to calculate thyroid lobe volume 
may explain this lack of significance. In a recent study, the %TcUT showed a good correlation 
with the scintigraphically determined thyroid volume. Although their method of volume 
calculation was different to ours, this is an interesting finding that has also been detected in 
people previously, and encourages ideas for future research.30,48 
Multiple other factors have been proposed to influence radioiodine therapy outcome in 
people, for example the disease severity, the use of antithyroid medication and its 
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withdrawal prior to the treatment, radioiodine dose, patient age, thyroid gland uptake of 
131I or technetium pertechnetate and the presence of autoantibodies.31,33,49-52 All these 
factors may also play a role in the outcome of radioiodine treatment in hyperthyroid cats. 
Another interesting finding in this study was the relationship between an increased number 
of hyperactive thyroid foci, resulting in an increased total thyroid volume, and a low post-
therapy TT4. This was contradictory to our hypothesis that persistent hyperthyroidism would 
more often occur in large hyperfunctioning volumes as opposed to smaller volumes that 
would more easily be overdosed. Eighty percent of the cats with a low TT4 post treatment 
suffered from bilateral disease with or without ectopic tissue. In unilateral disease, the 
suppressed thyroid tissue can restore itself after therapy and normalize the serum TT4 
concentration, while in bilateral disease all thyroid tissue may be destroyed. Therefore, the 
finding of a relationship between more affected thyroid foci and a low TT4 outcome is 
deemed logical and consistent with the findings of Nykamp et al. (2005).53 As the majority of 
the hyperthyroid cats are bilaterally affected and because of the possibility of iatrogenic 
hypothyroidism and the potentially negative effect of a low TT4 on renal function, this 
finding should be taken into consideration and owners should be informed of this risk.54,55 
The precise meaning of low TT4 values in this group of cats could not be assessed as follow-
up was limited to a control TT4 measurement performed by the referring veterinarian. True 
hypothyroidism could not be confirmed nor excluded and this group was therefore referred 
to as ‘low TT4’. The work performed and described in chapter 1 demonstrates that it is 
unlikely that healthy cats show low TT4 values due to normal variation. However, in case of 
hyperthyroid cats, these patients are usually older than the group of cats that was used in 
chapter 1 and the thyroid gland might respond differently after radioiodine treatment. An 
age-related decrease of TT4 has been suggested in healthy cats by one author, although no 
significant age effect was observed in a larger, more recent study.56,57  
The number of patients with a euthyroid outcome after radioiodine therapy was low in this 
study (66.5 %) as well as in chapter 3 (52 %). On the contrary, the number of cats with a low 
TT4 outcome was high in both studies (33.3% in chapter 3 and 24% in chapter 5). Although 
our results may be slightly biased by patient inclusion criteria, the large number of patients 
with a low TT4 outcome is still surprising. It has to borne in mind that given the differences 
in follow-up time and methods, the success rate of radioiodine therapy may have been 
overestimated in the past.8-11,28,53,58-61 However, given the established negative effect on 
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renal function, iatrogenic hypothyroidism or a low TT4 outcome is more and more of a 
concern.54,55,62-65 Although the ideal timing for follow-up has not been determined, we 
believe that our 6 month follow-up gives the remaining thyroid gland tissue enough time to 
recover. To explain the large number of patients with a low TT4 outcome, several theories 
can be put forward. One of the main limitations of this thesis is that follow-up after 
radioiodine therapy has been performed at the referring veterinarian. This means that there 
is variation in the laboratory assays and reference intervals that were used to categorize the 
patients as low TT4, euthryoid or hyperthyroid, and not all available assays have an equally 
good sensitivity and specificity.5 Although in chapter 1 no relevant fluctuations were seen 
for the serum TT4 in healthy cats, it is possible that cats respond differently after radioiodine 
therapy. The diagnosis of true iatrogenic hypothyroidism in cats is not straightforward and 
although to our knowledge none of the patients that were treated with radioiodine suffered 
from severe concurrent disease, it is possible that 6 months after therapy other diseases, 
such as chronic kidney disease, had turned up and falsely lowered the serum TT4 (non-
thyroidal illness).66-69 Finally, radioiodine activities used in cats are relatively much higher 
than in people with benign thyroid disease and the scoring system that we use to determine 
the activity of radioiodine to be administered might be insufficiently accurate and lead to 
relative overdosing of our patients.9,70 
 
The aim of this thesis was to investigate several (semi-)quantitative parameters related to 
the outcome of radioiodine therapy in hyperthyroid cats and this with an emphasis on 
parameters that can be acquired using a pre-therapy, diagnostic pertechnetate scan, in 
order to find parameters that could help in further optimizing radioiodine dose 
determination.  We have been the first to describe the %TcU of the salivary glands in 
healthy, adult cats and designed a formula to calculate thyroid lobe volume on planar 
scintigraphy in cats. Furthermore, we have found that the %TcU of the salivary glands and 
also of more important thyroid scintigraphic and blood parameters in normal animals 
showed no clinically relevant week-to-week variation that could confuse the diagnosis of 
hyperthyroidism in cats. Commonly used scintigraphic (semi-)quantitative thyroid 
parameters, such as the %TcUT and the T/S ratio have been found to show acceptable to 
good repeatability and reproducibility respectively, justifying their further use in practice. 
When looking into factors that could predict or influence radioiodine therapy outcome in 
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hyperthyroid cats we found a significant relationship with higher T/S ratios and the presence 
of multiple affected thyroid foci. To our surprise, total thyroid volume did not show a 
significant relationship with therapy outcome in this thesis. 
In general, little has been reported on this subject in cats and the therapy outcome is likely 
influenced by multiple factors, therefore a large number of parameters remain to be 
explored. Possible future investigations include the determination of the effect of 
antithyroid medication on therapy outcome and its ideal timing of withdrawal, the existence 
and role of autoantibodies in post-therapy hypothyroidism, the effect of patient age and 
disease duration, and the effect of a decreased renal function on radioiodine residence time 
in the body and consequently its effect on radioiodine therapy outcome. 
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Although the outcome of radioiodine therapy in hyperthyroid cats is generally known to be 
good, the downsides associated with therapy failure urge to investigate the underlying 
causes of therapy failure or to establish factors that may predict therapy outcome. The aim 
of this thesis was to investigate some of the parameters that have been proposed in 
literature to influence therapy outcome. These parameters were obtained by blood tests 
(TT4, TSH) and diagnostic pertechnetate scintigraphy (%TcU, T/B, T/S, thyroid volume). Aside 
from the studies looking into the effect of these factors on therapy outcome, it was 
important to evaluate their normal variation, reliability and reproducibility and to optimize 
the method of thyroid volume calculation in cats.  
 
In Chapter 1, the week-to-week variation of thyroid hormones and different scintigraphic 
parameters was investigated to see whether a degree of variation exists that could be 
clinically relevant. Measurement of the serum thyroid hormone concentrations or the use of 
thyroid scintigraphy are commonly used diagnostic tests for thyroid disease in cats and a 
strong variation of these parameters may therefore influence the interpretation of their 
results. The study included fourteen adult, healthy, experimental cats that underwent a 
thyroid pertechnetate scan at 3 time points with 7-day intervals. At the same time blood 
samples were collected to measure total T4 and TSH. The scintigraphic parameters that were 
calculated were the T/S ratio, the T/B ratio, the percentage technetium uptake in the thyroid 
glands (%TcUT) and additionally the percentage technetium uptake in the salivary glands 
(%TcUSG). Three different methods of background correction were used. Not all total T4 and 
TSH values were within the reported reference ranges. Also, both the %TcUT and the T/Bneck 
ratio showed values outside of the normal reported reference ranges. This may be caused by 
a different placement of the background regions of interest or may represent a normal 
variation. However, none of the parameters included in this study showed a clinically 
relevant week-to-week variation. 
 
In Chapter 2, inter- and intraobserver variability of several semi-quantitative and 
quantitative parameters used in feline thyroid scintigraphy was assessed. This had not been 
reported in literature before despite their common use in thyroid scintigraphic (semi-) 
quantification, and despite the fact that operator related factors may significantly affect the 
results, as these measurements mostly rely on manually drawing regions of interest on the 
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thyroid pertechnetate scans. The thyroid to salivary gland ratio (T/S), thyroid to background 
ratio (T/B) and the percentage technetium uptake for the thyroid gland (%TcUT) were 
evaluated. Additionally, inter- and intraobserver variability of the percentage technetium 
uptake of the salivary glands was determined (%TcUSG). One hundred hyperthyroid cats were 
included in the study and 3 observers made each measurement twice. The T/S ratio, most 
commonly used and reported in literature, showed a good repeatability and reproducibility. 
This was also true to the %TcUSG, although the clinical use of this parameter has not yet been 
determined. The inter- and intraobserver variability for the %TcUT was found to be 
acceptable. The T/B ratio scored considerably less good. The T/S ratio, the %TcUT and the 
%TcUSG also showed little to no difference in inter- and intraobserver variability, whereas 
this was clearly present for the T/B ratio. The findings of this study and the lower operator 
dependency of the T/S ratio and %TcU quantification suggest their preferential use in 
facilities that are accommodating a large or less experienced staff. 
 
In Chapter 3, after determining the repeatability and reproducibility of several commonly 
used (semi-)quantitative factors in thyroid scintigraphy, their relationship with radioiodine 
therapy outcome was investigated. Apart from multiple other factors that have been 
suggested in literature, also the degree of thyroid gland activity, which is represented by the 
uptake of pertechnetate or tracer activities of radioiodine by the thyroid gland on 
scintigraphy, may play a role. This thyroid gland uptake of pertechnetate can be represented 
by (semi)-quantitative factors such as the T/S ratio, the T/B ratio and the percentage 
technetium uptake by the thyroid glands (%TcU). Pertechnetate thyroid scans of 75 
hyperthyroid cats were included in the study and evaluated retrospectively. The statistical 
analysis was then performed both with and without correction for injected radioiodine 
activity in order to find a relationship between scan parameters and radioiodine therapy 
outcome. Only an increased T/S ratio was found to be significantly related to a persistent 
hyperthyroid outcome in both statistical analyses. A threshold value of 5.4 was determined 
for this T/S ratio, with a sensitivity of 73% and a specificity of 59%. The T/Bcircle ratio only 
showed a significant correlation to outcome in the first analysis without correction for the 
activity of radioiodine administered. Here, an increased risk for persistent hyperthyroidism 
compared to a final euthyroid outcome was seen with an increased T/Bcircle ratio. Regarding 
a low total T4 outcome no significant relationship with any of the investigated parameters 
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was found. The findings of this study suggest that semi-quantification of thyroid gland 
uptake is best performed using the T/S ratio and that a T/S ratio ≥ 5.4 is a possible indicator 
of an increased risk of persistent hyperthyroidism. 
 
In Chapter 4, several formulas to calculate thyroid volume based on pertechnetate 
scintigraphy that have been reported in literature were investigated. Even though thyroid 
gland volume has been suggested in both human and feline medicine to influence 
radioiodine therapy outcome, the ideal method to estimate thyroid gland volume on 
scintigraphy in cats has not yet been determined. Thirty-two hyperthyroid cats were 
included in the study and for each cat the volume of the thyroid lobes was determined first 
by ultrasonography, using the ellipsoid formula, and then by scintigraphy. Eight different 
formulas were evaluated for scintigraphic thyroid volume estimation: F1 [(π/6) × L × H × W], 
F2 [(π /2) × L × W²], F3 [0.33 × (area cm²)3/2], F4 [1.08 × (π /6) × L × W²], F5 (area × H), F6 
(0.27 × area × L), F7 (π × L × W²) and F8 [π × (4/3) × W³]. The results were compared with the 
ultrasonographically determined volumes, which were set as the gold standard. Assessing 
the thyroid lobes as cylindrical or spherical shaped and using the corresponding formulas, F7 
and F8, did not improve the correlation with the ultrasonographically determined thyroid 
volume. Although 3 formulas, F1, F4 and F6 were found promising, none of them were set 
up as feline specific or correlated to a high degree with ultrasonography. 
 
In Chapter 5, the limitations of the formulas from chapter 4 were addressed. A correction 
factor of 0.438, specifically for cats, was determined based on a mathematical comparison of 
length and width measurements of thyroid gland lobes of 28 cats on ultrasound and 
scintigraphy. This correction factor was introduced in a new formula to calculate feline 
thyroid lobe volume on a single planar scintigraphic scan: volume = 0.438 x length x width2. 
Thyroid scans of 167 hyperthyroid cats were included and the total thyroid volume for each 
cat was calculated. These results were analyzed to find a possible relationship between total 
thyroid volume and radioiodine therapy outcome. The largest total thyroid volumes were 
present in the group of cats remaining hyperthyroid after therapy but no statistical 
significance was reached. Significance was reached in the relationship between an increased 
number of hyperactive thyroid foci on scintigraphy and cats that showed a total T4 value 
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below the normal reference range after therapy. This is an important finding to be taken into 
consideration in cats that are bilaterally affected or have additional ectopic thyroid tissue. 
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Hoewel de resultaten van radiojood therapie in hyperthyreoïde katten over het algemeen 
goed zijn, is gezien de nadelige effecten die gepaard gaan met therapie falen, de zoektocht 
naar onderliggende factoren die het resultaat van de therapie zouden kunnen voorspellen 
meer dan gerechtvaardigd.  De doelstelling van deze thesis was om verschillende parameters 
te onderzoeken die in de literatuur vermeld worden met een mogelijke invloed op het 
resultaat van radiojood therapie. Zowel parameters in het bloed (TT4, TSH) als scintigrafische 
parameters (%TcU, T/B, T/S, schildklier volume) werden geïncludeerd. Naast het mogelijke 
effect van deze factoren op het resultaat van de radiojood therapie was het ook belangrijk 
om de normale variatie, de betrouwbaarheid en de reproduceerbaarheid van deze factoren 
te evalueren, evenals het optimaliseren van de methode waarop het schildklier volume 
berekend wordt.   
 
In Hoofdstuk 1 werd de week-tot-week variatie van verschillende schildklierhormonen en 
parameters die berekend worden op scintigrafie, onderzocht om te kijken of er sprake was 
een zekere graad van variatie die klinisch relevant zou kunnen zijn. Schildklieraandoeningen 
bij katten worden vaak verder onderzocht door het bepalen van schildklierhormoon 
concentraties in het bloed of door het gebruik van scintigrafie. Een sterke variatie van deze 
parameters zou de interpretatie van deze resultaten kunnen beïnvloeden. Veertien 
volwassen, gezonde, experimentele katten werden geïncludeerd in deze studie. Een 
schildklier pertechnetaat scan werd driemaal uitgevoerd met een tijdsinterval van 7 dagen. 
Tegelijkertijd werden telkens bloedstalen verzameld om totaal T4 en TSH te bepalen. De 
parameters die berekend werden op scintigrafie zijn de T/S ratio, de T/B ratio, het 
percentage opname van technetium in de schildklieren (%TcUT) en bijkomend het 
percentage opname van technetium in de speekselklieren (%TcUSG). Drie verschillende 
methodes voor achtergrond of ‘background’ correctie werden toegepast. Niet alle totaal T4 
en TSH waarden lagen binnen de beschreven normaalwaarden. Ook voor het %TcUT en de 
T/Bneck ratio werden waarden gevonden die buiten de normaalwaarden lagen die in de 
literatuur beschreven zijn. Dit is mogelijk te wijten aan een verschil in het plaatsen van de 
achtergrond of ‘background’ ‘regions of interest’ of kan een normale variatie 
vertegenwoordigen. Voor geen van de geïncludeerde parameters in deze studie werd er 
echter een klinisch relevante week-tot-week variatie geobserveerd. 
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In Hoofdstuk 2 werd de inter- en intrawaarnemer variabiliteit van verschillende semi-
kwantitatieve and kwantitatieve parameters in de scintigrafie geëvalueerd. Ondanks het 
frequent gebruik van deze parameters in de schildklier scintigrafie en het feit dat operator 
afhankelijke factoren deze metingen significant kunnen beïnvloeden, was hierover nog niets 
beschreven in de literatuur. De schildklier tot speekselklier ratio (T/S), schildklier tot 
achtergrond of ‘background’ ratio (T/B) en het percentage technetium pertechnetaat 
opname van de schildklier (%TcU) werden geëvalueerd. Bijkomend werd ook de inter- en 
intrawaarnemer variabiliteit van het percentage technetium pertechnetaat opname van de 
speekselklieren bepaald (%TcUSG). Honderd hyperthyreoïde katten werden geïncludeerd in 
deze studie en elke meting werd tweemaal uitgevoerd door drie waarnemers. De meest 
frequent gebruikte en in de literatuur gerapporteerde T/S ratio toonde een goede 
herhaalbaarheid en reproduceerbaarheid. Dit was eveneens het geval voor het %TcUSG, 
hoewel het gebruik van deze parameter in een klinische omgeving nog niet bepaald is. De 
inter- en intrawaarnemer variabiliteit voor het %TcUT werd aanvaardbaar bevonden, terwijl 
de T/B ratio aanzienlijk minder goed scoorde.  De T/S ratio en het %TcUT en %TcUSG toonden 
ook weinig tot geen verschil in inter- en intrawaarnemer variabiliteit, waar dit wel duidelijk 
aanwezig was voor de T/B ratio. De resultaten van deze studie en vooral de lagere operator 
afhankelijkheid van de T/S ratio en het %TcU, tonen aan dat de voorkeur uitgaat naar het 
gebruik van deze parameters, vooral in faciliteiten met een groot aantal of onervaren 
werknemers. 
 
Na het bepalen van de herhaalbaarheid en reproduceerbaarheid van verschillende vaak 
gebruikte (semi)-kwantitatieve factoren in de schildklier scintigrafie werd hun potentiële 
relatie met het resultaat van de radiojood therapie onderzocht in Hoofdstuk 3. Naast een 
aantal andere factoren die in de literatuur reeds voorop gesteld werden, is ook de schildklier 
activiteit, weergeven door de opname van pertechnetaat of kleine activiteiten radiojood 
door de schildklier tijdens scintigrafie, één van de factoren die een rol zou kunnen spelen in 
het beïnvloeden van het resultaat van de radiojood therapie. De opname van pertechnetaat 
door de schildklier kan vertegenwoordigd worden door (semi-) kwantitative factoren zoals 
de T/S ratio, de T/B ratio en het percentage opname van technetium door de schildklier 
(%TcU). Pertechnetaat schildklier scans van 75 hyperthyreoïde katten werden geïncludeerd 
in de studie en retrospectief geëvalueerd. De statistische analyses werden uitgevoerd zowel 
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met als zonder correctie voor de toegediende hoeveelheid radiojood met als doel een 
eventuele relatie te vinden tussen de schildklier parameters en het resultaat van de 
radiojood therapie. Enkel een verhoogde T/S ratio werd significant gerelateerd aan blijvende 
hyperthyreoïde in beide statistische analyses. Een drempel waarde van 5.4 werd bepaald 
voor deze T/S ratio met een sensititviteit van 73% en een specificiteit van 59%. De T/Bcircle 
ratio toonde enkel een significant resultaat in de eerste analyse zonder correctie voor de 
toegediende hoeveelheid radiojood. Daar werd een verhoogd risico voor blijvende 
hyperthyreoïde gezien ten opzichte van een finaal euthyreoïde uitkomst met een hogere 
T/Bcircle ratio. Geen van de onderzochte parameters kon significant gerelateerd worden aan 
een lage totale T4 waarde na radiojood therapie. De bevindingen van deze studie tonen aan 
dat voor semi-kwantificatie van schildklier activiteit het gebruik van de T/S ratio de voorkeur 
geniet en dat een T/S ratio ≥ 5.4 een mogelijke indicator is voor een verhoogd risico op 
blijvende hyperthyreoïde. 
 
In Hoofdstuk 4 werden enkele formules voor het berekenen van het schildklier volume, die 
reeds beschreven waren in de literatuur, onder de loep genomen. Hoewel het schildklier 
volume zowel in de humane als feline geneeskunde vooropgesteld wordt als één van de 
factoren die het resultaat van de radiojood therapie zou kunnen beïnvloeden, is de ideale 
methode om dit volume te bepalen met behulp van scintigrafie, een vaak gebruikte techniek 
in de diagnose van hyperthyreoïdie, nog niet gekend. Tweeëndertig hyperthyreoïde katten 
werden geïncludeerd in deze studie. Voor elke kat werd eerst het volume van de schildklier 
lobben bepaald met behulp van echografie en de formule van een ellipsoïde, gevolgd door 
de volumebepaling met behulp van scintigrafie. Voor de scintigrafie werden acht 
verschillende formules geëvalueerd: F1 [(π/6) × L × H × W], F2 [(π /2) × L × W²], F3 [0.33 × 
(oppervlakte cm²)3/2], F4 [1.08 × (π /6) × L × W²], F5 (oppervlakte × H), F6 (0.27 × oppervlakte 
× L), F7 (π × L × W²) en F8 [π × (4/3) × W³]. Deze resultaten werden vervolgens vergeleken 
met de volumes die bepaald werden met behulp van echografie, die als gouden standaard 
werden beschouwd. Een bijkomde evaluatie van de vorm van de schildklier lobben als 
cilinder- of sfeervormig en het gebruik van de corresponderende formules, F7 en F8, toonde 
geen betere correlatie aan met de echografisch bepaalde volumes. Hoewel 3 formules 
veelbelovend waren, met name F1, F4 en F6, was geen van deze opgemaakt voor het gebruik 
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bij katten, noch toonden ze een sterke correlatie met het echografisch gemeten schildklier 
volume.    
 
In Hoofdstuk 5 werden de limitaties van de formules uit hoofdstuk 4 verder benaderd. Een 
fantoomstudie werd uitgevoerd om een correctiefactor van 0.438 te berekenen, specifiek 
voor gebruik bij katten. Deze correctiefactor werd vervolgens geïntroduceerd in een nieuwe 
formule om het volume van schildklier lobben te berekenen met één enkele planaire 
scintigrafische scan: volume = 0.438 x lengte x breedte2. Schildklier scans van 167 
hyperthyreoïde katten werden geïncludeerd en het totale schildklier volume voor elke kat 
werd berekend. Een mogelijke relatie tussen het totale schildklier volume en het resultaat 
van de radiojood therapie werd vervolgens onderzocht. De grootste totale schildklier 
volumes waren aanwezig in de groep katten die hyperthyreoïd bleven na de therapie maar 
er werd geen statistische significantie bereikt. De relatie tussen een hoger aantal zones van 
hyperactief schildklierweefsel op de scintigrafie scan en katten met een totale T4 
concentratie onder de normaalwaarden na de behandeling, was wel statistisch significant. 
Dit is een belangrijke bevinding die in overweging dient genomen te worden bij katten die 
bilateraal aangetast zijn of waarbij er eveneens ectopisch schildklierweefsel aanwezig is.    
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